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Abstract
The primary objective of this thesis is to develop multiple hypothesis tests and simulta-
neous confidence intervals for comparisons of Gaussian means in longitudinal and similar
scenarios with correlated outcomes. One might wish to investigate differences between
treatment means separately at several specific points in time, or between means of several
time points separately for multiple treatment groups, whilst controlling a common type I
error rate for the entire set of comparisons. Global tests such as repeated measures anal-
ysis of variance are clearly unsatisfying in this situation. We describe flexible procedures
for approximate simultaneous inference within the framework of multiple contrast tests
(MCTs) where the different time points are treated as factor levels.
Two possible modeling strategies for the repeated measures are compared: a joint model
covering the entire span of measurement occasions (which is for Gaussian data typically a
linear mixed-effects model), or a novel approach for combining occasion-specific marginal
models i.e., one linear model per time point. Both strategies come with assets and
drawbacks: fitting a joint model requires a decision about how to model random effects
and/or error covariance structures, which is in many cases not trivial, but model selection
techniques can help out; on the other hand, covariance estimation in the combination of
marginal models is entirely data-driven, but the method comes with harsher assumptions
in the case of missing values.
Asymptotic procedures are fairly straightforward to contrive whereas a challenge with
small samples is that the degrees of freedom (DFs) to be used for computing the mul-
tivariate t reference quantile are unclear, especially for general unbalanced designs. We
explore a number of DF approximations via simulation; well-known adjustments such as
Kenward-Roger or Pinheiro-Bates turn out to perform well in many situations. Moreover,
we quantify the power advantage of our longitudinal MCTs over Bonferroni under various
configurations.
Rather than comparing only treatment groups per time point or only time points per
treatment group, we can also unite these hypotheses in one single family that embraces
both comparisons among treatments and among occasions under control of a common
type I error rate. This adds complexity to the problem, and especially finding proper DFs
is intricate. The use of different comparison-specific DFs appears to be a viable solution.
We extend our considerations to discrete outcomes such as proportions and counts. Again
we contrast the multi-model approach (now combining several generalized linear models)
with a single joint model, which is now fitted by generalized estimating equations. As the
subsequent inferences are asymptotic in nature, we gauge minimum sample sizes required
to ensure reasonable control of the type I error rate for binomial and Poisson outcomes,
respectively.
Application of the proposed methods is illustrated with six real datasets from medical,
toxicological, and horticultural research. We point out strengths and limitations of our
longitudinal MCTs, discuss their interpretation in the presence of missing data, and
outline a few extensions and alternatives.
Keywords: longitudinal data, linear mixed-effects model, multiple hypothesis
tests, simultaneous confidence intervals, degrees of freedom, missing values
Zusammenfassung
Kern dieser Arbeit ist die Ausarbeitung multipler Hypothesentests und simultaner Konfi-
denzintervalle fu¨r Mittelwertsvergleiche gaußverteilter Daten in longitudinalen und a¨hn-
lichen Szenarien mit korrelierten Messungen. So ko¨nnte man sich beispielsweise fu¨r Dif-
ferenzen zwischen Behandlungsmittelwerten getrennt an mehreren spezifischen Zeitpunk-
ten interessieren, oder fu¨r Differenzen zwischen Mittelwerten mehrerer solcher Zeitpunkte
getrennt fu¨r mehrere Behandlungsgruppen, unter Kontrolle einer gemeinsamen Fehlerrate
erster Art fu¨r die Gesamtheit der Vergleiche. Globaltests wie etwa die Varianzanalyse fu¨r
wiederholte Messungen sind in dem Fall ganz klar unbefriedigend. Wir beschreiben flexi-
ble Prozeduren fu¨r na¨herungsweise simultane Inferenz auf Basis multipler Kontrasttests,
wobei die verschiedenen Zeitpunkte als Faktorstufen aufgefasst werden.
Zwei mo¨gliche Modellierungsansa¨tze fu¨r die wiederholten Messungen werden gegenu¨ber-
gestellt: ein gemeinsames Modell, das sa¨mtliche Messzeitpunkte abdeckt (fu¨r gaußverteilte
Daten typischerweise ein lineares gemischtes Modell), oder ein neuartiger Ansatz, mit dem
sich zeitpunkt-spezifische marginale Modelle, d.h. ein lineares Modell pro Zeitpunkt, kom-
binieren lassen. Beide Strategien haben ihre Vor- und Nachteile: ein gemeinsames Modell
anzupassen erfordert eine Entscheidung daru¨ber, wie zufa¨llige Effekte und/oder Kovari-
anzstrukturen der Residuen zu modellieren sind, was sich in vielen Fa¨llen als nicht trivial
erweist, wenngleich Modellselektionstechniken hilfreich sein ko¨nnen; demgegenu¨ber ist die
Kovarianzscha¨tzung bei der Kombination marginaler Modelle vollsta¨ndig datenabha¨ngig,
jedoch erfordert die Methode strengere Annahmen im Fall fehlender Werte.
Asymptotische Verfahren lassen sich relativ leicht aufstellen, wohingegen bei kleinen Fall-
zahlen eine Herausforderung darin besteht, dass die Freiheitsgrade fu¨r die Berechnung von
Vergleichsquantilen aus der multivariaten t-Verteilung unklar sind, insbesondere fu¨r all-
gemeine unbalanzierte Anlagen. Wir untersuchen einige Na¨herungen mittels Simulation;
dabei zeigt sich, dass sich etablierte Methoden wie Kenward-Roger oder Pinheiro-Bates in
vielen Situationen gu¨nstig verhalten. Daru¨ber hinaus quantifizieren wir den Gu¨tevorteil
unserer longitudinalen multiplen Kontrasttests im Vergleich zu Bonferroni unter ver-
schiedenen Konfigurationen.
Anstatt nur Behandlungsgruppen pro Zeitpunkt oder Zeitpunkte pro Behandlungsgruppe
zu vergleichen, ko¨nnen wir diese Hypothesen genauso gut in einer einzigen Testfamilie
vereinigen, die sowohl Vergleiche zwischen Behandlungen als auch zwischen Zeitpunkten
umfasst unter Kontrolle einer gemeinsamen Fehlerrate erster Art. Damit wird das Prob-
lem noch einmal komplizierter, insbesondere die Bestimmung passender Freiheitsgrade.
Eine gute Lo¨sung ergibt sich, wenn man verschiedene vergleichsspezifische Freiheitsgrade
verwendet.
Wir erweitern unsere Abhandlung auf diskrete Endpunkte wie Proportionen und Za¨hl-
daten. Wiederum stellen wir den Ansatz mit mehreren Modellen (wobei wir jetzt mehrere
generalisierte lineare Modelle kombinieren) dem einzelnen Gesamtmodell, welches nun
mit Hilfe von verallgemeinerten Scha¨tzgleichungen angepasst wird, gegenu¨ber. Da die
darauf basierenden Inferenzen asymptotischer Natur sind, scha¨tzen wir die beno¨tigte
Mindestfallzahl ab, die eine vertretbare Kontrolle der Fehlerrate erster Art bei binomialen
beziehungsweise Poisson-Daten gewa¨hrleistet.
Die Anwendung der vorgeschlagenen Methodik wird anhand von sechs realen Datensa¨tzen
aus der medizinischen, toxikologischen und gartenbaulichen Forschung veranschaulicht.
Wir zeigen Sta¨rken und Schwa¨chen unserer longitudinalen multiplen Kontrasttests auf,
diskutieren deren Interpretation bei fehlenden Werten, und umreißen einige Erweiterun-
gen und Alternativen.
Schlagworte: longitudinale Daten, lineares gemischtes Modell, multiple Hy-
pothesentests, simultane Konfidenzintervalle, Freiheitsgrade, fehlende Werte
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NOTATION
General Notation
This list contains symbols that are recurrently used, but it is not exhaustive. A few
symbols have different meanings in different contexts e.g., β as linear model parameter
and type II error rate.
⊗ Kronecker product
1 column vector of ones
α type I error rate
b random-effect parameter
β fixed-effect parameter / type II error rate
c contrast coefficient
C contrast matrix
Γ correlation matrix
δ contrast margin
∆ difference
D random-effects covariance matrix
e unit vector
 residual error
η contrast
h index for contrasts
H0 null hypothesis
HA alternative hypothesis
i index for independent subject
I identity matrix
I expected Fisher information
j index for repeated measurements
J matrix of ones
J observed Fisher information
k index for treatments
NOTATION
λ Poisson parameter
Λ correlation matrix
m number of repeated measurements
µ mean
n sample size
n˜ effective sample size
N overall sample size
N (uni- or multivariate) normal distribution
ν degrees of freedom
p p-value
pi binomial proportion
φ variance inflation factor
q number of treatments
R residual covariance matrix / correlation matrix
R(α) working correlation matrix
ρ correlation
s2 variance estimator
σ2 variance
Σ covariance matrix
t critical value from a t-distribution
T t-type test statistic
T (uni- or multivariate) t-distribution
x dependent variable
X fixed-effects design matrix
y independent (outcome) variable
Y (outcome) random variable
z number of contrasts
Z z-type test statistic
Z random-effects design matrix
ABBREVIATIONS
List of Abbreviations
AIC Akaike information criterion
AICc second-order / small-sample Akaike information criterion
ANOM analysis of means
ANOVA analysis of variance
AUC area under the (response-time) curve
BIC Bayesian information criterion
CDF cumulative distribution function
CI confidence interval
CIM conditional independence model
CPB cardiopulmonary bypass
DF degrees of freedom
EACA -aminocaproic acid
ELM extended linear model
FWER familywise error rate
GEE generalized estimating equations
GLM generalized linear model
GLMM generalized linear mixed-effects model
GLS generalized least squares
HgCl2 mercuric chloride
ICH International Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use
KR Kenward-Roger (degrees of freedom)
LMM linear mixed-effects model
LVCF last value carried forward
ABBREVIATIONS
MANOVA multivariate analysis of variance
MAR missing at random
MCAR missing completely at random
MCP multiple comparison procedure
MCT multiple contrast test
MI multiple imputation
ML maximum likelihood
MMM multiple marginal models
MNAR missing not at random
OLS ordinary least squares
PB Pinheiro-Bates (degrees of freedom)
PDF probability density function
REML restricted maximum likelihood
SCI simultaneous confidence interval
SE standard error
SI single imputation
UIT union intersection test
Logical validity is not a guarantee of truth.
David Foster Wallace, Infinite Jest
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1 Introduction
Simultaneous comparisons of means are frequently desired in all fields of experimental
research, typically with the aim to control the familywise type I error rate (FWER) at a
preset level α. But what embraces the “family” i.e., the set of comparisons whose type
I errors deserve to be jointly controlled, is often a controversial issue (e.g., Stone and
Chuang-Stein 2013; Wason et al. 2014), especially if multiple levels of several factors are
to be compared.
Adjusting for multiplicity of comparisons among more than two treatment groups is
widespread, as can be seen from the popularity of the tests for all-pairwise (Tukey 1953)
1953 and many-to-one comparisons (Dunnett 1955). By contrast, additional sources of
multiplicity, such as multiple outcomes or repeated measures, are often swept under the
carpet. We believe that this practice is inconsistent because the multiplicity arising
from e.g., several observational time points is not very different from the multiplicity
arising from several group comparisons in that it can equally invalidate a conclusion if
not adjusted for.
The presence of non-randomized factors further complicates matters. Time points in a
longitudinal experiment are an example of a repeated factor that is by its very nature un-
randomizable and gives rise to stochastic dependence among measurements. The defining
property of longitudinal data is that each experimental unit is measured repeatedly over
time so that values from the same individual are positively correlated (Fitzmaurice et al.
2011). This runs contrary to the assumption of uncorrelated samples, which is the basis
of most statistical methods for simultaneous inference.
There is obviously a gap to fill between the complex experimental designs that are car-
ried out in practice and lead to correlated measurements, and the widely-used simplistic
statistical analyses that ignore dependencies in the data. This becomes apparent with
experimental setups that involve
a) at least one randomized factor (or between-subjects variable) whose different levels
are randomly assigned to different experimental units,
b) at least one repeated factor (or within-subjects variable) whose different levels are
investigated using the same experimental unit,
and every subject is exposed to exactly one level of the randomized factor but multiple
levels of the repeated factor. Quan et al. (2005) called this a “two-dimensional multiplic-
ity problem” (for the case of one randomized and one repeated factor), but in principle
it can be extended to higher dimensions e.g., if there is also a spatial component to the
experimental design. This thesis is mainly—but not exclusively—concerned with longi-
tudinally repeated measurements in controlled experiments, so the levels of the repeated
factor will often be referred to as time points or occasions, and those of the randomized
factor will usually be called treatments.
Imagine a classical repeated measures situation where the observed outcomes are cor-
related between occasions (repeated measurements) but uncorrelated across treatments
(due to randomization). Widespread statistical techniques such as multivariate analysis
of variance (MANOVA) and repeated measures ANOVA compare the treatment means
simultaneously and jointly at multiple occasions i.e., they provide only some global state-
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ment of “significance” expressed as p-value(s) and rely on unrealistic assumptions such
as multisample sphericity (Huynh 1978). Other well-known procedures for multiple end-
points, like the T 2 test (Hotelling 1931), the ordinary and generalized least squares (OLS
and GLS) methods by O’Brien (1984), and the approximate likelihood ratio test of Tang
et al. (1989), are also just global procedures, and many of them are limited to compar-
isons of two groups only (see e.g., Sankoh et al. 1997, 1999; Wassmer et al. 1999). So if
interest lies in analyzing the occasions simultaneously but separately, all this is neither as
detailed nor as insightful as typically requested by researchers.
In practice questions like “Which treatment is better than control?” or “Can we show a
dose-related trend?” may be asked for each of several points in time. Thus the goal is to
study the effects of treatments separately and simultaneously at several occasions, which
enables us to localize interesting effects rather than just claim their existence. Similarly,
questions like “When is the treatment’s effect superior to baseline?” or “At which point
in time does the treatment cause the highest effect?” may be asked for several treatments,
suggesting to assess the effects of occasions separately and simultaneously within several
treatment groups. Here separately means that we want inference for each and every time
point rather than for the whole time span in its entirety, and simultaneously means that
the FWER is to be controlled at level α for the whole set of elementary comparisons.
On top of that, both types of questions can be combined into one test family. Researchers
may want to assess differences among treatments as well as among occasions, with the
overall FWER to be bounded by α. Then the multiple inference problem is not only
two-dimensional but also two-directional in the sense that comparisons are carried out
across randomized treatments and also across dependent occasions.
For any such research questions to be meaningful, the number of time points should be
smallish (i.e., probably not more than five or six) as vast amounts of single test results
rarely lead to enlightening conclusions. If there are lots of serially repeated measurements,
it is certainly wiser to resort to a summary measure of the evolution over time, such as the
area under the curve (AUC) or the slope of a linear model fit. Moreover, the measurement
occasions should preferably not be picked at haphazard but rather have inherent medical
or biological relevance. In a clinical application, some endpoint could be assessed pre- and
post-surgery and after one month of convalescence. Similar scenarios with meaningfully
defined points in time arise in many life sciences from agriculture (e.g., growth stages of
crops) to zoology (e.g., larval instars of insects).
Awareness of multiplicity issues in longitudinal designs has risen in the past few years,
but flawed solutions are still omnipresent in the applied sciences, as a recent survey by Liu
et al. (2010) shows. Comparing treatments with individual Dunnett or Tukey tests per
occasion without any further adjustment seriously inflates the overall rate of type I errors
(e.g., Hoffman et al. 2008) and thus invalidates the claim made at an alleged α level. On
the other hand, an overall Tukey test for all combinations of treatments and occasions
will blur the results of the target effects by lots of uninteresting comparisons. Correcting
for the multiplicity of occasions via Bonferroni is unnecessarily conservative, especially
when occasions are highly correlated. Ad hoc solutions to cushion the conservatism
of Bonferroni (e.g., Shi et al. (2012) proposed a simple correction factor depending on
intraclass correlation) often have a very limited range of application, or it is unclear in
what situations they are able to control the FWER.
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So we see there is want for generally applicable methodology that takes the characteristics
of repeated measurement data into account and produces valid but not unnecessarily
conservative results. The prodecure must cope with three major challenges of longitudinal
data:
1. Measurements from the same individuals are positively correlated i.e., adjoining
occasions are likely to behave in a similar way, and correlation tends to decrease
with greater separation in time.
2. Variability is likely to change over the course of the study (heteroskedasticity).
3. Missing values are the rule rather than the exception, and data may be incomplete
due to individuals dropping out of the study.
As a consequence, longitudinal data require a thoughtful analysis using methods that
are geared to handling correlated parameters. The principal goal of this thesis is to
develop and characterize a framework for multiple inference in longitudinal data settings
with either Gaussian or discrete endpoints, especially focusing on how to account for
heteroscedastic errors and incorporate dependency structures of repeated measurements.
The methods described and discussed in this work are an application of multiple contrast
tests (MCTs) as described in Hothorn et al. (2008). MCT procedures already exist for
related scenarios such as multiple endpoints (Hasler and Hothorn 2011) and repeated
measurements (Hasler 2013); however, these are not based on a proper modeling strategy
for the data and hence cannot easily include covariates or missing values, which makes
them inflexible in practice. In addition, the repeated measures MCTs only allow for
single-group comparisons of time points.
We believe that a sound procedure for multiple inference in longitudinal settings must
have its foundation in a convincing model of the data. To estimate effect sizes and
(co-)variances, we consider linear mixed-effects models (LMMs) for Gaussian endpoints
(Verbeke and Molenberghs 2000), generalized estimating equations (GEEs) for discrete
outcomes (Hardin and Hilbe 2013), and alternatively a novel approach combining separate
occasion-specific models (Pipper et al. 2012).
In addition to localizing effects of interest, we usually want to quantify them, which
we cannot achieve with the p-value(s) produced by a global test. Hence we think that
the presentation of adjusted p-values should be replaced—or at least accompanied—by
simultaneous confidence intervals (SCIs) that give a measure of uncertainty about the
effect estimates. We subscribe to the opinion of Cochran and Cox (1957, p. 5), who
wrote:
In many experiments it seems obvious that the different treatments must have produced
some difference, however small, in effect. Thus the hypothesis that there is no difference is
unrealistic: the real problem is to obtain estimates of the sizes of the differences.
Regulatory bodies have not long ago started encouraging to put this into practice. The
International Conference on Harmonisation (ICH) guideline E9 (1998, p. 25–26), which is
relevant for Europe, the United States, and Japan, declares that “estimates of treatment
effects should be accompanied by confidence intervals, whenever possible” and emphasizes
“the need to provide statistical estimates of the size of treatment effects together with
confidence intervals (in addition to significance tests)”. The longitudinal MCT procedures
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that we propose are particularly suited to meet these requirements as they do not only
yield adjusted p-values for single comparisons but also SCIs that are compatible i.e.,
reject the null hypothesis if and only if the corresponding test does.
The remainder of this thesis is organized as follows. Chapter 2 introduces six example
datasets from medicine, toxicology, and horticulture to further motivate the problem
under study. In Chapter 3 we review some relevant statistical concepts and techniques
that will be used as building blocks in later chapters. Chapter 4 introduces longitudinal
MCTs for Gaussian outcomes along with extensive simulations of their size and power,
applications to example data, and approximate power calculations. Chapter 5 extends
the longitudinal MCTs to data with discrete endpoints, assesses finite-sample properties
of these asymptotic procedures, and illustrates their application to real data. Chapter
6 spotlights some related ideas, alternatives, and possible extensions. Strengths and
limitations of the proposed methods are discussed in Chapter 7, followed by a concise
summary of the main results and conclusions in Chapter 8.
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2 Example Data
The application of novel and modified statistical procedures to real-world data is an
integral part of this thesis. Our six data examples arise from various research disciplines
but have in common that the underlying experimental questions can be expressed as
multiple comparisons among levels of a randomized factor separately and simultaneously
at several levels of a repeated factor, or multiple comparisons among levels of a repeated
factor separately and simultaneously for several levels of a randomized factor.
We introduce in 2.1 a clinical trial on bradykinin receptor antagonism as quantified by
D-dimer concentrations at five characteristic and medically important points in time.
In 2.2 we present a toxicological study measuring the body weights of rats that were
force-fed with mercuric chloride over the course of two years, and there are substantial
dropout rates at later occasions. Both the bradykinin and the mercuric chloride data
have Gaussian endpoints and fairly large sample sizes. The problem of small samples
occurs in 2.3 with a placebo-controlled trial of two novel drugs where the patients’ heart
rates are recorded over time.
Our fourth data example in 2.4 is an entomological study where the repeated measure-
ments were taken from multiple parts of the plant. Another count dataset will be intro-
duced in 2.5: it is a clinical trial on the efficacy of progabide in the treatment of epilepsy,
measured as the number of seizures i.e., a discrete rate rather than a continuous endpoint.
The final example dataset has an endpoint that is a proportion: the efficacy of a biopes-
ticide on the mortality of different developmental stages of an insect is investigated; these
data are presented in 2.6.
Statistical analyses of all six datasets using the methodology developed in this thesis are
going to be shown in detail in chapters 4 (for the Gaussian outcomes) and 5 (for the
discrete outcomes).
2.1 Bradykinin Receptor Antagonism
Cardiopulmonary bypass (CPB) puts cardiac surgery patients in jeopardy of postoper-
ative bleeding, which in turn may require transfusion of blood products. This bleeding
is often caused by fibrinolysis i.e., fibrin in blood clots is degraded to little protein frag-
ments called D-dimers. Consequently, D-dimers are commonly used as a biomarker for
fibrinolysis.
It is clearly desirable to avoid blood transfusion during and after surgical intervention,
therefore researchers have been seeking strategies to prevent fibrinolytic degradation.
It is known that CPB promotes fibrinolysis via a peptide called bradykinin and the
associated bradykinin B2 receptor. Balaguer et al. (2013) investigated whether bradykinin
B2 receptor antagonism can reduce fibrinolysis. They conducted a randomized, double-
blind trial at Vanderbilt University Medical School, Nashville, TN between 2007 and
2012 (ClinicalTrials.gov identifier: NCT00223704). 115 patients about to undergo cardiac
surgery with the aid of a heart-lung machine (“on-pump”) were randomized to one of
three intravenous treatments:
• HOE 140, a specific bradykinin B2 receptor antagonist,
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• -aminocaproic acid (EACA), a well-known antifibrinolytic drug,
• normal saline (placebo).
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Figure 1: Bradykinin data. Top: individual patient trajectories (dotted) and sample mean
trajectories per treatment arm (solid) of log-concentrations of D-dimer; bottom: boxplots.
One of the secondary endpoints was the concentration of D-dimer in blood samples taken
at five selected time points:
• prior to surgical incision (baseline),
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• after 30 minutes “on-pump”,
• after 60 minutes “on-pump”,
• after separation from the heart-lung machine (post-bypass),
• on the first postoperative day.
The goal was to quantify fibrinolysis (as measured via D-dimer concentrations) over the
course of CPB until the day after. The time intervals between measurement occasions are
obviously unequal; nonetheless, observations from the same patient are for sure correlated.
The raw data were kindly provided by Dr. Mias Pretorius, Division of Clinical Pharmacol-
ogy and Department of Anesthesiology, Vanderbilt University Medical School, Nashville,
TN upon condition that artificial data be generated for use in any publication. So to
avoid copyright infringements, we create and evaluate a fake dataset based on sample
sizes, means, variances, and covariances of the (log-transformed) original values; these
summary statistics are listed in Table 17 in Appendix C.
Prior to drawing data, we exclude patients 92 and 93 (both randomized to HOE 140)
for whom no D-dimer measurements are available at all; we further exclude patient 99
(randomized to placebo) who was measured with implausible D-dimer concentrations of
zero at the first two time points. Thus we are left with 38 patients in the HOE 140 group
and 37 patients in the placebo and EACA arms.
Assuming that the natural logarithms of D-dimer concentrations in each treatment arm
are multivariate normal, we draw random variates from five-dimensional normal distri-
butions N5(µ,Σ) with mean vector µ and a 5 × 5 covariance matrix Σ of time points
using R package mvtnorm (Genz and Bretz 2009; Genz et al. 2014). Figure 1 displays the
simulated bradykinin dataset; a full table is presented in Table 18 in Appendix C.
One relevant research question for these data could be: when do which active treatments
(HOE 140, EACA) reduce D-dimer concentrations (thus: reduce fibrinolysis) compared
to control. We want to ask the question for treatment differences separately and simulta-
neously for each time point while controlling a common FWER. Another objective could
be to assess the differences to baseline separately and simultaneously for each treatment
arm. The analysis of bradykinin dataset with methods proposed in this thesis will be
presented in 4.4.1.
2.2 Mercuric Chloride
Mercuric chloride (HgCl2) was used to tan leather, disinfect seeds, embalm bodies, pre-
serve wood, etch steel, and for many other purposes, but has fallen into disrepute after
the toxicity of mercury compounds became known to the public. A long-term bioassay
of the National Toxicology Program (1993, study number C60173), beginning in March
1983, investigated toxic effects of HgCl2 in rodents. As part of this study, 180 female
F344 rats were randomized to three dose groups: 0, 2.5, or 5 mg HgCl2 per kg body
weight, administered in 5 ml/kg deionized water by gavage five days a week. The an-
imals were caged together in sets of five receiving the same treatment. Among other
endpoints, their body weights were monitored over the course of two years. The study
was conducted at the International Research and Development Corporation (IRDC) in
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Mattawan, MI. Raw data are available from the National Toxicology Program’s web
database (http://tools.niehs.nih.gov/ntp_tox); the complete dataset is shown in
Table 19 in Appendix C.
We evaluate the body weights at three points in time: when the study is halfway through
(after 53 weeks), at the interim analysis after 65 weeks (when 30 animals are sacrificed to
assess safety endpoints), and at the end of the study after 105 weeks (Figure 2, top and
middle). Different research questions are imaginable here e.g., one could be interested in
estimating the effects (with 95% confidence intervals) of low and high dosage in compar-
ison to the vehicle control separately and simultaneously for each measurement time. A
corresponding statistical analysis will be presented in 4.4.2.
One complication with this dataset is missing values (Figure 2, bottom). Few animal
drop out prior to the interim analysis in week 65: only two were found moribund or dead,
one in each of the active dose groups. At the end of the second year, however, about half
of the data points are missing in each treatment group: ten animals per dose group were
sacrificed for interim analyses, and many more found moribund or dead.
2.3 Heart Rates
The efficacy of two novel drugs, AX23 and BWW9, was assessed in a placebo-controlled
clinical trial described by Milliken and Johnson (1992). 24 women were randomly assigned
to one of the active drug arms or control, resulting in three groups of eight subjects each.
The clinical endpoint of interest was the heart rate, measured for each woman at four
subsequent occasions every five minutes. Complete sets of observations are available for
all subjects. Table 20 in Appendix C shows the full dataset.
Plotting these data (Figure 3) reveals that heart rate patterns over time are quite different
among the three treatments. The rates seem to be slightly decreasing over time for control
and BWW9 whereas AX23 leads to higher rates at the second and third time point
compared to the first and last. The difference between BWW9 and control is relatively
constant over time. We also observe that BWW9 has the smallest and control the largest
variance at all time points.
One research question we can answer with this dataset is: which treatments increase the
heart rate compared to control at any particular occasion? This suggests comparing the
treatment arms separately and simultaneously for each of the four measurement times.
Another reasonable goal is to find out for each treatment arm whether there are relevant
differences of heart rates over time, leading to comparisons between time points separately
and simultaneously for each treatment. We will analyze the data in 4.4.3.
2.4 Greenhouse Whiteflies
The whitefly Trialeurodes vaporariorum is a common greenhouse pest and feared by grow-
ers because of its ability to cause dramatic economic loss. Since spraying chemicals is
undesirable in a greenhouse environment, horticulturists have been searching for alter-
natives for efficient control of whiteflies. One solution that has arisen in the context of
integrated pest management is the application of antagonists such as predatory bugs, but
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Figure 2: Mercuric chloride data. Top: individual rat trajectories (dotted) and sample mean
trajectories per treatment group (solid) of body weights; middle: boxplots; bottom: numbers of
missing values.
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Figure 3: Heart rate data. Top: individual patient trajectories (dotted) and sample mean
trajectories per treatment arm (solid) of heart rates; bottom: boxplots.
their effectiveness depends, among other factors, on the microclimatic environment. It is
also important that the predators can find their prey, who might prefer different parts of
the plant than their enemies.
An experiment was set up to study the preferences of whiteflies in the presence of the
predator bug Macrolophus pygmaeus either in a conventional glasshouse or in two types
of foil tunnels equipped with potted plants. The numbers of whitefly larvae per plant
at midsummer were counted seperately for the three parts of each plant (top, middle,
bottom), and we consider each of these plant samples as an independent experimental
unit with three repeated measurements. There were 84 samples from the glasshouse and
42 from each of the two foil tunnels.
The data are graphed in Figure 4. We find by visual inspection that whiteflies obviously
prefer the lower regions of the plant and avoid staying at the top. In fact, there are hardly
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any whiteflies at the top of most plants. Especially the conditions in foil tunnel 1 seem to
reduce the number of whiteflies at the bottom and middle of the plant. Furthermore, we
see that a few plants are heavily infested with whiteflies whereas others are practically
pest-free. The data are clearly skewed to the right.
Unlike with the other datasets introduced in this chapter, the outcome here is measured
repeatedly at multiple parts of the plant instead of multiple occasion i.e., spatial rather
than temporal replication, but the methods and principles discussed in this thesis apply
just as well. A few observations are missing from one of the foil tunnels (indeed, three
plants could not be sampled at all).
We want to assess how the microclimatic environment influences the whiteflies’ preference
for the top, middle, or bottom parts of the plant. To this end we compare whitefly counts
between the three parts of the plant separately and simultaneously for the glasshouse and
both foil tunnels. Additionally, the question whether any environment provides better
conditions for whitefly control than the others can be investigated with comparisons of
environments separately and simultaneously per part of the plant. The corresponding
analyses using statistical methods established in this thesis will be undertaken in 5.4.1.
These data are a subset of a larger series of experiments conducted by Elias Bo¨ckmann at
the Institute of Horticultural Production Systems, Department Phytomedicine, Leibniz
University Hannover in 2013. Table 22 in Appendix C shows the raw data in full.
2.5 Epileptic Seizures
Thall and Vail (1990) present data from a placebo-controlled clinical trial on the efficacy
of progabide in the treatment of epilepsy, with 31 patients randomized to progabide
and 28 to placebo. The outcome of interest is the number of seizures, recorded in two-
week intervals two, four, six, and eight weeks after randomization. Their paper also
gives a baseline value, which is the number of seizures in the eight-week interval before
randomization; we divided this by four to make it intuitively comparable to the two-week
intervals after randomization.
Figure 5 shows that the mean numbers of seizures are very similar in both arms, and
they are also more or less constant over time. The data are heavily skewed to the right:
most patients experience up to 20 or 30 seizures during two weeks, but there are a few
exceptions, for example one patient in the progabide arm with 102 seizures in the first
interval after randomization. This person’s individual profile is way higher than any other
patient’s profile. Generally, individuals with relatively many (few) seizures tend to have
similarly many (few) seizures in all intervals, so the numbers of seizures in a patient are
positively correlated over time.
One question to be answered with these data is whether progabide is capable of reducing
the rate of seizures during any two-week interval after initiation of the treatment. The
analysis using comparisons separately and simultaneously for each time point will be
presented in 5.4.2. The full dataset is given in Table 21 in Appendix C.
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Figure 4: Greenhouse data. Top: individual sample trajectories (dotted) and mean trajectories
per environment (solid) of whitefly counts at each of three different parts of the plant; middle:
boxplots; bottom: numbers of missing values.
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Figure 5: Epileptic seizure data. Top: individual patient trajectories (dotted) and sample mean
trajectories per treatment arm (solid) of seizures per two weeks; bottom: boxplots.
2.6 Azadirachtin
Seeds of the neem tree (Azadirachta indica) contain a secondary metabolite called azadi-
rachtin that is known to disrupt the development of insects and act as an antifeedant. On
the other hand it is non-toxic to mammals; therefore azadirachtin has become increasingly
popular as a biological insecticide for organic farming and integrated pest management.
Neem extracts can be applied either as a spray on the plant surface or as a drenching solu-
tion to be taken up via the roots. The disadvantage of spraying is the limited duration of
effect due to azadirachtin degrading very fast under the influence of ultraviolet radiation.
Soil application of azadirachtin is particularly appealing for the purpose of plant protec-
tion because it is systemically distributed all over the plant and quickly translocated to
the insect feeding sites.
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Figure 6: Azadirachtin data. Top: individual pot trajectories of relative larval and pupal mor-
talities with different substrates; bottom: boxplots.
We consider an investigation of the effect of soil-applied azadirachtin on larval and pupal
mortality of the greenhouse whitefly Trialeurodes vaporariorum. 60 tomato plants in sin-
gle pots were randomly arranged on a greenhouse table. Five female whitefly adults were
placed on one well-developed leaf per plant, given the opportunity to lay eggs so that a
population is initiated, and then removed again after one day. Then they were treated
with different doses of the commercial product “NeemAzal-T”, a liquid formulation con-
taining 1% of the active ingredient azadirachtin.
It was hypothesized that the root uptake of azadirachtin may depend on the organic
matter content in the soil. Thus half of the plants were grown in commercial substrate
and the other half in a 1:1 mixture of substrate and sand. Within each of these portions
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of 30 plants, they received three different treatment dosages in sets of ten:
• 1 ml drench (amounting to 10 mg Azadirachtin) per kg of soil,
• 1.5 ml drench (amounting to 15 mg Azadirachtin) per kg of soil,
• 2 ml drench (amounting to 20 mg Azadirachtin) per kg of soil.
The dose recommended by the manufacturer is 1 ml per kg of soil.
Four values were recorded for each single pot:
• the total number of larvae that hatched from the eggs,
• the number of larvae found dead,
• the number of larvae that pupated,
• the number of pupae found dead.
The data are displayed in Figure 6 as larval and pupal mortalities. An important char-
acteristic is that the numbers of whiteflies exposed to the neem treatments are highly
variable between single plants, ranging from 27 to 275 (larvae) and from 1 to 185 (pupae).
Larval and pupal mortality proportions are likely to be correlated since they were observed
from the same experimental units. We will evaluate them in 5.4.3 using the methods
proposed in this thesis, focusing on two research questions. First, what is the impact
of raising the dosage beyond the manufacturer’s recommendation on larval and pupal
mortality? And second, do we see a difference when sand is added to the substrate?
The data were taken from a series of experiments carried out by Josephine Karanja at
the Institute of Horticultural Production Systems, Department Phytomedicine, Leibniz
University Hannover in 2014, and published in Karanja et al. (2015). The raw values of
the subset considered in this thesis are shown in Table 23 in Appendix C.
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3 Methods
This chapter introduces some statistical concepts and methods that are to be used as
building blocks for the longitudinal MCTs in Chapters 4 and 5. We review linear mixed-
effects models (LMMs) and consider different structures for the random effects and resid-
ual covariances in 3.1. Selection of a model from a set of candidates using the AICc
criterion is described in 3.2. Generalized linear models (GLMs) and generalized esti-
mating equation (GEEs) for discrete data are introduced in 3.3 and 3.4. The idea of
combining multiple marginal models is presented in 3.5. We describe general simulta-
neous inference in 3.6, and multiple contrast tests (MCTs) are in the spotlight of 3.7,
with a critical assessment of existing MCT procedures for correlated data settings. 3.8
lists various small-sample approximations for the degrees of freedom (DF) to be used in
longitudinal MCTs. Different definitions of power in multiple testing are summarized in
3.9. We conclude the chapter with an overview of missing data issues in 3.10.
3.1 Linear Mixed-Effects Models
3.1.1 General Concepts
A standard way of processing longitudinal data involves fitting a linear mixed-effects
model (LMM) that contains fixed-effect parameters governing the model’s mean structure,
and random effects that usually reflect the randomization or hierarchical structure of the
experiment and imply a certain covariance matrix. Motivated by Cnaan et al. (1997), we
adopt here a very general notion of LMMs to emphasize that their great flexibility shall
be exploited in many ways: random effects may be included or not; error variances may
be modeled as homo- or heteroscedastic; and error covariances may or may not be taken
as zero. Thus our general1 LMM can be one that contains, apart from the error term,
only fixed effects. Using notation similar to that of Laird and Ware (1982), we write the
model as
yi = Xiβ + Zibi + i , i = 1, . . . , n
where yi is a vector of responses from subject i, Xi and Zi are known design matrices for
the fixed and random effects, and β are the fixed-effects coefficients shared by all subjects.
The random effects parameters bi and residual errors i are conventionally assumed to
follow Gaussian distributions with mean zero and covariance matrices D (same for all bi)
and Ri:
bi ∼ N (0,D) and i ∼ N (0,Ri).
In addition, we assume that random effects and errors are independent of one another:
Cov(bi, i) =
(
D 0
0 Ri
)
.
The marginal expectation of yi is
E(yi) = Xiβ
1This notion of general is not to be confused with the class of generalized linear models (see 3.3),
which allow for error distributions other than Gaussian but are inherently fixed-effects models.
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with marginal variance
V ar(yi) = Σi = ZiDZ
T
i + Ri,
that is composed of a between- and a within-individual portion, so in summary
yi ∼ N (Xiβ, ZiDZTi + Ri).
The generalized least squares (GLS) estimator for the fixed-effect parameters is
βˆ =
(
n∑
i=1
XTi Σˆ
−1
i Xi
)−1 n∑
i=1
XTi Σˆ
−1
i y
−1
with estimated variance
V ar(βˆ) =
(
n∑
i=1
XTi Σˆ
−1
i Xi
)−1
where Σˆi is the restricted maximum likelihood (REML) solution to Σi (Patterson and
Thompson 1971), which is commonly preferred to maximum likelihood (ML) as the latter
is biased because it ignores the degrees of freedom used for estimating the fixed effects. We
refer to the literature for minutiae on LMM theory and computation: excellent reference
texts are Searle et al. (1992), Verbeke and Molenberghs (2000), Pinheiro and Bates (2000),
McCulloch and Searle (2001), and Fitzmaurice et al. (2011).
We would like to spotlight two important special cases of our general LMM concept:
Conditional independence model (CIM): One common simplification relies on the
so-called conditional independence assumption
Ri = σ
2I
i.e., the residual errors are assumed independent, conditional on the random effects.
This implies that all within-subject association must be absorbed by the random-effects
covariance matrix D. In addition, the errors are assumed to be homoscedastic.
Extended linear model (ELM): The “other extreme” (so-termed by Cnaan et al.
1997) is to leave out any random effects other than the errors i.e., to set Zi = 0. This
yields an extended linear (fixed-effects) model
yi = Xiβ + i
that may account for heteroscedasticity and correlation through its error covariance ma-
trices Ri on which we may impose a pattern (e.g., compound symmetric or autoregressive)
or leave them completely unstructured (see 3.1.2 for an overview of options). This model
still comes within our notion of general LMMs even though it is downgraded—but note
that the errors are also random.
In practice, the choice whether to fit a CIM, an ELM, or an LMM including both random
effects (other than ) and some structure on the error covariances will be subject-matter-
driven, and we do not feel obliged to give any general “statistical” recommendation here.
We discuss consequences of over- and underfitting in 3.1.3. In case of uncertainty, model
selection tools may be consulted, on which we will elaborate in 3.2.
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3.1.2 Residual Covariance Patterns
An open problem when fitting an LMM is to decide upon a model for the error covariances
Ri = σ
2Λi. The simplest variant is to set Λi = I for all i = 1, . . . , n, leading to the CIM. In
practice, however, allowing for heteroscedasticity and/or correlatedness of within-subject
errors can improve the model fit substantially. This is for sure indispensable in ELMs with
no random effects (besides the errors) but may also be advantageous in any LMM where
the random effects specification captures the within-subject associations insufficiently.
In any case the goal is not to devise the correct covariance structure (whatever that
means) but rather to find a viable and economical approximation. Indeed estimating a
full unstructured correlation matrix and heterogeneous variances is often self-defeating:
1. Parameters may be unestimable, especially for small datasets.
2. With increasing dimensionality (i.e., number of occasions) estimation quickly be-
comes a computational burden.
3. Lots of parameters are wasted even when a much more parsimonious structural
model would serve the same purpose.
This undesirable situation can be resolved by
a) checking thoroughly to what degree heteroscedasticity needs to be modeled, and
b) imposing a sparse parametric pattern on the matrix of within-subject correlations.
General considerations on the choice of variance and correlation structure are given in
the following. A good strategy is probably to work out a few plausible models for the Ri
and “let the data choose” be means of a selection criterion (see 3.2).
To describe structural covariance modeling, we decompose the covariance matrix of the
within-subject errors into a variance part Vi and a correlation part Λi which are inde-
pendent of one another:
Ri = ViΛiVi
where Vi is a diagonal matrix with strictly positive entries on the main diagonal, and Λi
is symmetric and positive definite with all diagonal elements equal to one.
Variance Structures: For any subject i belonging to treatment group k, the variance
part is
Vi =
 σi1 . . .
σim

with σij the square root of the variance at measurement occasion j. Now we obviously
do not want to model subject-specific variances; patterns of practical relevance allow the
variance to vary across measurement occasions j = 1, . . . ,m and/or treatment groups
k = 1, . . . , q i.e., we work with σjk. We consider four variance schemes of increasing
complexity:
• Fully homoscedastic: σjk = σ
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Variances are assumed constant across both treatment groups and measurement oc-
casions. This is the simplest model but highly unrealistic in any actual longitudinal
dataset.
• Heteroscedastic over time: σjk = σj
Variances changing in the course of time are a common occurrence in longitudinal
studies, and it may be reasonable to assume that they are not considerably different
in the treatment groups.
• Heteroscedastic over treatments: σjk = σk
Variances being constant over time but different from treatment to treatment are
unlikely to occur in longitudinal data but possibly in other repeated measurement
settings e.g., with multiple endpoints.
• Fully heteroscedastic: σjk
Variances are allowed to vary between measurement occasions and treatment groups.
Such a detailed model will be difficult to fit and to motivate with small sample sizes
but may be justified for larger datasets.
A rather parsimonious strategy to model heteroscedasticity could involve a variance func-
tion of some sort e.g., an exponential or power variance function.
Correlation Structures: The second component of the residual covariance matrix Ri
is the correlation part Λi. We list here some frequently used correlation patterns and
discuss their applicability to longitudinal and repeated measures settings. The matrices
are exemplified for m = 4, and since they are symmetric, only their upper triangles are
displayed. The restriction |ρ| ≤ 1 applies to all correlation parameters with or without
subscripts.
• Independence (IND):
Λi = Im =

1 0 0 0
1 0 0
1 0
1

The most naive way to deal with a repeated measures situation is to flatly ignore any
correlation among the time points. The assumption of independent errors (which
is implicit in the standard linear model) is highly unrealistic for longitudinal or any
other correlated data and will lead to grossly invalid standard errors (SEs).
• Compound symmetry (CS):
Λi =

1 ρ ρ ρ
1 ρ ρ
1 ρ
1

Compound symmetry requires just one parameter ρ to be estimated but on the other
hand implies that all measurements are equally correlated. This is a questionable
assumption for longitudinal data, where the strength of association is likely to
decrease with increasing separation in time.
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• First-order autoregressive (AR(1)):
Λi =

1 ρ ρ2 ρ3
1 ρ ρ2
1 ρ
1

AR(1) is equally parsimonious in parameters as CS but able to reflect that corre-
lation decreases (exponentially) with increasing time gaps between occasions. This
makes it a favored pattern for longitudinal data. As a limitation, it requires that
measurements are obtained at equally spaced points in time. This restriction can
be overcome with the generalization to CAR(1). Higher-order autoregressive struc-
tures are conceivable but rarely realized in practice.
• Continuous first-order autoregressive (CAR(1)):
Λi =

1 ρ|t2−t1| ρ|t3−t1| ρ|t4−t1|
1 ρ|t3−t2| ρ|t4−t2|
1 ρ|t4−t3|
1

The continuous generalizaton of AR(1) is appropriate if the measurements are not
equally spaced in time as they take into account the lags |tj′ − tj| between time
points tj and tj′ , with j, j
′ = 1, . . . ,m. For data with constant lags, CAR(1) is the
same as AR(1).
• Toeplitz (TOEP):
Λi =

1 ρ ρ2 ρ3
1 ρ ρ2
1 ρ
1

Toeplitz structures assume that correlation of (equally spaced) occasions varies
with their separation in time. Unlike with AR(1), however, there is no restriction
to exponential decay. This flexibility comes at the cost of having to estimate m− 1
correlation parameters instead of just one.
• Unstructured (UN):
Λi =

1 ρ12 ρ13 ρ14
1 ρ23 ρ24
1 ρ34
1

A completely unstructured pattern will reflect the data’s correlation structure most
accurately, thus minimizing the risk of misspecification. However, the absence of
constraints for the matrix elements inflates the number of parameters to m(m+1)
2
.
Further correlation patterns include higher order autoregressive (e.g., AR(2)), moving
average (MA), autoregressive moving average (ARMA), antedependence (ANTE), factor
analytic (FA), spherical, Huynh-Feldt (HF), and various spatial structures; in addition,
banding can be introduced where all entries in higher off-diagonals are set to zero. For an
overview of covariance patterns for longitudinal and repeated measures designs consult
e.g., Jennrich and Schluchter (1986), Diggle et al. (1994), Wolfinger (1993), Wolfinger
(1996), and Littell et al. (2006).
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3.1.3 Modeling Random Effects and Error Covariances
When facing a practical data problem, one has to decide on a model for Vi and Λi and/or
the random effects. The dilemma here is that both under- and overfitting can be detri-
mental. In real-data problems, we need to distinguish between appropriate simplifications
and problematic misspecifications that ignore vital features of the data. A realistic goal
is to find “a good enough” model (Cheng et al. 2010) rather than “the best” or even “the
correct” one.
Imposing a parametric structure always bears the risk of getting it wrong. Various re-
searchers have studied misspecifications of random effects or covariance structures and
their impact on fixed-effects inference. Jacqmin-Gadda et al. (2007) and Schielzeth and
Forstmeier (2009) warned against overoptimistic inferences as a consequence of insufficient
random-intercept-only models. Likewise, Gurka et al. (2011) showed that underspecifi-
cation (e.g., only CS due to only a random intercept) inflates the type I error rate for
fixed-effect tests.
To avoid such underfitting and “be on the safe side”, one could be tempted to generally
estimate UN correlation and separate variances per time point (in an ELM), or the
most complex random-effects structure (in a CIM). This seems appealing at first sight
and may be fine when the sample size is large relative to the number of time points.
However, Littell et al. (2000) pointed out that UN always fits but the SE estimates may
be unstable. Park et al. (2001) assessed type I error rates and power and stated that
especially with large numbers of occasions, estimating UN covariances becomes inefficient.
Lu and Mehrotra (2010) proposed to always use UN in order to avoid biased estimates of
β under missingness at random (MAR) but also admitted this may lead to convergence
problems. So for small to medium sample sizes (as they are common practice in the life
sciences) one runs the risk of overfitting the data and getting very instable covariance
estimates, or even of being unable to actually fit the model in the first place.
A simple illustration clarifies this matter. Assume that we have four treatment groups in
our experiment and the endpoint is evaluated repeatedly at five successive time points.
In the simplest case (pooled variance estimate across time points and parsimonious cor-
relation structure such as AR(1)) only two parameters are spent to model the covariance
structure. By contrast, fitting unstructured heteroscedastic model inflates the number of
parameters for the covariance matrix to 15 (five variances and ten pairwise correlations).
If we wanted to generalize the model even further and include separate covariance matri-
ces for different groups, the number of parameters to be estimated would literally rocket
upwards (20 variances and 40 pairwise correlations).
Thus in many cases a reasonable approximation with few parameters is more useful than
an overparameterized correlation matrix or maximal random effects. And instead of
choosing a covariance pattern oneself, one could set up a collection of candidate model
and “let the data choose”. This idea of selecting among various covariance structures
appears in Jennrich and Schluchter (1986) and Wolfinger (1993, 1996) and is supposed to
minimize the risk of gross misspecification. Keselman et al. (1998) compared AIC and the
Bayesian information criterion (BIC) of Schwarz (1978) for this purpose, however with
the rather irrelevant focus on their ability to pick the “correct” model. We will pursue
the model selection approach in 3.2.
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3.2 AICc Model Selection
In real-world life sciences, the “true” process that generated a given dataset is complex
and per se unknown and unknowable. Hence often a model of some kind is employed
to provide a passably simple approximation to the truth. Such a model is useful for
obtaining estimates of parameters with a practical interpretation, for making inference
about such parameters, and for predictions. At the end of the day, it is a tool that helps
to understand what is going on. However, a model is not, and cannot be, truth itself. In
other words, the intent of modeling is not to rebuild the true underlying mechanism but
to grasp its most important features.
The predominant modus operandi of arriving at a model deemed good is to pick one (e.g.,
because it has been used before or others have used it before or just because it “feels”
right) and then settle for it. Such an approach involves a good deal of arbitrariness. A
more objective strategy is to assemble an entire set of plausible candidate models and
then select the best approximating model by means of a sensible criterion. For this
purpose we utilize a concept that is well-founded in information theory: the Kullback-
Leibler distance (Kullback and Leibler 1951) measures the loss of information when the
unknown true mechanism f is approximated with model g, indexed with parameters θ:
I(f, g) =
∫
f(x) log
(
f(x)
g(x|θ)
)
dx.
From this perspective it becomes obvious that a good model captures as much information
about the true process as possible (i.e., does not underfit the data) without overinter-
preting data structures that are essentially just noise (i.e., not overfitting the data). This
is the familiar bias-variance tradeoff in statistics.
A straightforward way of harnessing information theory for practical model selection is
Akaike’s information criterion (AIC) (Akaike 1974), which estimates the relative expected
Kullback-Leibler distance:
AIC = −2`(θˆ) + 2K
where `(θˆ) = log(L(θˆ|y)) is the maximized log-likelihood given the data andK the number
of model parameters. When presented with a set of R candidate models, AIC chooses the
one that provides the best approximation to the unknown truth in terms of Kullback-
Leibler distance. Contrary to a common misbelief, suchlike model selection makes no
assumption that the true model is among the candidates (Burnham and Anderson 2002).
When the sample size is small relative to the number of estimated model parameters,
the so-called second-order AIC or AICc (Sugiura 1978; Hurvich and Tsai 1989) should
be preferred to AIC:
AICc = AIC +
2K(K + 1)
n−K − 1
= −2`(θˆ) + 2K
(
n
n−K − 1
)
where n is the sample size. The small-sample bias adjustment has a noticable impact
for n
K
< 40, as recommended by Burnham and Anderson (2002). AIC and AICc are
asymptotically equal.
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A single AICc value is not interpretable; it becomes only meaningful in the context of
the candidate set that contains R different models. Therefore the transformation
∆l = AICcl − AICcmin
is useful where AICcmin is the minimum AICc among the set of R candidate models. The
“best” model is assigned ∆ = 0, and all other models get values greater than zero.
Another handy measure is the Akaike weight
wl =
e−
∆l
2∑R
r=1 e
−∆r
2
,
which can be interpreted as the probability that model l is the best model in a Kullback-
Leibler sense i.e., conditional on the data and the candidate set.
3.3 Generalized Linear Models
Generalized linear models (GLMs) as introduced by Nelder and Wedderburn (1972) and
detailed in McCullagh and Nelder (1989) extend the classical linear model (e.g., Searle
1971) to discrete outcomes such as counts, rates, and proportions. Suppose a setting with
observational units i = 1, . . . , n in treatment groups k = 1, . . . , q, then a GLM is built on
three components:
1. a distributional assumption for the outcome that is a member of the exponential
family (such as Gaussian, binomial, or Poisson) and implicates an expression for
the expected value of the random variables Yi = (Yi1, . . . , Yini)
E(Yi) = µi
as well as the variance
V ar(Yi) = φV (µi) = φai,
2. a linear predictor
ηi =
q∑
k=1
xikβk = xiβ,
3. a link function
g(µi) = ηi
that connects the linear predictor to the expected value of the outcome variable.
In consequence, we assume linearity and additivity of effects on the link.
We consider three widespread special cases of GLMs:
Gaussian: The standard linear model for Gaussian data can be viewed as a GLM with
identity link function
g(µi) = µi,
and the variance is independent of the mean so that
φ = σ2 and V (µi) = 1.
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Poisson: The canonical link under Poisson assumption is
g(µi) = log(µi),
and the variance is equal to the mean:
V (µi) = µi.
Binomial: The canonical link function for binomial data is
g(µi) = logit(µi) = log
(
µi
1− µi
)
but other links such as probit or complementary log-log are conceivable as well. The
binomial variance is
V (µi) = µi(1− µi).
For both Poisson and binomial GLMs we have φ = 1 unless there is overdispersion,
meaning that the data exhibit variability that exceeds the sampling variance according
to Poisson or binomial theory. Then a variance inflation factor φ > 1 can estimated from
the data in a quasi-likelihood framework (Wedderburn 1974). Alternative remedies for
overdispersion include estimating robust “sandwich” variances (Zeileis 2006) or switch-
ing to another distribution (e.g., use negative binomial for counts, or beta-binomial for
proportions).
3.4 Generalized Estimating Equations
A popular way to model correlated discrete outcomes are generalized estimating equations
(GEEs) as introduced by Liang and Zeger (1986) and Zeger and Liang (1986). This
technique can be viewed as an extension of GLMs to non-independent settings. No joint
likelihood has to be specified with GEEs.
Using notation from 3.3, consistent estimates of β are found by solving
U(β) =
n∑
i=1
∂µi
∂β
V−1i (Yi − µi) = 0
with working covariance matrix
Vi = φA
1
2
i Ri(α)A
1
2
i
where Ai is the diagonal matrix of the aik as defined in 3.3, and Ri(α) a working corre-
lation matrix depending only on a parameter α. This gives
(βˆ − β)√n asym.∼ N (0,K)
with
K = lim
n→∞
n
(
n∑
i=1
∂µTi
∂β
Vi
∂µi
∂βT
)−1( n∑
i=1
∂µTi
∂β
ViCov(Yi)Vi
∂µi
∂βT
)(
n∑
i=1
∂µTi
∂β
Vi
∂µi
∂βT
)−1
.
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The robust sandwich covariance estimator of K is obtained by inserting consistent esti-
mates for β, φ, and α, and (Yi − µi)(Yi − µi)T for Cov(Yi) (e.g., Halekoh et al. 2006).
This yields consistent estimates of the covariances even under misspecification of Ri(α)
(Hardin and Hilbe 2013). The alternative would be a naive covariance estimation directly
from the data.
Another strategy for modeling correlated discrete outcomes is offered by the family of
generalized linear mixed-effects models (GLMMs) (e.g., Breslow and Clayton 1993). They
require to specify a complete joint distribution of the data and account for within-subject
correlation by introducing random effects to the linear predictor of a GLM. This can make
them practically challenging (Bolker et al. 2009) and also computationally instable (Zhang
et al. 2011). And if the distributional assumptions for the random effects and sampling
variability are violated, GLMM estimates will be biased.
Another crucial difference between GEEs and GLMMs lies in the interpretation of model
parameters: GEE estimates are to be viewed as population-averaged effects whereas
fixed-effect estimates from a GLMM have a subject-specific meaning i.e., they describe
changes within individuals (e.g., Zeger et al. 1988; Young et al. 2007; Zhang et al. 2012).
Note that there are covariates that cannot change within a subject such as sex, race,
species, etc.
One way to overcome some of the limitations of GLMMs is to “marginalize” them i.e.,
model the marginal mean rather than a mean that is conditional on random effects. These
marginalized multilevel models (Heagerty and Zeger 2000; Wang and Louis 2004; Griswold
et al. 2013) extend the interpretability of GLMM parameters and are less sensitive to
misspecifications.
3.5 Multiple Marginal Models
3.5.1 General Methodology
Instead of basing multiple inferences on a single model that includes all time points, Pip-
per et al. (2012) propose a different strategy. Their approach combines multiple marginal
models (MMM) i.e., one model per time point, from which a joint correlation matrix is
determined. Adjusted p-values and SCIs are computed by incorporating the correlation
between the respective score contributions of the time points from the different models.
A big advantage of this method is that one does not have to bother about how to model
the covariance structure. Moreover, it is easy to include covariates and generalize the
method to endpoints of different types (e.g., discrete, time-to-event). Strong FWER con-
trol, however, is ensured only asymptotically; the small-sample behavior of this approach
is largely unexplored to date.
The parameters of interest are the group effects βj; they are estimated as βˆj through
m marginal models fitted separately for time points j = 1, . . . ,m, and their correlations
are obtained via “stacking” the score contributions (derivatives of the log-likelihood) of
these parameter estimates.
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We can see that asymptotically
(βˆj − βj)
√
n =
1√
n
n∑
i=1
−I−1j Ψ˜ij + oP (1)
=
1√
n
n∑
i=1
Ψij + oP (1)
where I−1j is the row in the inverse Fisher information matrix that corresponds to βj,
Ψ˜ij is the score function for the ith of measurements i = 1, . . . , n, and oP (1) denotes a
sequence of random vectors converging to zero in probability (e.g., van der Vaart 1998,
theorem 5.21). Now the idea of Pipper et al. (2012) is to “stack” the βj, βˆj, and Ψij over
all j = 1, . . . ,m so as to get
(βˆ − β)√n = 1√
n
n∑
i=1
Ψi + oP (1),
which is the m-variate asymptotic version of the above. According to the multivariate
central limit theorem, the left side converges in distribution to m-variate normality:
(βˆ − β)√n d−→ N (0,Σ).
We can estimate Σ consistently as
Σˆ =
1
n
n∑
i=1
Ψ̂
′
iΨ̂i
where the Ψ̂i are obtained by plugging the parameter estimates from the m marginal
models into Ψi.
This approach is sufficiently general to allow for various classes of marginal models (e.g.,
logistic regression, Cox proportional hazards model, . . . ), even in the same analysis. Here
we consider only simple linear regression and define design vectors
x
(j)
i = (1, x
(j)
i1 , . . . , x
(j)
iq )
T
for treatment groups k = 1, . . . , q. Now if the effect we are interested in is in the first
coordinate of γ(j) in a linear marginal model
y
(j)
i = x
(j)T
i γ
(j) + 
(j)
i , 
(j)
i ∼ N (0, σ2)
for the jth time point, then Ψij is the first coordinate of
−E
(
1
σ2
x
(j)
i x
(j)T
i
)−1
x
(j)
i
(
y
(j)
i − x(j)Ti γ(j)
)
which we can use to get the estimate Ψ̂ij and hence Ψ̂i and also Σ̂, which provides us
with the prerequisites to do simultaneous inference for the βˆj (see 3.7).
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3.5.2 Parameterization
An important observation with finite samples is that the parameterization of the marginal
models can have an impact on the estimated covariances and thus on the inference.
Consider an occasion-specific linear model for individuals i in treatment groups k:
yi =
q∑
k=1
βkxik + i , i = 1, . . . , n.
Two straightforward ways to parameterize the model are:
1. β1 is the mean of a reference group and β2 through βk are the other group means’
differences to β1 (this is R’s standard parameterization for factors, also known as
“treatment contrasts”);
2. βk is the kth group mean.
Either parameterization will yield correct effect estimates, but the associated covariance
estimates may differ. The crux of the matter is that the method of Pipper et al. (2012)
uses the observed Fisher information J from which it calculates the empirical covariances.
J is asymptotically equal to I = E(J ), the expected Fisher information. With small
to moderate sample sizes, however, I and J may take quite dissimilar values, and the
empirical covariances may grossly differ from the expected ones.
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Figure 7: Mean percentage deviation (± standard deviation) of the observed and expected
variance estimates for the comparison β2−β3 in a setup involving three standard normal variates,
each of them with sample size n.
We can illustrate this issue in a simple setup with three samples of n randomly drawn
standard normal variates each, using the implementation of the method in the R package
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multcomp (Hothorn et al. 2015). Fitting a one-way ANOVA model to these data and
estimating the variance of β2 − β3 from the model, we get the truly expected variance
only with the second parameterization. Figure 7 shows the mean percentage deviation
(plus/minus standard deviation) of the observed from the expected variance of β2 − β3
as estimated from 1000 simulated datasets. We recognize that the impact of parameter-
ization is tremendous with small sample sizes: for n = 5, the observed variance (using
the first parameterization) deviates from the expected one by more than 30% on average.
Even with n as large as 50 independent units per sample, their mean deviation is still
10%. Several hundreds, or even thousands, of sampling units are required to force the
mean percentage deviation down to a few percent.
What is happening here is that the first parameterization has trouble estimating covari-
ances of zero with small to moderate sample sizes; it will yield non-zero values where
there should be zeroes. Using the second parameterization, we are off the hook: it uses
strictly different portions of the data to estimate different parameters, so it is preferable
for our purpose. The whole problem vanishes with increasing sample size because the
observed and expected Fisher information, and thus variance, are asymptotically equal.
3.6 Simultaneous Inference
3.6.1 General Concepts
Assessing more than one statistical hypothesis at one time is called simultaneous infer-
ence. This is like asking multiple specific questions and expecting one specific answer
per question, and more often than not also an overall answer to the set of questions as
a whole. Directing several enquiries to the same set of data, however, usually results in
a multiple comparison problem. Multiplicity can arise from several group comparisons
being made, several endpoints being investigated, several subgroups being analyzed, etc.
The common goal with simultaneous inference is to control a joint rate of type I errors
occurring over the whole set (or “family”) of hypotheses. Hochberg and Tamhane (1987,
p. 5) defined a family as “any collection of inferences for which it is meaningful to take
into account some combined measure of errors”. In this context we appreciate the notion
of a “claimwise” error rate as proposed by Phillips et al. (2013); this emphasizes that a
claim can consist of diverse elementary hypotheses that are meaningful together.
Performing a series of level α tests for the elementary hypotheses without any further
adjustment usually inflates the type I error rate of the entire claim. We want to focus here
on methods that control the FWER in the strong sense i.e., the probability of incorrectly
rejecting one or more true elementary nulls is to be bounded by α, no matter which and
how many elementary nulls are true or false. The inferential procedures discussed in this
work control the FWER (at least approximately) in the strong sense for a claim that
may comprise comparisons among treatment groups as well as comparisons among time
points.
When comparing multiple treatments separately and simultaneously at multiple occa-
sions, it is sufficient for claiming an effect if at least one treatment difference is significant
at least at one occasion. Likewise, when comparing multiple occasions separately and
simultaneously for multiple treatment groups, an effect may be claimed if at least one
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occasion difference is significant for at least one treatment. Hence the claims we want to
make are formulated as union-intersection tests (UITs), and adjustment is needed as the
goal is to bound the FWER (approximately) by α. A UIT involves testing the intersection
of elementary null hypotheses against the union of alternatives:
H0 =
⋂
H
(i)
0
HA =
⋃
H
(i)
A
The global H0 is rejected if at least one elementary H
(i)
0 is rejected (Roy 1953).
The results of many simultaneous inference procedures can be expressed either as ad-
justed p-values or SCIs, but intervals are superior to p-values in multiple ways (Gardner
and Altman 1986): both convey information about statistical significance, but SCIs in
addition allow to assess the magnitude of an effect on the original scale, its direction
(decrease or increase), and its subject-matter relevance. Therefore SCIs are much more
useful for direct interpretation with respect to the research questions of interest.
3.6.2 Multiple Comparison Procedures
The simplest and best-known adjustment for multiplicity is based on Bonferroni’s in-
equality (Bonferroni 1935, 1936)2, leading to the corrected type I error bound
α˜ =
α
z
and to adjusted p-values (which are then to be compared with α) for hypotheses h =
1, . . . , z given by
p˜h = min(zph, 1).
This method is universally applicable to ensure strong FWER control but also notorious
for being conservative unless test statistics are independent.
Just minimally more powerful is the correction of Sˇida´k (1967) with its adjusted α bound
of
α˜ = 1− (1− α) 1z .
Unlike the Bonferroni method, it controls α exactly (in a probabilistic sense), however
only under independence of test statistics. In the presence of correlation among tests, its
achieved type I error level can lie considerably below the nominal α.
This conservativity can be cushioned by incorporating dependence of test statistics by
means of their joint parametric distribution. Tukey’s pairwise comparisons using the
studentized range distribution, Dunnett’s comparisons with a control, or the analysis of
means (ANOM) are examples how α can be better exploited under dependence. These
are all single-step tests procedures (meaning that the same critical value applies to all
test statistics), and all of them can be viewed as special cases of multiple contrast tests
(MCTs), which we will consider in depth in 3.7.
Stepwise test procedures offer another strategy to lessen conservativity as they uniformly
improve the power of corresponding single-step tests. The Bonferroni-Holm step-down
2In fact, Boole’s inequality is applied here.
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test (Holm 1979) is uniformly more powerful than Bonferroni; similarly, the single-step
many-to-one test of Dunnett (1955) can be made uniformly more powerful in step-down
(Naik 1975; Marcus et al. 1976; Dunnett and Tamhane 1991) or step-up (Dunnett and
Tamhane 1992, 1995) variants3.
The trouble with stepwise techniques is that compatible SCIs are, if available at all,
cumbersome to derive and in most cases noninformative. Guilbaud (2008) and Strass-
burger and Bretz (2008) established SCI bounds corresponding to Holm-type step-down
(“sequentially rejective”) tests; these bounds stick to the margin δh (usually δh = 0 ∀ h)
for all rejected hypotheses, and hence provide no additional information compared to
the p-values unless all hypotheses are rejected. Compatible SCIs for step-down Dunnett
tests, following suggestions by Bofinger (1987) and Stefansson et al. (1988), have the
same unpleasant property. SCIs compatible with step-up Dunnett tests do not exist to
date. We consider the unavailability of assuredly informative SCIs a major deficiency
that outweighs the achievable gain in power, hence stepwise procedures will not play a
role in the remainder of this work.
Elaborate treatise of simultaneous inference is provided in the textbooks by Hochberg and
Tamhane (1987) and Hsu (1996) as well as a series of recent review articles (Dmitrienko
and D’Agostino, Sr. 2013; Alosh et al. 2013; Dmitrienko et al. 2013; Huque et al. 2013).
The books by Dmitrienko et al. (2010) and Dickhaus (2014) connect mathematical theory
and biomedical applications. Software-specific overviews are delivered e.g., in Bretz et al.
(2010, using R) or Westfall et al. (2011, using SAS).
3.7 Multiple Contrast Tests
3.7.1 General Methodology
Multiple contrast tests (MCTs) are a convenient and supremely flexible method for testing
multiple hypotheses and obtaining compatible SCIs. They control the familywise α in the
strong sense and take dependencies among tests into account. Basic MCT methodology
was outlined in Mukerjee et al. (1987) and Bretz et al. (2001a) and extended to a wide
class of (semi-)parametric models by Hothorn et al. (2008).
Many well-known and widely applied multiple comparison procedures can be formulated
in terms of MCTs e.g., comparisons to a control (Dunnett 1955), all-pairwise comparisons
(Tukey 1953), comparisons versus the grand mean (“analysis of means”, see Pallmann
and Hothorn 2016), changepoint alternatives (Hirotsu et al. 2011), and Williams’ trend
test (Williams 1971, 1972; Bretz 2006). Beyond that, arbitrary sets of contrasts can be
tailored to a specific research problem.
MCTs provide both global and localized significance decisions, and the latter can be
based upon either multiplicity-adjusted p-values or SCIs. So an MCT gives answers to
three question:
• “Is there an effect?” −→ global test,
• “Where is the effect?” −→ local adjusted p-values,
3The step-down Dunnett test can be viewed as an extension of Holm (1979), in contrast to the step-up
Dunnett test being an extension of Hochberg (1988).
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• “Where is the effect, and how big is it?” −→ SCIs.
To begin with, we consider a one-way layout with randomized treatment groups k =
1, . . . , q and independent observations i = 1, . . . , nk within each group, and we assume
homoscedasticity across all treatments. We review testing a single contrast first before
extending our considerations to multiple contrasts and in a second step.
A Single Contrast: The basic module of an MCT is a single contrast
η = cTβ = c1β1 + · · ·+ cqβq
i.e., a linear combination of parameters β = (β1, . . . , βq)
T defined by coefficients c =
(c1, . . . , cq)
T where more often than not
∑q
k=1 ck = 0. Replacing β with an estimate βˆ
gives the estimated contrast ηˆ, and the standardized version of this is
Z =
ηˆ − δ
SE(η)
where δ is the expected value of η under H0 (often chosen to be 0), and
SE(η) = σ
√√√√ q∑
k=1
c2k
nk
with σ being the square root of the common variance. Z constitutes a contrast test
statistic about the null hypothesis
H0 : η = δ.
SE(η) is a known quantity if σ is known, and then Z is standard normal under H0:
Z ∼ N (0, 1).
In practice, σ is usually unknown and must be estimated from the data; replacing σ with
its estimate s in SE(η) yields the test statistic
T =
η − δ
ŜE(η)
,
which is t-distributed under H0 with ν = n− q degrees of freedom:
T ∼ T (ν).
Multiple Contrasts: If a set of several standardized contrasts T = (T1, . . . , Tz) is to
be assessed simultaneously, the global H0 is composed of elementary nulls
H
(h)
0 : ηh = δh,
and the joint null is the intersection
H0 =
⋂
H
(h)
0 .
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In statistical practice, several contrasts are assembled in a family (or “claim”) such that
their joint investigation gives a detailed and meaningful answer to the research questions.
This was described by Mukerjee et al. (1987) as vectors being “strategically located within
the alternative region”. The comparisons of interest are specified via a coefficient matrix
C = (c1, . . . , cz) = (chk)
that is composed of multiple coefficient vectors. The quantities of interest are the con-
trasts
η = Cβ,
and more often than not these contrasts are interdependent i.e., non-orthogonal, and
then correlations can be exploited to sharpen the test procedure. Some of the most
commonly used contrasts with their coefficient matrices (examplified for comparisons of
four parameters) are:
• many-to-one comparisons to a common control:
CDunnett =
 −1 1 0 0−1 0 1 0
−1 0 0 1
 ,
• all-pairwise comparisons:
CTukey =

−1 1 0 0
−1 0 1 0
−1 0 0 1
0 −1 1 0
0 −1 0 1
0 0 −1 1
 ,
• comparisons to the grand mean (for a balanced setup):
CGrandMean =

3
4
−1
4
−1
4
−1
4−1
4
3
4
−1
4
−1
4−1
4
−1
4
3
4
−1
4−1
4
−1
4
−1
4
3
4
 ,
• Williams trend test (for a balanced setup):
CWilliams =
 −1 0 0 1−1 0 1
2
1
2−1 1
3
1
3
1
3
 .
The correlations of test statistics depend on these coefficient matrices.
The test statistic corresponding to the hth contrast is
Th =
ηˆh − δh
ŜE(ηh)
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where
ηˆh =
q∑
k=1
chkβˆk,
and the SE is now estimated as
SE(ηh) = s
√√√√ q∑
k=1
c2hk
nk
.
The joint distribution of T = (T1, . . . , Tz) is z-dimensional t (Cornish 1954; Dunn and
Massey, Jr. 1965) with ν DF, and R describing the correlation among the test statistics:
T ∼ Tz(ν,R).
With homoscedastic and independent errors, the DF is quite simply
ν =
q∑
k=1
(nk − 1),
and the elements of R are uniquely defined by the sample sizes and contrast coefficients
i.e., by known quantities:
Corr(Th, Th′) = ρhh′ =
∑q
k=1
chkch′k
nk√(∑q
k=1
c2hk
nk
)(∑q
k=1
c2
h′k
nk
) .
For instance, the many-to-one test as defined via CDunnett compares all groups to the
control, so this piece of information is shared by all comparisons, and it can easily be
seen that the pairwise correlation of contrasts is 0.5 for balanced sample sizes.
For the two-sided case, we reject H
(h)
0 if
|Th| > ttwoz,1−α(ν, Rˆ)
where ttwoz,1−α(ν, Rˆ) is the two-sided equicoordinate 1− α quantile of Tz(ν, Rˆ). The corre-
sponding adjusted p-value is calculated as
ph = 1−
∫ |T obsh |
−|T obsh |
. . .
∫ |T obsh |
−|T obsh |
tz(x; ν,R) dx
where T obsh is an observed value of Th, and tz(x; ν,R) is the PDF that corresponds to
Tz(ν,R). One elementary hypothesis is declared significant if its corresponding adjusted
p-value is below the pre-defined familywise significance level, which is traditionally 0.05.
The global null is declared significant if the minimum p-value is below the significance
level (maximum test).
SCIs are often preferred to p-values as they give a measure for the uncertainty of the
estimate on the scale of the observations rather than on an abstract probability scale.
SCI bounds with coverage probability 1− α are given by
ηˆh ∓ ttwoz,1−α(ν,R) ŜE(ηh).
The hth elementary hypothesis is rejected if δh is not included in the corresponding SCI.
The global null is rejected if at least one SCI does not include the corresponding δh.
These SCIs have two convenient properties:
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1. They are compatible with test decisions from adjusted p-values: a (1 − α) SCI
excluding the point of no effect is always associated with an adjusted p-value smaller
than α; hence SCIs can be readily used for hypothesis testing.
2. Their bounds are always informative; this stands in contrast to other methods (e.g.,
stepwise procedures) whose usefulness is thereby limited.
Inference for directional one-sided problems can be carried out in a very similar way
(e.g., Bretz et al. 2010). Efficient computation of probabilities and quantiles from a
multidimensional t-distribution is described in Genz and Bretz (2009); see also Appendix
A.2 for details on multivariate t-distributions.
Numerous extensions of MCTs have been proposed in the past few years. Hothorn et al.
(2008) discussed multiple comparisons for a wide range of parametric models (ANOVA
and regression models, GLMs, linear and nonlinear mixed-effects models, Cox and Weibull
models). Hasler and Hothorn (2008) and Herberich et al. (2010) made suggestions for
mastering heteroscedasticity. Dilba et al. (2006) and Hare and Spurrier (2007), among
others, transfered the principle of MCTs to hypotheses involving ratios instead of differ-
ences of means.
In this thesis we study MCTs for settings when neither independence nor homoscedas-
ticity can be assumed, and comparisons are to be made among randomized treatment
groups and/or among repeated occasions. We will be dealing with modeling stategies for
estimating β and the associated covariance matrix Σ and how to incorporate them in
the MCT procedure. Before that, however, we review two similar MCT procedures that
already exist.
3.7.2 MCTs with Correlated Outcomes
In recent years, MCT variants were developed for two inferential problems related to ours
that both involve correlated outcomes. We review these multivariate MCTs and repeated
measures MCTs briefly and expound why they are of limited avail for our specific matter.
MCTs for Multiple Endpoints: Hasler and Hothorn (2011) developed multivariate
MCTs and showed the benefit of acknowledging the correlation between multiple end-
points. Their method could be applied to our longitudinal setting directly by treating
measurement occasions as endpoints. However, this is nonsatisfying from different points
of view:
1. The procedure only allows for comparisons among treatments per time point but
not among time points per treatment.
2. It is not straightforwardly adaptable to data with additional covariates.
3. Covariances of endpoints are always assumed as heteroscedastic (variances) and
unstructured (correlation), either for all treatment groups or even separately for
each treatment (Hasler 2014a); in a scenario involving a mere four groups and five
time points, say, there are 60 covariance parameters to estimate! It is obvious that
this is undesirable, and may indeed be unnecessary, especially with small sample
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sizes. We will aim at sparsity in parameters, which can be achieved with patterned
covariance models or by introducing random effects.
4. It is fairly unclear how to deal with incomplete measurements, which disqualifies the
method from being applied to longitudinal data where missing values and dropout
are a frequent occurrence. Admittedly, there are workarounds, but they are either
assumption-laden (such as estimating the means from all available data but the
covariances only from the complete cases) or technically complicated (e.g., multiple
imputation techniques).
MCTs for Repeated Measures: Hasler (2013) discussed MCTs for comparing means
between the levels of a repeated factor in a single-treatment setup. Being confronted with
the challenge of finding a workable DF approximation, he fabricated as a purely empirical
solution
νHasler = n− 1− z − 1
m− 1
where n is the number of independent units, z the number of comparisons, and m the
number of time points, and approved its small-sample performance under H0 via simula-
tions. This procedure is evidently unsuited for our purposes:
1. The method addresses comparisons among time points but no comparisons of treat-
ments.
2. Most real-world problems involve more than one treatment group, so the limitation
to a single group is unacceptable.
3. Beyond that, it raises similar difficulties as the multi-endpoint MCTs: most impor-
tantly, it is inflexible as regards coping with additional covariates, and missingness
cannot be adequately acknowledged without making restrictive assumptions.
In conclusion, the existing MCTs for multiple endpoints and repeated measures are inflex-
ible in several respects. The goal of this dissertation is to widen their scope of application
to practically relevant scenarios under less restrictive premises. Direct extensions of these
two variants of MCTs, however, are unpromising as they will retain existing limitations;
thus our strategy shall be based on more flexible modeling of the data.
3.8 Approximations to the Degrees of Freedom
As the multivariate t is only an approximation to the joint distribution of test statis-
tics, a proper approximation for its degrees of freedom (DF) is especially relevant with
small sample sizes. However, there is no hope to find any “correct” DF for arbitrary
settings, and it is rather an open question which of the many suggestions circulating in
the literature works best under given circumstances.
Any useful DF approximation should reflect the amount of “information” contained in
the data (Faes et al. 2009). In the context of longitudinal data this could mean the
DF needs to capture the number of independent subjects, the number of total repeated
measurements, and the strength of within-subject correlation.
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We collect here a couple of possibly useful approaches for small sample sizes, some of which
are well-known and some rather innovative, and assess their applicability to multiple
comparisons in longitudinal designs. As n grows large, all approximations tend to infinity,
and the asymptotic reference distribution becomes multivariate normal.
Naive: The naive lower boundary post for any useful DF approximation is
νnaive = n− rank(X)
= n−mq
where n is the number of independent subjects, m the number of occasions, and q the
number of treatment groups. It basically ignores that there are repeated measurements
and only takes independent replications into account; hence it most likely understates the
amount of information in the data (unless all observations are perfectly correlated). Using
νnaive in the presence of small and moderate sample sizes should lead to conservative tests.
Residual: Another simplistic approximation is the DF of the residual error variance of
each fixed factor
νres = N − rank(X)
= N −mq
where N is the total number of measurements. It acts as if the repeated measurements
were independent observations and will therefore lead to overoptimistic results in the
presence of longitudinal correlation, at least with finite samples. So νres may be viewed
as an upper boundary post, and it is fairly obvious that any sensible DF approximation
should lie in the interval ]νnaive, νres[.
Between-within: An attempt to achieve a tradeoff between the naive and residual DFs
is known (especially to SAS users) as between-within method (Schluchter and Elashoff
1990) and calculated as
νbw = N − rank(X)− rank(Z).
It has been shown to yield unsatisfactory results in simulation studies (see the end of this
section) and will therefore not be pursued any further.
Containment: The approximation popularly referred to as the SAS containment DF
computes
νcont = N − rank(X Z)
which is the rank contribution of random terms that syntactically contain the fixed effect
under consideration to the covariate matrix (X Z) (e.g., Verbeke and Molenberghs 1997;
SAS Institute 2009). The implications of the term “syntactically” in this context need
to be clarified: assume a mixed model with fixed effect A, random effect B, and interac-
tion A*B which contains A syntactically. However, A*B could be denoted by C as well,
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which does not alter the model but syntactically (and only syntactically!) removes the
interaction term involving A and thus change the value of νcont.
So a big drawback of the containment method is its ambiguity: one and the same statisti-
cal model can be written in different ways, possibly leading to different numerical results
for νcont. The fact that computation of νcont is intrinsically tied to SAS syntax makes it
hard to implement the method in other software packages such as R.
Pinheiro-Bates: The suggestion described by Pinheiro and Bates (2000, p. 91) and
used in their nlme software (Pinheiro et al. 2015) is similar in spirit to the containment DF
but untainted by peculiarities of the SAS syntax. In its general form the approximation
is computed as
νPB = mi − (mi−1 + pi)
where mi denotes the number of units at level i = 1, . . . , Q + 1, and pi the DF sum
associated with the terms estimated at the ith level. This gives m0 = 1 in the presence
of a fixed-effects intercept and m0 = 0 otherwise, and obviously mQ+1 = N .
For the case of a cell-means model without an intercept (which is a pseudo one-way
model) the formula simplifies to
νPB1 = N − n−mq + 1.
This is the DF for the interaction effect of treatments and time points which, however,
turns out to be too large for our longitudinal MCTs. On the other hand, the simplification
νPB2 = n−m
gives the DF for the treatment effect, and this is the DF we will use in the longitudinal
MCTs in Chapter 4.
Satterthwaite: The approximation suggested by Satterthwaite (1941 1946) is found
by matching first and second moments and is probably best known for appearing in
Welch’s t-test (Welch 1938, 1947), but has also been applied to fixed-effect tests in LMMs
(Giesbrecht and Burns 1985; Fai and Cornelius 1996). It does not only depend on the
experimental design (through the cell sample sizes nb) but also on the data itself through
the (estimated) cell variances σ2 = (σ21, . . . , σ
2
s):
νSatt =
(∑s
b=1
σ2b
nb
)2
∑s
b=1
(σ2b/nb)
2
nb−1
.
For homoscedastic data (i.e., constant σ2b ), νSatt is equal to νres; and with increasingly
heterogeneous variances over time (which are the same across treatments), νSatt tends to
νres
m
(Figure 8). If heterogeneity patterns were not restricted to be equal across treatment
groups, νSatt would tend to
νres
mq
for increasingly non-constant variances. The Satterthwaite
approximation is the basis for the Kenward-Roger method, which we will investigate in
more detail.
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Figure 8: Satterthwaite approximation to the degrees of freedom in a setup with q = 3 treatments,
m = 3 occasions, and 3 ≤ nk ≤ 10 subjects per treatment group under different configurations of
the variances.
Kenward-Roger: Kenward and Roger (1997) proposed a small-sample approximation
for testing (contrasts of) fixed effects from REML-based LMMs. They observed that
fixed-effect tests motivated by asymptotic theory may perform poorly when sample sizes
are small, and attributed this problem to two sources of bias:
1. The fact that the covariance matrix for the fixed effects is estimated from data and
not known introduces extra variability, which is not properly acknowledged for, as
shown by Kackar and Harville (1984).
2. The asymptotic estimator of the fixed-effect covariance matrix underestimates in
the presence of small samples, as discussed by Harville and Jeske (1992).
Kenward and Roger explained how both issues—which are nicely reviewed in a broader
context by Littell (2002)—can be straightened out using Taylor series expansions. Their
method entails more than an adjustment to the DF; it is a corrective that comes in three
parts:
1. a corrected (i.e., inflated) estimator of the fixed-effect covariance matrix that re-
moves both sources of bias mentioned above, which is then used to build a Wald-type
statistic F ;
2. a scaling factor λ that is estimated from the data and multiplied by the Wald
statistic F so that F ∗ = λF is approximately F -distributed with numerator DF z
(the number of contrasts) and denominator DF ν;
3. an approximation to ν obtained by matching first and second moments of the
Wald statistic F ∗ and its approximative distribution Fz,ν ; this is essentially a
Satterthwaite-type DF calculation on the corrected covariance estimate.
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In addition, Kenward and Roger tweaked their solution a little to ensure that it gets λ
and ν right (meaning “exact”) for two special cases with true F distributions, namely
the balanced one-way ANOVA and Hotelling’s T 2 test.
Extended derivations and results for the Kenward-Roger method are given by Alnosaier
(2007); among other things, he lists a number of conditions under which the DF are
identical to the Satterthwaite method because the corrected covariance matrix is equal
to the uncorrected one e.g., for all fixed-effects linear models but also many balanced
LMMs.
Kenward and Roger (2009) themselves provide an improved bias correction for the covari-
ance estimates under nonlinear covariance structures. Skene and Kenward (2010a) deal
with inference for fixed effects with repeated measurements in mixed models in the pres-
ence of tiny sample sizes: they propose replacing the fixed-effect covariance matrix with a
bias-adjusted sandwich estimator. However, this approach has seriously low power, which
they attempt to tackle with a modified Box correction (Skene and Kenward 2010b).
Effective sample size: Taking the number of independent units as sample size (as in
νnaive) is likely to underestimate the information provided by the data whereas taking
the total number of measurements (as in νres) probably overestimates it. The extent
of under- or overstating depends on the correlation among the repeated measures. To
obtain a well-balanced compromise for the amount of information available, a concept
worth considering is effective sample size (ESS), which is the size of a (hypothetical)
uncorrelated sample containing as much information as the correlated data at hand.
Faes et al. (2009) propose it as an instrument to approximate the DF with small samples.
In the general framework of an LMM, the ESS associated with the pth model parameter
βp is
n˜(βp) =
V̂ar(βˆp)
V˜ar(βˆp)
N∑
i=1
ni
where V̂ar(βˆp) is the pth element of the variances of βˆ
V̂ar(βˆ) =
(
N∑
i=1
XTi Σ
−1
i Xi
)−1
and V˜ar(βˆp) the pth element of
V˜ar(βˆ) =
(
N∑
i=1
XTi W
−1
i Xi
)−1
with Wi = diag(Σi).
They showed that calculation of the ESS simplifies e.g., when acting on the assumption
of an AR(1) structure, which is reasonable with longitudinal data. Then we get
n˜ =
n[m− (m− 2)ρ]
1 + ρ
where ρ is the AR(1) correlation coefficient; in practice ρ is estimated from the data
and plugged in. We can construct the ESS-based DF by replacing the total number of
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experimental units n (as in νnaive), or the total number of measurements N (as in νres),
by the effective sample size n˜:
νESS = n˜−mq.
Notice that νESS = νnaive with ρ = 1, and νESS = νres with ρ = 0 (Figure 9); these
special cases are, of course, unlikely to arise with real-world data.
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Figure 9: ESS approximation to the degrees of freedom in a setup with q = 3 treatments, m = 3
occasions, and 3 ≤ nk ≤ 10 subjects per treatment group under different values of the AR(1)
correlation parameter ρ.
Adjusted: We have designed an approximation that “adjusts” νnaive by adding a cor-
rection term that raises the DF with small sample sizes but vanishes as n grows large:
νadj = n−mq + m
2q2
n
.
This behavior can be seen from Figure 10: νadj ascends less steeply than the other DF
approximations with increasing nk. Note that the “adjustment” leading to νadj does not
have any profound theoretical background but rather arose empirically.
Whenever an approximation does not yield a whole-number DF (which can happen with
Satterthwaite/Kenward-Roger, ”adjusted”, and ESS), we round it down to the nearest
integer.
DFs for MMM: The residual DF associated with the jth marginal linear model is
ν(j)res = n
(j) − q(j)
where n(j) and q(j) are the numbers of independent units and treatment groups, respec-
tively, that are present at occasion j. A practicable approximation to the DF for a set of
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Figure 10: Comparison of different approximations to the degrees of freedom in a setup with
q = 3 treatments, m = 3 occasions, and 3 ≤ nk ≤ 10 subjects per treatment group.
occasion-wise comparisons of treatments is the minimum of the marginal models’ residual
DFs:
νmin = min
j
ν(j)res.
In case of substantial sample size imbalance over time, this DF will get conservative.
Alternatively, the average of the marginal models’ DFs could be used:
ν¯ =
1
m
m∑
j=1
ν(j)res.
For treatment-wise comparisons of occasions these approximations are rather poor; an ad
hoc alternative for the kth treatment group is
ν(k)res = nk − 1,
and the DF for the set of treatment-wise comparisons of occasions is again approximated
as the minimum (or average) of the ν
(k)
res.
Now we have assembled a variety of candidate DFs, and the question is which one(s) to
use for our longitudinal MCTs. A number of simulation studies have been conducted to
compare small-sample DFs under a multitude of conditions such as different covariance
structures, imbalance of the data, and varying sample sizes. The optimal choice is influ-
enced by the complexity of the covariance structure and the degree of imbalance, with
small sample sizes making the impact of a poor choice on the type I error rate more
severe; the results are usually very similar for moderate to large sample sizes.
Several studies showed the Kenward-Roger method to perform superior, or at least com-
parable, to other small-sample solutions under various data conditions e.g., by Guerin
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and Stroup (2000), Schaalje et al. (2002), Spilke et al. (2004, 2005), Alnosaier (2007),
and Arnau et al. (2009). Nonetheless, inflation of the type I error rate has been reported
for Kenward-Roger as well, particularly with very small samples and imbalance e.g., by
Schaalje et al. (2002), Valderas Gomez et al. (2005), and Gregory (2011). We will evaluate
the usefulness of various DF approximations for longitudinal MCTs with small sample
sizes numerically in Chapter 4.
3.9 Power
The power 1 − β of a hypothesis test is the probability of correctly rejecting H0. This
definition is straightforward for single tests; for a multiple comparison procedure (MCP),
however, it is far from obvious what “the power” is. Indeed there exist various notions
of power in the context of multiple testing; see e.g., Hochberg and Tamhane (1987, p.
129) or Horn and Vollandt (1998). We introduce here four widely adopted MCP power
definitions in a nutshell.
We consider two-sided MCTs composed of elementary null hypotheses Hh0 : ηh = δh, h =
1, . . . , z stating that some linear combination of means, ηh, is equal to a pre-defined
margin, δh. The global null hypothesis H0 =
⋂b
h=1H
h
0 is the intersection of elementary
nulls. We let A = {h : HhA : ηh 6= δh} denote the subset of contrasts that are truly
under the alternative. Further we let Th denote the test statistic corresponding to the
hth hypothesis and t an appropriately chosen critical point from a reference distribution
such as multivariate t.
Per-pair power: P (|Th| > t | h ∈ A)
The probability of rejecting a Hh0 for which the corresponding contrast ηh is truly under
the alternative. This is a special case of the per-subset power (Einot and Gabriel 1975),
and larger subsets than pairs are easily conceivable (triplets, quadruplets, . . . ).
Any-pair power: P (∃ h ∈ A : |Th| > t)
The probability of rejecting at least one Hh0 for which the corresponding contrast ηh is
truly under the alternative (Ramsey 1978). Any-pair power is also called minimal power
(e.g., Westfall et al. 2011) or disjunctive power (Senn and Bretz 2007).
All-pairs power: P (|Th| > t ∀ h ∈ A)
The probability of simultaneously rejecting all Hh0 for which the corresponding contrasts
ηh are truly under the alternative (Ramsey 1978). Other names for all-pairs power are
complete power (e.g., Westfall et al. 2011) and conjunctive power (Senn and Bretz 2007).
Global power: P (∃ h : |Th| > t)
The probability of rejecting at least one Hh0 , no matter if the corresponding contrast
ηh (or, in fact, any contrast) is truly under the alternative (e.g., Hayter and Liu 1992).
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Power according to this definition is “contaminated” with type I errors from contrasts
that are truly under the null.
For one-sided tests there is the additional problem of incorrect directional decisions,
sometimes called type III errors (Harter 1957), but this is usually negligible unless the
effects are very close to zero.
3.10 Missing Data
3.10.1 General Problem
Missing values are observations that were not recorded but should have been. Data points
may be missing intermittently (e.g., due to failure of recording values because of technical
errors) or there can be dropout towards the end (e.g., due to death or loss of follow-up in
clinical studies). In longitudinal setups, incomplete measurements are the rule and not
some curious exception. Thus any method that cannot handle missings in a proper way
is practically very limited.
When pondering whether a method yields valid estimates and inferences in the presence
of incomplete data, it is crucial to consider the underlying missingness process i.e., the
reason why certain data points are unavailable. When ignoring this, a data analyst may
easily run into trouble and obtain biased estimates, underestimate SEs, lose control over
type I error rates and coverage probabilities, or impair the power of a test.
Key questions to be asked are: can the observed data be regarded a random subsample of
the (hypothetical) complete data? And: how is a data point’s probability to be missing
related to observed and unobserved values? Unfortunately, the missingness process is
usually unknown and cannot be made out from the data. Therefore it can be wise to
avoid all too restrictive assumptions about the causes of missingness.
The standard classification of missingness mechanisms that dates back to Rubin (1976) is
recapitulated subsequently, followed by a brief review of various techniques how to handle
missing data in practice.
3.10.2 Missingness Mechanisms
We denote the (intended) complete set of measurements for the ith individual by
Yi = (Yi1, . . . , Yim)
T
and assign response indicators
Rij =
{
1 if Yij is observed,
0 if Yij is missing
that can be summarized in an indicator vector
Ri = (Ri1, . . . , Rim)
T ,
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and divide Yi into observed and missing values:
Yi = (Y
O
i , Y
M
i )
T .
To draw a distinction between three general mechanisms of missingness, we adopt the
nomenclature in Little and Rubin (2002):
Missing completely at random (MCAR): The probability to be missing depends
neither on the observed values nor on the unobserved ones:
P (Ri|Y Oi , Y Mi , Xi) = P (Ri|Xi).
Missing at random (MAR): The probability to be missing is independent of the
unobserved values, conditional on the observed ones:
P (Ri|Y Oi , Y Mi , Xi) = P (Ri|Y Oi , Xi).
Not missing at random (NMAR): The probability to be missing cannot be assumed
independent of the observed and unobserved values:
P (Ri|Y Oi , Y Mi , Xi).
One should not be confused by the somewhat deceptive terminology: MAR involves a
good deal of what could be perceived as “non-randomness” in everyday speech. Similarly,
MCAR and MAR are sometimes called “ignorable” missingness, in contrast to the term
“non-ignorable” for NMAR. These names are clearly misleading in the sense that they
suggest one need not bother about the missingness process. In fact, “ignorability” means
that when adopting a direct likelihood approach (see 3.10.3), one does not have to model
the missingness process explicitly.
3.10.3 Remedies
It is obvious that a valid missingness method should yield consistent estimates, and
resulting tests should have correct size unter H0. Various solutions have been proposed
to deal with the problem of missing values, among them many ad hoc approaches that
are at best inefficient and at worst seriously flawed. On the other hand, better solutions
can be computer-intensive—or, as a matter of fact, super-simple. We will review a few of
the most popular strategies for coping with incomplete data and reveal their strengths,
limitations, and pitfalls.
Many missing data techniques involve some form of imputation, which can be described
as sort of a “repair method” for datasets with missing values. A dataset is “completed”
by filling the gaps in the original data with “plausible” values. Then the suchlike im-
puted data set is analyzed as though there had been no missings, or with appropriate
modifications. The usefulness of the results patently depends on the definition of what
is considered a “plausible” value, and whether additional uncertainty is accounted for.
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Last value carried forward (LVCF): For every subject, missing entries are filled by
inserting the last observed value before the gap. This is probably the most detrimental
strategy around since it is prone to be biased even under MCAR, and the bias may go
either upwards or downwards (Molenberghs et al. 2004). The condition necessary for
LVCF to yield consistent estimates under MCAR (i.e., that the value remains constant
after dropout) is hardly ever met in practice. In addition, the approach suffers from
unduly low SE estimates. Contrary to common belief, LVCF does not necessarily lead
to conservative inferences. Related approaches such as carrying the baseline forward or
carrying the “worst” value forward are equally bad.
Single mean imputation: This method comes in two variants. The simpler one is to
fill gaps in the dataset with the unconditional (arithmetic) mean of the observed values
of a variable. In a refined version, imputation values are estimated conditionally as
predicted means from regression on the other variables using only complete cases (Buck
1960). Both versions require MCAR, and SEs are likely to be underestimated.
Single (stochastic) imputation (SI): For each missing data point one imputation
value is randomly drawn from
f(Y Mi |Y Oi , Xi)
i.e., from the conditional distribution of missing values given the observed values and
covariates. The process of imputation, however, gives rise to an additional source of
uncertainty which must be accounted for in the analysis. Deriving an analytical expression
for the SE can become inutterably complicated.
Multiple (stochastic) imputation (MI): This difficulty of SI can be overcome by
repeatedly imputing values and evaluating each of these “completed” datasets. Several
imputation values are drawn from
f(Y Mi |Y Oi , Xi)
for each missing entry, thus generating a series of “completed” datasets, each of which
is evaluated and then the results are combined in a thoughtful manner. This makes it
straightforward to incorporate the uncertainty associated with imputation. MI techniques
are most valuable when both response values and covariates are missing. A widely applied
MI technique is multivariate imputation by chained equations (Rubin 1987; van Buuren
and Groothuis-Oudshoorn 2011; van Buuren 2012). Imputation is performed v times,
thereby creating v “filled-up” datasets, each of which is evaluated separately to obtain
estimates βˆ(a) for a = 1, . . . , v. In a last step, the v results are combined adequately. The
combined estimate is the unweighted average
βˆ = β¯ =
1
v
v∑
a=1
βˆ(a),
and the combined estimated covariance is
Ĉov(βˆ) = W + (1 +
1
v
)B.
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This captures within-imputation variability
W =
1
v
v∑
a=1
Ĉov
(
βˆ(a)
)
as well as variability between imputations
B =
1
v − 1
v∑
a=1
(βˆ(a) − β¯)(βˆ(a) − β¯)T .
MI yields valid results under the assumption of MAR, and thus as well when MCAR is
assumed.
Apart from these imputation-based methods, there are also approaches that do not require
the gappy data to be completed with “plausible” values.
Complete case analysis: All subjects with missing observations are removed i.e., only
completers are included in the analysis. This requires MCAR for obtaining unbiased es-
timates, but even under that assumption it is obviously inefficient to throw away data,
in particular if relatively many subjects have relatively few missing entries. As a conse-
quence, SEs will be unnecessarily large, CIs too wide, and p-values too high. The bias
under MAR can go in either direction (Molenberghs et al. 2004; Kenward and Roger
2009).
Available case analysis: The data are used as they are i.e., neither are parts of the
data deleted (as with the complete case analysis) nor filled up artificially (as with impu-
tation methods). Although stunningly simple, this is a valid approach under both MAR
and MCAR if the joint distribution of responses is modeled with a full likelihood (e.g.,
using an LMM), and both means and within-subject association are correctly specified
in the model. Laird (1988) and Kenward and Molenberghs (1998) pointed out that the
covariance of βˆ has to be estimated from the observed and not the expected information
matrix.
There are other techniques for coping with missingness that lead to utilizable results
under M(C)AR but will not be discussed here in depth e.g., inverse probability weighting
(Seaman and White 2013) or predictive mean matching (Rubin 1986; Little 1988). In
case of MNAR, the missingness process has to be included, which is achieved by jointly
modeling Yi and Ri e.g., by using a selection model or pattern mixture model (Kenward
and Molenberghs 1999).
In practice it is often helpful to resort to methods that deal with missingness in a natural
way, such as joint modeling with LMMs. There is a wealth of simulation studies that
advise to use an LMM (or MI) and warn against naive approaches like complete case
analysis or LVCF (Mallinckrodt et al. 2001ab; Liu and Gould 2002; Mallinckrodt et al.
2004; Molenberghs et al. 2004; Beunckens et al. 2005; Barnes et al. 2008; Siddiqui et al.
2009). Siddiqui (2011) further claims that the full likelihood model is preferable to MI.
The MMM approach corresponds to an available case analysis per time point, but there
is no joint likelihood involved for the entire set of data. Therefore it can lead to bias in
the case of MAR. GEEs do not specify a full likelihood either and suffer from the same
drawback under MAR.
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4 Longitudinal MCTs with Gaussian Endpoints
Biological and medical research frequently generates continuous outcome variables for
which it is reasonable to assume that the observed values are symmetrically distributed
and tend to accumulate around their mean, and also that the variance is independent of
the mean. These attributes in their entirety suggest the assumption of a Gaussian dis-
tribution for the data, which paves the way for a wealth of statistical analysis techniques
to be applicable.
If the task is to compare multiple means of Gaussian data from uncorrelated samples (e.g.,
due to randomization in controlled experiments), standard MCTs using parameter and
variance estimates from a classical linear model are straightforward (see 3.7). Matters
become more intricate as soon as not all samples involved are stochastically independent
e.g., because of experimental units being measured repeatedly at consecutive points in
time.
We present and compare two competing modeling strategies for such data: the first one
is to fit a joint model (an ELM, a CIM, or some more general LMM) that captures all
observations at all occasions; the alternative is to fit one marginal model per occasion and
thereupon combine them so as to derive the joint correlation across time points. Either
modeling approach can be used to estimate mean parameters and covariances for use in
a subsequent MCT procedure.
We develop a unified framework for multiple hypothesis tests and SCIs in setups with
dependency structures. Specifically, we apply MCTs to arbitrary linear contrasts of
correlated means under heteroscedasticity. In the presence of large samples we can rely
on asymptotic theory; the crunchpoint is how to get (approximately) valid simultaneous
tests and SCIs with small sample sizes. This is practically relevant in many fields of
application but still a more or less open question to date. We aim to tweak MCTs for
the sake of proper type I error rate control with small sample sizes, evaluate the power
of longitudinal MCTs based on joint and multiple marginal models and quantify the
superiority over Bonferroni-style adjustments.
This chapter is structured as follows: we develop and characterize simultaneous compar-
isons of multiple treatment means at several occasions in 4.1, and simultaneous compar-
isons of multiple occasion means within several treatment groups in 4.2. Then the next
step is to hybridize them: in 4.3 we discuss strategies how comparisons of both types can
be amalgamated in one and the same family under FWER control. Examples of real-
data analyses showing the proposed methods in action are presented in 4.4. Approximate
power calculations for longitudinal MCTs with Gaussian outcomes are presented in 4.5.
4.1 Comparing Multiple Treatments at Multiple Occasions
We start with simultaneous inference for several treatment groups at each of several points
in time. The desire to protect an FWER over the entire set of elementary hypotheses
requires us to account for the multiplicity of treatments as well as occasions. On the
other hand, the longitudinal correlation of occasions can be exploited to cushion the con-
servatism of the procedure compared to a Bonferroni adjustment. We show in 4.1.1 how
different modeling strategies may be employed to estimate parameters for subsequent
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multiple contrast testing and construction of SCIs so that we can pinpoint interesting
effects with (approximate) control of α. A short numerical illustration of how the longi-
tudinal correlation influences the correlation matrix of test statistics in the longitudinal
MCT is given in 4.1.2. Results of α and power simulations are presented in 4.1.3.
4.1.1 Procedure
Suppose we have a random variable Yjki that describes a Gaussian outcome measured
from independent individuals i = 1, . . . , nk in randomized treatment groups k = 1, . . . , q
at repeated occasions j = 1, . . . ,m. The realizations of Yjki are denoted by yjki. There
are n =
∑q
k=1 nk independent units, and the total number of observations is N , which
equals mn if all subjects are measured at all occasions (i.e., no missing values). The
combinations of occasions and treatment groups are indexed with b = 1, . . . , s where
s = mq.
To reflect the data’s mean structure, variability, and dependencies among repeated mea-
surements in a model framework, we may take either of two basic modeling approaches:
joint modeling with an LMM (as outlined in 3.1), or a combination of marginal linear
models (as in 3.5). Both approaches provide us with estimates of β and Σ that we can use
for simultaneous inference about the fixed-effects parameters in our longitudinal MCTs.
Joint modeling: We focus on two basic types of joint models that are special cases of
our general LMM notion:
• an extended linear model (ELM) where the residuals may exhibit correlation and
heteroskedasticity over time and possibly also across treatment groups, or
• a conditional independence model (CIM) that assumes constant residual variance
and independent errors, conditional on the random effects.
Whichever LMM we fit, the fixed effects will be parameterized in cell means style i.e.,
one mean parameter for every combination of treatment group and occasion. This entails
maximum flexibility for all shapes of means across time and treatments. The cell means
design matrix (for complete and balanced data without additional covariates) is
X = Imq ⊗ 1nq
where I is an identity matrix and 1 is a column vector of ones. Handling incompleteness
and including covariates is straightforward.
Considerably harder is the choice of a covariance structure for the joint model. The
CIM requires to model random effects that reflect the dependencies among repeated
measurements. With the simplest random subject effects, the random-effects design
matrix (for complete and balanced data without additional random factors) is
Z = 1q ⊗ In.
If we allow for occasion-specific random subject effects, it becomes
Z =
 1q ⊗ e1...
1q ⊗ em

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where ej is the jth unit vector of size m. Likewise, we could make the random sub-
ject effects both occasion- and treatment-specific, but this might already run us into
computational trouble when actually trying to fit the model.
Many practical experiments are more complex and contain additional hierarchies e.g., the
subjects might be hospitalized in different clinics (if they are patients), live in different
cages (if they are lab animals), or belong to different spatial blocks (if they are plants
in the field). The CIM can smoothly incorporate the hierarchical architecture of the
experiment via random effects.
In the ELM framework we are required to make two choices as the residual covariance
matrix is assembled from a variance portion and a correlation portion; we described a
variety of possible choices in 3.1. In case we decide to fit an LMM that includes both
random effects and some residual covariance structure, the agony of choice intensifies.
If unsure about which is the most appropriate model—and this should really be the
standard situation—a reasonable option is to let an information criterion do the job. So
having assembled several plausible models for the random effects and/or residual covari-
ances, we entrust AICc (see 3.2) with picking the “best” of them. We must keep in mind,
however, that AICc (or any other information-based criterion) judges the “goodness” of
a model relative to its competitors in the candidate set. It says nothing about whether
it is good in an absolute sense—it might just be the best in a set of terrible models.
Multiple marginal models: The other strategy is to fit one linear model separately
for every measurement occasion j = 1, . . . ,m. The jth of these marginal models is
y(j) = X(j)β(j) + (j)
where the superscript index signalizes belonging to occasion j. The design matrix X(j)
needs to be arranged such that there is one parameter for each of the treatments’ means,
and possible covariates4. The dependency structure across time points is established from
−E
(
1
σ2
X(j)X(j)T
)−1
X(j)
(
y(j) −X(j)Tβ(j)
)
as described in 3.5 and Pipper et al. (2012).
Multiple Contrast Tests: Whatever modeling approach (ELM, CIM, some other
LMM, or marginal models) has provided us with estimates of β and Σ, we continue
with simultaneous inference under the assumption of the βˆ being multivariate normal
and Σˆ a consistent estimator of Σ.
We define the comparisons of interest in a coefficient matrix C. Assume the model
parameterization is such that all treatment means at the first occasion come first, followed
by the treatment means at the second occasion, and so on. Then the coefficient matrix
is block-diagonal and can be constructed as the Kronecker product of an m-dimensional
identity matrix and an “elementary” coefficient matrix C0 as
C = Im ⊗C0.
4The covariates may, at least in principle, even differ between models.
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As an example, the full contrast coefficient matrix for many-to-one comparisons among
q = 3 treatment groups separately and simultaneously at m = 4 occasions is
CtrtDun = I4 ⊗CDun
=

1 0 0 0
0 1 0 0
0 0 1 0
0 0 0 1
⊗ [ −1 1 0−1 0 1
]
=

−1 1 0 0 0 0 0 0 0 0 0 0
−1 0 1 0 0 0 0 0 0 0 0 0
0 0 0 −1 1 0 0 0 0 0 0 0
0 0 0 −1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 −1 1 0 0 0 0
0 0 0 0 0 0 −1 1 0 0 0 0
0 0 0 0 0 0 0 0 0 −1 1 0
0 0 0 0 0 0 0 0 0 −1 1 0

.
The subsequent computation of MCTs i.e., adjusted p-values and SCIs, is to a great
extent identical to the standard MCT procedure described in 3.7, albeit with one cru-
cial difference: the correlation matrix of the test statistics no longer contains just known
quantities (sample sizes and contrast coefficients) but also covariances reflecting the longi-
tudinal correlation and possible heteroscedasticity in the repeated measurements. These
covariances are a priori unknown, and we get by with plugging in their estimates from
MMM or a joint model, which makes our longitudinal MCT procedure approximate.
By means of the coefficients in C we formulate contrasts
ηh =
s∑
b=1
chbβb
and use them to specify a set of elementary linear hypotheses, the hth pair of which (for
two-sided inference) is
H
(h)
0 : ηh = δh versus H
(h)
A : ηh 6= δh
where more often than not δh = 0 ∀ h. The hth test statistic is computed as
Th =
ηˆh − δh√
chΣ̂cTh
with estimated contrast
ηˆh =
s∑
b=1
chbβˆb.
The exact distribution of T under H0 is unclear but may be approximated as z-variate t
with ν DF and correlation Γ˜:
T
appr.∼ Tz(ν, Γ˜).
It is not straightforward to see what the DF should be in general, and especially not in the
presence of unbalanced data e.g., when numbers of repeated observations differ between
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experimental units. A whole range of possible DF approximations for small samples were
listed in 3.8.
The asymptotic distribution of T is z-variate normal with correlation Γ˜:
T
asym.∼ Nz(0, Γ˜).
Details on the multivariate normal and t-distribution are given in Appendix A. We will
explore the performances of both the asymptotic and the approximate procedure with
different DF approximations in a simulation study in 4.1.3.
The covariance matrix of test statistics T = (T1, . . . , Tz) under H0 is
Σ˜ = CΣCT
so that we obtain Γ˜ as
Γ˜ = VΣ˜V
where V = diag(Σ˜)−
1
2 is the inverse of a matrix with the square root of the diagonal
elements from Σ˜ on its diagonal and all off-diagonal elements zero. As Σ is unknown in
practice, we plug in a consistent estimate Σ̂ (from a joint model or the MMM approach)
so as to get ̂˜Σ and ̂˜Γ.
An elementary hypothesis H
(h)
0 gets rejected if
|Th| > ttwoz,1−α(ν, ̂˜Γ)
with ttwoz,1−α(ν,
̂˜Γ) the two-sided equicoordinate (1 − α) quantile of Tz(ν, ̂˜Γ). Bounds of
SCIs with coverage probability 1− α are obtained as
ηˆh ∓ ttwoz,1−α(ν, ̂˜Γ)√chΣ̂cTh .
Adjusted p-values are given by
ph = 1−
∫ |T obsh |
−|T obsh |
. . .
∫ |T obsh |
−|T obsh |
tz(x; ν,
̂˜Γ) dx
where T obsh designates an observed value of the test statistic Th, and tz(x; ν,
̂˜Γ) is the PDF
corresponding to Tz(ν, ̂˜Γ). The z-dimensional integral needs to be solved numerically e.g.,
using a software implementation of the Genz-Bretz algorithm (Genz and Bretz 2009).
Since the global null hypothesis is the intersection of elementary nulls
H0 =
z⋂
h=1
H
(h)
0
we reject the global H0 if at least one of the H
(h)
0 is rejected. This implies a maximum-type
test with test statistic
Tmax = max
h
|Th|
whose p-value is computed as
p = min
h
ph.
One-sided testing problems are addressed in a similar fashion; see e.g., Bretz et al. (2010).
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4.1.2 Numerical Illustration
Imagine the simple case of n experimental units randomized to q = 2 treatments called
A and B, and some continuous outcome is measured twice from each of them (m = 2), at
two different points in time. Assume that observations are independent across treatments
(due to randomization) but correlated across time points (due to repeated measurements)
with covariance matrix
Σ =
[
1 0.9
0.9 1
]
for both treatments A and B. We are interested in comparisons of treatments A and B in
a cell means model sseparately and simultaneously for occasions 1 and 2, requiring the
coefficient matrix
C2 =
[ −1 0 1 0
0 −1 0 1
]
.
The covariance matrix of the cell means model is
Λ2 = I2 ⊗Σ =

1 0.9 0 0
0.9 1 0 0
0 0 1 0.9
0 0 0.9 1
 .
Note that the means we want to compare (µA1 vs. µB1 and µA2 vs. µB2) are indeed
uncorrelated! The two test statistics, however, are not:
Σ˜2 = C2Λ2C
T
2 =
[
2 1.8
1.8 2
]
.
Standardizing Σ˜2 by its diagonal elements gives the correlation matrix
Γ˜2 = diag(Σ˜2)
− 1
2 Σ˜2 diag(Σ˜2)
− 1
2 =
[
1 0.9
0.9 1
]
.
The identity Γ˜ = Σ is of course not true for general Σ and C.
Extending the case to q = 3 treatment groups shows how the longitudinal MCT puts
figures to the “off-diagonal blocks” of Σ˜ that are occupied by zeroes in standard MCTs.
Suppose we want to carry out many-to-one comparisons among treatments A, B, and C
separately and simultaneously for occasions 1 and 2, using the coefficient matrix
C3 =

−1 0 1 0 0 0
−1 0 0 0 1 0
0 −1 0 1 0 0
0 −1 0 0 0 1
 .
The model covariance matrix is
Λ3 = I3 ⊗Σ =

1 0.9 0 0 0 0
0.9 1 0 0 0 0
0 0 1 0.9 0 0
0 0 0.9 1 0 0
0 0 0 0 1 0.9
0 0 0 0 0.9 1
 ,
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so again the means to be compared are uncorrelated. The covariance matrix of test
statistics
Σ˜3 = C3Λ3C
T
3 =

2 1 1.8 0.9
1 2 0.9 1.8
1.8 0.9 2 1
0.9 1.8 1 2

has got non-zero elements in the “off-diagonal blocks”, and so does the correlation matrix
Γ˜3 = diag(Σ˜3)
− 1
2 Σ˜3 diag(Σ˜3)
− 1
2 =

1 0.5 0.9 0.45
0.5 1 0.45 0.9
0.9 0.45 1 0.5
0.45 0.9 0.5 1
 .
We see how the longitudinal correlation “propagates” to the correlation matrix of test
statistics and at the end of the day makes the test less conservative than Bonferroni.
4.1.3 Simulation Study
Our methods have asymptotically correct size when using the multivariate normal refer-
ence distribution, and are only approximate with the reference distribution being mul-
tivariate t; therefore we are interested in their actual behavior especially with small to
moderate sample sizes as they are common in biological and clinical practice. We in-
vestigate via simulation what sizes of samples are required for the asymptotic procedure
to achieve acceptable performance. Then we study the small-sample variant using an
approximation to the DF. The fact that there is no generally “correct” DF leads to un-
certainty about which approximation to use in practice. We undertake simulations to
assess the performance of a number of DFs numerically. Furthermore, we compare the
powers of longitudinal MCTs based on joint models and MMM with that of simplistic
Bonferroni-type procedures.
Type I error: To assess the behavior of the asymptotic procedures, we consider bal-
anced settings with q = {3, 4, 5} treatment groups, m = {3, 4, 5} time points, and
nk = {10, 20, . . . , 120} subjects per group with longitudinal observations being corre-
lated and heteroscedastic over time. Simulation data for each treatment group are drawn
from an m-variate normal distribution Nm(µ,Λ) with mean vector µ = (10, . . . , 10) and
joint covariance matrix
Λ = ABA
where B = (ρjj′), j 6= j′ is an m×m Toeplitz matrix with elements ρjj′ = 1− |j−j′|10 that
is pre- and postmultiplied by A = diag(
√
1,
√
2, . . . ,
√
m). With m = 4, for instance, this
yields
Λ =

1 1.27 1.39 1.40
2 2.20 2.26
3 3.12
4
 .
We simulate 5000 datasets under H0 and carry out many-to-one (Dunnett), all-pairwise
(Tukey), or grand-mean (ANOM) comparisons among treatments per measurement oc-
casion for two-sided hypotheses using parameter and covariance estimates obtained from
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a) a joint ELM assuming AR(1) correlation and heterogeneous variances over time,
b) a joint CIM with occasion-related random subject effects,
c) the combination of marginal occasion-specific linear models,
and check for each of them whether the minimum adjusted p-value is less than the nominal
α = 0.05 bound.
The simulation results are displayed in Figure 11. The type I error rates of all methods are
slightly inflated to around 7 to 8% with nk = 10 but level off at the nominal 5% once the
sample sizes exceed 30 or 40. This holds true for many-to-one, all-pairwise, and grand-
mean comparisons. Varying the number of treatment groups seems to have no influence
on the achieved test sizes whatsoever. However, when the number of occasions increases
(which raises the overall heteroscedasticity in our simulation setting), the CIM-based
tests become conservative, probably indicating that the simple random-effects structure
is not adequate.
Having seen that at least 30 to 40 subjects per group are necessary for the asymptotic
procedure to keep the type I error rate, we study the small-sample properties of the
approximate procedure with different DFs for the multivariate t-distribution. The simu-
lation setup is identical to the asymptotic one, with the only difference that we reduce the
sample size per treatment to nk = {4, 6, 8, 10, 12, 14}. Then we fit models as described
above and compute longitudinal MCTs using
• νnaive, νESS, νadj, νPB, and νres as DF approximations for the joint ELM with AR(1)
correlation and heterogeneous variances over time,
• the same DF methods and additionally νKR for the CIM with occasion-related
random subject effects, and
• the minimum νres of all marginal models for MMM.
So in total each simulation dataset is evaluated twelve times, and we record for each
evaluation the number of rejections of the global H0.
Results from 5000 simulation runs are displayed in Figure 12. Unsurprisingly, the residual
DF, when applied to a CIM or an ELM, provokes liberal test decisions with type I error
rates of 10% and above in the presence of small sample sizes; on the other hand, the
naive DF makes the test severely conservative with almost no power for nk ≤ 6. So quite
predictably, νnaive and νres act as boundaries for the remaining DFs.
All CIM-based tests are more conservative (or less liberal) than their ELM counterparts
using the same DF approximation, especially for m > 3. A similar behavior could be
observed in the asymptotic simulations as well.
The Pinheiro-Bates DF performs excellent even when nk is very small. The DF based
on the ESS is conservative for nk ≤ 8 but comes very close to the nominal α of 0.05 as
the sample size increases. The Kenward-Roger method for the CIM performs very well
in most situations and only gets a little conservative with m = 4 and m = 5, but this is
probably due to the CIM and not the DF itself. Our own “adjusted” DF does a fairly
good job across most scenarios but not substantially better than other DFs. The MMM
approach also comes very close to a size of 5% even with the smallest sample sizes and
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Figure 11: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons among q = {3, 4, 5} Gaussian treatment means separately and simultaneously
at m = {3, 4, 5} occasions, with nk independent subjects per treatment group (5000 simulation
runs).
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Figure 12: Simulated type I error rates for many-to-one, all-pairwise, and grand-mean compar-
isons among q = {3, 4, 5}Gaussian treatment means separately and simultaneously atm = {3, 4, 5}
occasions, with nk independent subjects per treatment group, and different small-sample degrees
of freedom (5000 simulation runs).
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shows consistently good control of α across all simulated setups. There are no sailent
discrepancies between many-to-one, all-pairwise, and grand-mean contrasts.
Power: Now that we have figured out sample sizes nk that ensure α is kept for the
asymptotic procedures based on either joint or multiple marginal models, and also de-
tected DF approximations that work well for small sample sizes, one may wonder if the
methods differ in terms of statistical power. Another relevant question is whether ap-
proximating the joint distribution of test statistics as multivariate t is actually worth the
effort. Or asked differently, how much worse (in terms of power) is a simple foolproof
solution like calculating MCTs occasion-wise, or even pairwise z- or t-tests, followed by
a Bonferroni adjustment?
We focus our asymptotic power investigations on many-to-one, all-pairwise, and grand-
mean comparisons of q = {3, 4, 5} groups simultaneously for m = {3, 4, 5} time points
and nk = 100. Simulation data are drawn similar as for the α simulations, but now we
mimic a treatment effect in one non-control group that arises only at the last time point.
Thus, for one of the treatments the mean vector is now µ = (µ, . . . , µ, µ+ ∆) with non-
centralities ∆ = {0, 0.1, . . . , 1.5}. This leads to a scenario with exactly one many-to-one
and one grand-mean comparison being under HA; the number of all-pairwise tests under
the alternative is q − 1.
We generate 1000 datasets for each combination of parameter values and evaluate them
fivefold:
1. Calculate standard z-tests for all single comparisons and adjust the resulting p-
values with Bonferroni. This means turning a blind eye to any correlations among
test statistics.
2. Perform an (asymptotic) MCT within each time point and adjust via Bonferroni
for the multiplicity of time points. This approach incorporates the portion of cor-
relation that originates from multiple test statistics being built with overlapping
subsets of β̂, but ignores the correlation among time points.
3. Base the longitudinal MCT on a joint CIM with occasion-depending random subject
effects.
4. Base the longitudinal MCT on a joint ELM with variance heterogeneity and AR(1)
correlation on the residual covariance matrix.
5. Fit multiple occasion-specific marginal models and combine them with the MMM
method to obtain joint covariance estimates for use in a longitudinal MCT.
Strategies 3 to 5 account for correlations among both time points and test statistics.
The empirical curves of global power i.e., the probability of rejecting at least one ele-
mentary H0, are shown in Figure 13 (in most panels the blue, brown, and green curves
overlap, and so do the gray and pink ones). All three methods that acknowledge de-
pendence among repeated measurements have clearly superior power compared to the
Bonferroni-corrected t-tests and MCTs. This may not strike the eye at first sight, but
the vertical distances between the curves indicate a power advantage of 7 to 8 percentage
points at the steepest point near ∆ = 0.7. The power curves for joint and marginal
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models-based MCTs are almost indistinguishable in the majority of cases; only the CIM-
based comparisons of treatments per occasion prove again somewhat conservative as
the number of occasions increases. The power advantage of Bonferroni-corrected single
MCTs over Bonferroni-corrected single t-tests is marginal (around 1%) throughout the
simulation settings.
All power considerations up to this point assumed a true underlying Toeplitz correlation
with ρ1 = 0.90 for adjoining measurements, then ρ2 = 0.80, etc. Now we want to
shed light upon the actual impact of longitudinal correlation on the powers of joint and
marginal model-based MCTs. For q = 3 treatments and m = 3 occasions, we investigate
four different correlation patterns:
B1 =
 1 0.95 0.901 0.95
1
 , B2 =
 1 0.90 0.801 0.90
1
 ,
B3 =
 1 0.80 0.501 0.80
1
 , B4 =
 1 0.50 0.201 0.50
1
 .
The corresponding power curves are displayed in Figure 14 (again we see lots of over-
lap just like before). We recognize that the power advantage of both joint and multiple
marginal models-based MCTs over Bonferroni-type adjustments increases with the cor-
relation among occasions. The power gain when accounting for longitudinal dependence
is actually negligible unless ρ1 ≥ 0.9. Across all settings considered, the ELM assuming
AR(1) and MMM perform nearly identically whereas the CIM can have slightly lower or
higher power, depending on the correlation ρ; this is again indication of the conditional
independence assumption being not quite appropriate in these cases.
The simulation setting for the small-sample power is similar to the asymptotic one, but
now exact rather than asymptotic tests are used for the Bonferroni-corrected methds (i.e.,
separate t-tests instead of z-tests, and separate MCTs that have a multivariate t reference
distribution instead of multivariate normal), and we use small-sample adjustments for
our longitudinal MCTs: νPB with the joint ELM, νKR with the joint CIM, and the
minimum νres of the marginal models for MMM. We consider true treatment differences
of ∆ = {0, 0.2, . . . , 4} in one group at one point in time in settings with nk = 10.
The overall picture of the simulation results shown in Figures 60 and 61 in Appendix
D is very similar to that of the asymptotic procedure. The power curves of all methods
that incorporate longitudinal correlation are very alike, and the power advantage over
Bonferroni-type adjustments grows with the number of occasions and with the strength
of the longitudinal correlation.
4.2 Comparing Multiple Occasions within Multiple Treatments
Having developed a procedure for multiple comparisons of treatments at several occasions
in 4.1, we now change direction and go into multiple comparisons of occasions within
several treatment groups. We expound the method, which is indeed very similar, in
4.2.1, and illustrate it numerically in 4.2.2. Simulation results under H0 and HA are
presented in 4.2.3 for both the asymptotic and the small-sample procedures.
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Figure 13: Simulated powers for asymptotic many-to-one, all-pairwise, and grand-mean compar-
isons among q = {3, 4, 5}Gaussian treatment means separately and simultaneously atm = {3, 4, 5}
occasions, with nk = 100 independent subjects per treatment group (1000 simulation runs).
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Figure 14: Simulated powers for asymptotic many-to-one, all-pairwise, and grand-mean compar-
isons among q = 3 Gaussian treatment means separately and simultaneously at m = 3 occasions,
with nk = 100 independent subjects per treatment group, and different longitudinal correlations
(1000 simulation runs).
4.2.1 Procedure
The modeling step for comparisons of occasion means within several treatment groups is
the same as described in 4.1.1: we may either fit a joint model embracing all time points
(or fit several candidate joint models and hand them over to AICc), or m occasion-
specific marginal models and then combine them with the MMM method to devise the
joint correlation over time. Having obtained model estimates of both β and Σ, we
can continue with simultaneous inference. The coefficient matrix C for the MCT is
4 LONGITUDINAL MCTS WITH GAUSSIAN ENDPOINTS 61
conveniently built as the Kronecker product of an “elementary” coefficient matrix and a
q-dimensional identity matrix as
C = C0 ⊗ Iq.
We exemplify this for Dunnett-type comparisons of m = 4 occasions separately and
simultaneously within m = 3 treatment groups and get
CoccDun = CDun ⊗ I3
=
 −1 1 0 0−1 0 1 0
−1 0 0 1
⊗
 1 0 00 1 0
0 0 1

=

−1 0 0 1 0 0 0 0 0 0 0 0
0 −1 0 0 1 0 0 0 0 0 0 0
0 0 −1 0 0 1 0 0 0 0 0 0
−1 0 0 0 0 0 1 0 0 0 0 0
0 −1 0 0 0 0 0 1 0 0 0 0
0 0 −1 0 0 0 0 0 1 0 0 0
−1 0 0 0 0 0 0 0 0 1 0 0
0 −1 0 0 0 0 0 0 0 0 1 0
0 0 −1 0 0 0 0 0 0 0 0 1

.
The remainder of the MCT procedure is along the lines of what we described for com-
parisons among treatment means at multiple occasions in 4.1.1, and we investigate the
same DF approximations for small samples.
4.2.2 Numerical Illustration
Similar to the illustration in 4.1.2, suppose there are q = 2 treatments (A and B) to
be compared separately and simultaneously at two points in time whose longitudinal
correlation is
Σ =
[
1 0.9
0.9 1
]
,
and the comparisons are defined by the coefficient matrix
C2 =
[ −1 1 0 0
0 0 −1 1
]
.
As opposed to 4.1, now we compare correlated mean parameters:
Λ2 = I2 ⊗Σ =

1 0.9 0 0
0.9 1 0 0
0 0 1 0.9
0 0 0.9 1
 .
The test statistics themselves, however, are uncorrelated :
Σ˜2 = C2Λ2C
T
2 =
[
0.2 0
0 0.2
]
,
and correspondingly
Γ˜2 =
[
1 0
0 1
]
.
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4.2.3 Simulation Study
Just as with comparisons among treatments, it is unclear what sample sizes are necessary
for the asymptotic procedures to preserve α, and what DF approximation to use with
smallish sample sizes. Thus we hope to find answers via simulation. Beyond that, we
compare the powers of the longitudinal MCTs with Bonferroni-style adjustments.
Type I error: The setup of our simulation study for type I error rates is identical
to the one from 4.1.3, except that the comparisons are now between occasion means
within multiple treatment groups. Simulation results of the asymptotic procedures for
nk between 10 and 120 are shown in Figure 15. They give a slightly different picture
compared to comparisons among treatments per time point. In the MMM approach
the realized α for all-pairwise comparisons skyrockets to 14 to 23% for nk = 10 and
requires sample sizes of 50 and more to come close to the nominal test size. In contrast,
comparisons based on the ELM generally perform well except for the slight inflation of α
when nk is relatively small. Tests relying on the CIM can again turn a little conservative
as the number of occasions rises.
For the approximate small-sample procedure, simulated type I error rates based on 5000
simulation runs are presented in Figure 16. We see once more that the naive DF makes
the procedure extremely conservative; on the contrary, MCTs using the residual DF are
prone to rejecting too many true null hypotheses; so both these DFs are out of the
question.
The ESS-based, Pinheiro-Bates and “adjusted” DFs keep the nominal α but tend to
conservatism, especially for nk < 10 in setups with m > 3 occasions. The Kenward-
Roger method performs well across most scenarios but seems to turn slightly liberal with
increasing number of occasions. MMM can become fairly liberal especially for m > 3.
Power: The simulation setup is again very similar to that in 4.1.3 but now with com-
parisons between time points instead of treatment groups. The joint models and MMM
remain the same as before but their competitors change somewhat: as two-sample tests
and MCTs based on simple linear modeling would be inappropriate for comparing the
correlated occasion means, we rather use CIMs with random subject effects to base our
tests on, and then adjust them via Bonferroni for the multiplicity of treatment groups
(and also of the comparisons in case of pairwise tests). All power simulations are carried
out with 1000 replications.
Figure 17 shows that for comparisons of occasions within each treatment group, the
superiority of joint modeling or the MMM approach compared to procedures that adjust
for multiple time points with Bonferroni is beyond any doubt. The ELM with AR(1)
correlation, the CIM with random subject effects, and MMM performs equally well.
Their power advantage is bigger for all-pairwise contrasts compared to many-to-one and
grand-mean because the number of comparisons under the alternative is m − 1 for the
former but only 1 for the latter. Increasing the number of time points diminishes the
power of all procedures.
The impact of the strength of longitudinal correlation is illustrated in Figure 18. The
gap between the asymptotic power curves of procedures with or without incorporation
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Figure 15: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons among m = {3, 4, 5} Gaussian occasion means separately and simultaneously
for q = {3, 4, 5} treatments, with nk independent subjects per treatment group (5000 simulation
runs).
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Figure 16: Simulated type I error rates for many-to-one, all-pairwise, and grand-mean compar-
isons among m = {3, 4, 5} Gaussian occasion means separately and simultaneously for q = {3, 4, 5}
treatments, with nk independent subjects per treatment group, and different small-sample degrees
of freedom (5000 simulation runs).
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Figure 17: Simulated powers for asymptotic many-to-one, all-pairwise, and grand-mean compar-
isons among m = {3, 4, 5} Gaussian occasion means separately and simultaneously for q = {3, 4, 5}
treatments, with nk = 100 independent subjects per treatment group (1000 simulation runs).
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of longitudinal correlation increases with the correlation. Even under relatively weak
dependence (ρ1 = 0.50, ρ2 = 0.20), the gain in power is similar to the maximum achievable
gain for comparisons of treatment groups within time points—but the latter requires very
high correlation (ρ1 = 0.95, ρ2 = 0.90) for this.
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Figure 18: Simulated powers for asymptotic many-to-one, all-pairwise, and grand-mean compar-
isons among m = 3 Gaussian occasion means separately and simultaneously for q = 3 treatments,
with nk = 100 independent subjects per treatment group, and different longitudinal correlations
(1000 simulation runs).
We use the setup, models, and DFs as in 4.1.3 for simulating the power with small sample
sizes. Figure 62 in Appendix D shows results based on 1000 simulation runs. Again the
procedures that exploit the longitudinal correlation are clearly superior to the simple
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Bonferroni-type adjustments, but now MMM has somewhat lower power compared to
the joint modeling approaches.
The small-sample power comparisons of different correlations with m = q = 3 (Figure 63
in Appendix D) also show this pattern: the power advantage of procedures that account
for longitudinal correlation increases dramatically as the correlation increases, but MMM
is not as quite as powerful as joint modeling.
In summary, comparisons among occasions per treatment group benefit much more from
incorporating longitudinal correlation than comparisons among treatments per occasion,
and substantial gain is achieved already with relatively weak longitudinal dependence.
With finite samples, the MMM approach can have lower power compared to joint mod-
eling.
4.3 A Duplex Procedure
Now that we have established procedures for multiple comparisons of treatments at each
of several occasions as well as for multiple comparisons of occasions within each of several
treatment groups, the next step is to combine them. Suppose the subject-matter issue
is such that comparisons of both types are of interest, and we are willing to claim an
effect if at least one comparison of treatments is significant at least at one occasion, or
if at least one comparison of occasions is significant at least for one treatment group i.e.,
any significant effect in any direction is sufficient to reject the global H0. This calls for
a duplex procedure that embraces comparisons among treatments and among occasions
and controls the FWER over the entire set of hypotheses, at least approximately with
small sample sizes.
The strategy shall be to take the longitudinal MCTs from 4.1 and 4.2 as building blocks.
We estimate β and Σ using either joint modeling or MMM. Elementary hypotheses are
specified in a coefficient matrix C that includes contrasts of both types. One apparent
challenge here is how to find a critical value (or values) if the corresponding DFs are
widely different for the two types of comparisons. This is less of a problem when sample
sizes are relatively large but should be properly addressed for smallish dimensions.
We describe the method and several approaches to approximate the small-sample DFs
in 4.3.1. The impact of longitudinal dependence on the correlation of test statistics is
illustrated in 4.3.2. We show simulation results for size and power in 4.3.3.
4.3.1 Procedure
The statistical procedure itself resembles the basic one described in 4.1.1, with the differ-
ence that we have now comparisons among treatments and among occasions at the same
time. The coefficient matrix that reflects this set of comparisons (again exemplified for
many-to-one comparisons of q = 3 treatments and m = 4 occasions) can be assembled
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from CtrtDun of 4.1.1 and C
occ
Dun of 4.2.1 as
CbothDun =
[
CtrtDun
CoccDun
]
=

−1 1 0 0 0 0 0 0 0 0 0 0
−1 0 1 0 0 0 0 0 0 0 0 0
0 0 0 −1 1 0 0 0 0 0 0 0
0 0 0 −1 0 1 0 0 0 0 0 0
0 0 0 0 0 0 −1 1 0 0 0 0
0 0 0 0 0 0 −1 1 0 0 0 0
0 0 0 0 0 0 0 0 0 −1 1 0
0 0 0 0 0 0 0 0 0 −1 1 0
−1 0 0 1 0 0 0 0 0 0 0 0
−1 0 0 0 0 0 1 0 0 0 0 0
−1 0 0 0 0 0 0 0 0 1 0 0
0 −1 0 0 1 0 0 0 0 0 0 0
0 −1 0 0 0 0 0 1 0 0 0 0
0 −1 0 0 0 0 0 0 0 0 1 0
0 0 −1 0 0 1 0 0 0 0 0 0
0 0 −1 0 0 0 0 0 1 0 0 0
0 0 −1 0 0 0 0 0 0 0 0 1

.
Inferences from this asymptotic procedure will be under control of the FWER with large
sample sizes. Matters get more complicated, however, for small samples because the
DFs to be used are even less obvious than with comparisons of treatments or occasions
alone. The point is that, depending on the DF method used, the DFs assigned to each
type of comparison (within treatment groups or within time points) can be substantially
different.
Suppose we are using the Kenward-Roger method to determine DFs. This yields a vector
ν = (ν1, . . . , νz) where νh is the DF associated with the hth comparison. The question is
how to incorporate these multiple DFs into our inference framework with a multivariate
t-distribution from which an equicoordinate critical point is to be calculated. We make
three suggestions and investigate their performances later on:
1. Apply the minimum DF
νmin = min
h
(ν1, . . . , νz)
to all comparisons i.e., use
Tz(νmin, Γ˜)
as reference distribution for all test statistics. This approach is “exact” (to the
extent the Kenward-Roger method is “exact”) only in completely balanced and
homoscedastic settings, and likely to be conservative otherwise.
2. Use the average DF
ν¯ =
1
z
z∑
h=1
νh
for all comparisons and thus
Tz(ν¯, Γ˜)
as joint reference distribution of all test statistics. Just like the νmin approach, this
is only “exact” (in the above sense) with complete balance and homoscedasticity.
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In general, it should be “exact on average” (again in the above sense) meaning that
nominal test size should be achieved; however, some adjusted p-values should be
too small and others too large, and likewise, some SCIs should be too narrow and
some too wide.
We may run into trouble with strategies 1 and 2 when there is heavy imbalance and/or
heteroscedasticity. One possible corrective is to use different DFs for different com-
parisons. Games and Howell (1976) proposed such an approach for all-pairwise mean
comparisons, and Hasler and Hothorn (2008) extended it to arbitrary linear contrasts
using MCTs. They used Satterthwaite DFs, but without a Kenward-Roger adjustment
of the covariances.
3. Apply the contrast-specific DFs as computed by the Kenward-Roger approximation
so that
Tz(νh, Γ˜)
is used as reference distribution for the hth test statistic. The adjusted p-value
corresponding to the hth elementary (two-sided) hypothesis is found by integrating
from −|Th| to |Th| over Tz(νh, Γ˜). This should be “exact” (again in the above sense)
even with imbalance and heterogeneous variances. The method is computationally
tedious as it involves multiple integration steps; an R program is given in Appendix
E.
We also need to point out that a procedure assigning different DFs to elementary hy-
potheses leads to different critical values for single test statistics of the same family to
be compared with; what follows is no longer a simultaneous test procedure in the sense
of Gabriel (1969).
These three general ideas can be applied in a similar way to DFs that, unlike the Kenward-
Roger method, do not produce contrast-specific DFs but “only” one DF for comparisons
among treatments and one DF for comparisons among time points. In this case averaging
will be weighted according to the number of comparisons of each type i.e.,
ν¯ =
ztrtνtrt + zoccνocc
z
where νtrt and νocc are the DFs for comparisons of treatments per occasion and occasions
per treatment, respectively, ztrt and zocc are the numbers of comparisons of each type,
and ztrt + zocc = z.
We study the performance of νmin, ν¯, and contrast-specific νh via simulation in 4.3.3.
4.3.2 Numerical Illustration
We draw on the heuristical illustrations of 4.1 and 4.2 and start again by assuming a
longitudinal correlation of
Σ =
[
1 0.9
0.9 1
]
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in each of treatment groups A and B i.e., an overall correlation matrix
Λ2 = I2 ⊗Σ

1 0.9 0 0
0.9 1 0 0
0 0 1 0.9
0 0 0.9 1

for the cell means model. The coefficient matrix now comprises comparisons among
treatments as well as among time points:
C2 =

−1 0 1 0
0 −1 0 1
−1 1 0 0
0 0 −1 1
 .
This leads to a covariance matrix of test statistics
Σ˜2 = C2Λ2C
T
2 =

2 1.8 0.1 −0.1
1.8 2 −0.1 0.1
0.1 −0.1 0.2 0
−0.1 0.1 0 0.2

and the corresponding correlation matrix
Γ˜2 =

1 0.9 0.16 −0.16
0.9 1 −0.16 0.16
0.16 −0.16 1 0
−0.16 0.16 0 1
 .
Again we see that the two test statistics for comparisons of treatments per occasion (T1
and T2) are highly correlated whereas those for comparisons of occasions per treatment
(T3 and T4) are uncorrelated. In addition, there is a weak positive correlation between T1
and T3 as well as between T2 and T4; these are the comparisons that have the same figure
(–1 or 1) in the same place of their respective contrast coeffient vectors. There is also a
weak negative correlation between T1 and T4 as well as between T2 and T3, which are the
comparisons that have figures with opposite signs in the same place of their respective
contrast coeffient vectors.
4.3.3 Simulation Study
Similar to the simulation study in 4.1.3 and 4.2.3, we explore the asymptotic properties
of our test procedure and seek to determine what sample sizes are required to keep the
nominal type I error level. Then we address the problem which of the DF strategies
(minimum, average, comparison-specific) works best with small sample sizes. Power
analyses will focus on the question how much can be gained in comparison to performing
separate sets of comparisons among treatments and occasions (like in 4.1 and 4.2) and
adjusting with Bonferroni.
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Type I error: Type I error simulations of the asymptotic procedures are carried out
as described in 4.1.3, but with contrast coefficient matrices such that comparisons of
treatment groups per time point and time points per treatment group are under joint
control of α = 0.05. Each setting is repeated 1000 times.
Figure 19 shows that the simulated type I error rates of the CIM-based asymptotic
procedures range between 6 and 12% for nk = 10 but stabilize around 5% as soon as nk
exceeds 30 or 40. The asymptotic MMM method can be substantially more liberal with
type I error rates between 12 and 20% for nk = 10, and requires around 50 subjects per
group to achieve acceptable control of α.
For small samples of nk = {4, 6, 8, 10, 12, 14}, we employ a joint CIM and the MMM
approach, but the reference distribution is no longer multivariate normal. Instead we use
the minimum, (weighted) average, or comparison-specific DFs as described in 4.3.1 for
the multivariate t reference distribution.
The simulation results in Figures 20, and 21 show that, just as expected, the minimum
DF usually yields the lowest and the average DF the highest type I error rates, and the
separate DF approach lies inbetween. For the CIM with Kenward-Roger DFs (Figure 20),
all three approaches are fairly similar; only when the number of time points is larger than
the number of treatments, the minimum DF tends to make the tests a bit conservative.
The discrepancy between the three DF approaches is larger for MMM (Figure 21). Here
the average DF substantially inflates the type I error rates. The separate DF solution
performs very well, and using the minimum DF leads to conservative decisions.
In summary, the approach with separate DFs proves to be the best choice for most cases.
In situations with very small sample sizes where the type I error level is slightly exceeded,
the minimum DF can actually improve α control, but otherwise it makes the procedure
conservative. Averaging the DFs is obviously the poorest solution and likely to lead to
type I error inflation. All these considerations become practically irrelevant with larger
sample sizes.
Power: We simulate the asymptotic powers of longitudinal MCTs based on a CIM or
MMM, either jointly or separately for comparisons of treatment groups and time points.
Jointly means that all elementary hypotheses are part of one big family of comparisons
that are performed under joint type I error control. Separately means that all elementary
hypotheses of comparisons among treatment means are part of one family and all elemen-
tary hypotheses of comparisons among occasion means are part of another family, and
each of them is tested separetely with control of α, followed by a Bonferroni adjustment
of the resulting adjusted p-values (i.e., multiplication by two) to keep the overall type
I error rate. This way we can assess the additional power benefit of incorporating the
correlation between comparisons among treatments and comparisons among occasions.
Settings with ∆ = {0, 0.1, . . . , 1} and nk = 100 are simulated.
We see from Figure 22 that the large-sample power of the asymptotic duplex procedure
does not depend on the underlying modeling strategy. The maximum power difference
between joint and separate testing of contrast (the vertical distance between the dashed
and solid line of the same color) is between 3 and 5 percentage points. The power
of the asymptotic procedure increases with the longitudinal correlation of measurement
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occasions (Figure 23), but the power difference between the joint and separate procedure
does not.
For the small-sample procedure simulated with nk = 10 for ∆ = {0, 0.2, . . . , 2}, the power
of the CIM-based procedure with the Kenward-Roger method is discernibly greater than
with MMM (Figures 24 and Figure 25). We also observe that the power advantage of
using the joint test compared to separate tests for both types of comparisons is now larger
than with the asymptotic procedure.
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Figure 19: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons among q = {3, 4, 5} Gaussian treatment means separately and simultaneously
at m = {3, 4, 5} occasions and among m = {3, 4, 5} Gaussian occasion means separately and
simultaneously for q = {3, 4, 5} treatments, with nk independent subjects per treatment group
(1000 simulation runs).
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Figure 20: Simulated type I error rates for many-to-one, all-pairwise, and grand-mean compar-
isons among q = {3, 4, 5}Gaussian treatment means separately and simultaneously atm = {3, 4, 5}
occasions and among m = {3, 4, 5} Gaussian occasion means separately and simultaneously for
q = {3, 4, 5} treatments, with nk independent subjects per treatment group, based on a conditional
independence model with average, minimum, and separate Kenward-Roger DFs (1000 simulation
runs).
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Figure 21: Simulated type I error rates for many-to-one, all-pairwise, and grand-mean compar-
isons among q = {3, 4, 5}Gaussian treatment means separately and simultaneously atm = {3, 4, 5}
occasions and among m = {3, 4, 5} Gaussian occasion means separately and simultaneously for
q = {3, 4, 5} treatments, with nk independent subjects per treatment group, based on multiple
marginal models with average, minimum, and separate DFs (1000 simulation runs).
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Figure 22: Simulated powers for asymptotic many-to-one, all-pairwise, and grand-mean compar-
isons among q = {3, 4, 5}Gaussian treatment means separately and simultaneously atm = {3, 4, 5}
occasions and among m = {3, 4, 5} Gaussian occasion means separately and simultaneously for
q = {3, 4, 5} treatments, with nk = 100 independent subjects per treatment group (1000 simulation
runs).
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Figure 23: Simulated powers for asymptotic many-to-one, all-pairwise, and grand-mean compar-
isons among q = 3 Gaussian treatment means separately and simultaneously at m = 3 occasions
and among m = 3 Gaussian occasion means separately and simultaneously for q = 3 treatments,
with nk = 100 independent subjects per treatment group and different longitudinal correlations
(1000 simulation runs).
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Figure 24: Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons among
q = {3, 4, 5} Gaussian treatment means separately and simultaneously at m = {3, 4, 5} occasions
and among m = {3, 4, 5} Gaussian occasion means separately and simultaneously for q = {3, 4, 5}
treatments, with nk = 10 independent subjects per treatment group (1000 simulation runs).
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Figure 25: Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons among
q = 3 Gaussian treatment means separately and simultaneously at m = 3 occasions and among
m = 3 Gaussian occasion means separately and simultaneously for q = 3 treatments, with nk = 10
independent subjects per treatment group and different longitudinal correlations (1000 simulation
runs).
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4.4 Application to Example Data
We illustrate the use of our longitudinal MCTs for Gaussian outcomes with the dataset
on bradykinin receptor antagonism, mercuric chloride, and heart rates that we introduced
in 2.1, 2.2 and 2.3.
4.4.1 Bradykinin Receptor Antagonism
The data on bradykinin receptor antagonism were presented in 2.1 and will now be
evaluated with longitudinal MCTs based on either joint or multiple marginal models. A
similar analysis of this dataset appeared in Pallmann et al. (2015).
Comparing multiple drugs simultaneously at multiple occasions: One relevant
research question is: when do which active drugs (HOE 140, EACA) reduce D-dimer
concentrations (thus: reduce fibrinolysis) compared to placebo? We want to answer this
question separately and simultaneously for each measurement occasion (except baseline)
while controlling a common FWER. So we are out for many-to-one comparisons of drugs
(HOE 140 vs. placebo and EACA vs. placebo) at each of four non-baseline occasions.
This we can achieve with longitudinal MCTs using estimates from an AICc-selected
ELM or CIM, or a combination of occasion-specific marginal models. For comparison, we
also compute ordinary MCTs for each of the four time points, followed by a Bonferroni
adjustment (i.e., multiplication by four).
We fit various candidate models for AICc to choose from. The set of ELMs involves
all combinations of four variance structures (constant, heterogeneous over time, hetero-
geneous across treatment arms, heterogeneous both over time and across treatments)
and three correlation patterns (CS, AR(1), UN) i.e., a total of twelve candidate models.
AICc selects the most complex model with UN correlation and heteroscedasticity between
occasions and treatments; all other candidate models are substantially inferior (∆AICc
> 25).
The candidate set of CIMs comprises three models with random patient effects being
unstratified, occasion-specific, or both occasion- and drug-specific. Here AICc does not
pick the most complex alternative but rather the model with occasion-specific random
effects, which implies an UN correlation matrix that is the same for all three drugs and
is therefore similar to that of the selected ELM. This similarity becomes apparent in the
resulting correlation matrices of test statistics for many-to-one comparisons of treatments
and occasions (Figures 26 and 27). Notice that the most complex random-effects structure
would correspond to UN correlation matrices differing between treatment arms i.e., a
configuration even more complicated than those of all ELMs in the candidate set.
Our subsequent inferences build upon parameter and covariance estimates from the AICc-
selected joint models and the combined marginal models, respectively, as detailed in
Section 4. We have seen in the simulation studies in 4.1.3, 4.2.3, and 4.3.3 that sample
sizes of nk > 30 are sufficient for the asymptotic procedure to control α; therefore we
begin with an asymptotic analysis of the bradykinin data.
We find that neither drug affects D-dimer concentrations in the initial phase after 30
minutes but EACA is superior towards the end of the surgical procedure: it reduces
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Figure 26: Bradykinin data: correlation matrices of test statistics for many-to-one comparisons
of treatments per time point (except baseline).
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Figure 27: Bradykinin data: correlation matrices of test statistics for many-to-one comparisons
of time points per treatment group.
D-dimer significantly compared to placebo after 60 minutes and when the patient is
separated from the heart-lung machine (Table 1). This effect cannot be shown for HOE
140, which seems to even slightly increase D-dimer levels during CBP, although not
statistically significant. After one day the beneficial effect of EACA vanishes, and we
observe only a minor reduction of D-dimer log-concentrations that is similar (but non-
significant) for both treatments.
The estimated SEs reveal that there is variance heterogeneity over time: variability of
D-dimer rises over the course of the surgical intervention but declines and stabilizes the
day after. The ELM estimates SEs that additionally differ between comparisons of drugs:
they are distinctly higher for HOE 140 than for EACA during surgery (i.e., after 30 and
60 minutes and post-bypass) but a little lower at baseline and after one day.
The adjusted p-values do not differ much between the three modeling strategies that
acknowledge temporal correlation. In contrast, occasion-specific MCTs followed by a
Bonferroni adjustment have increased p-values, indicating that there is power to gain
by exploiting the dependence of occasions. So we conclude it is essential to incorporate
some, at least half-decent estimate of the correlation over time whereas the choice of
modeling approach is of secondary importance here. This becomes also apparent from
the SCIs displayed in Figure 28. Intervals obtained from CIM or MMM analyses are
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Table 1: Simultaneous inference for the bradykinin data: estimated differences of D-dimer log-
concentrations, standard errors, and adjusted p-values for occasion-wise many-to-one comparisons
of HOE 140 and EACA against placebo.
Estimate SE(ELM) SE(CIM, MMM) p(ELM) p(CIM) p(MMM) p(Bonf)
30 min on-pump: EACA - Placebo -0.246 0.170 0.176 0.607 0.656 0.672 1.000
30 min on-pump: HOE140 - Placebo 0.191 0.213 0.174 0.933 0.856 0.865 1.000
60 min on-pump: EACA - Placebo -0.668 0.208 0.208 0.009 0.009 0.010 0.010
60 min on-pump: HOE140 - Placebo 0.186 0.250 0.207 0.973 0.939 0.944 1.000
Post-bypass: EACA - Placebo -1.088 0.176 0.211 <0.001 <0.001 <0.001 <0.001
Post-bypass: HOE140 - Placebo 0.169 0.249 0.210 0.984 0.965 0.968 1.000
Postoperative day 1: EACA - Placebo -0.259 0.155 0.144 0.439 0.369 0.382 0.511
Postoperative day 1: HOE140 - Placebo -0.290 0.127 0.143 0.133 0.240 0.250 0.310
Postoperative day 1: HOE140 − Placebo
Postoperative day 1: EACA − Placebo
Post−bypass: HOE140 − Placebo
Post−bypass: EACA − Placebo
60 min on−pump: HOE140 − Placebo
60 min on−pump: EACA − Placebo
30 min on−pump: HOE140 − Placebo
30 min on−pump: EACA − Placebo
−1 0
Estimated Difference of log(Concentration) [ng/ml]
MCTs + Bonferroni CIM ELM MMM
Figure 28: Bradykinin data: 95% simultaneous confidence intervals for asymptotic many-to-one
comparisons of treatments per time point (except baseline) based on AICc-selected joint models
(CIM and ELM), combined marginal models (MMM), and Bonferroni-adjusted MCTs per time
point.
about the same width whereas those from ELM analysis can be a little wider or narrower
due to their using comparison-specific SE estimates. The Bonferoni-basd SCIs are always
a little wider than those of the CIM- and MMM-based longitudinal MCTs that both use
the same SE estimates.
Table 2: Simultaneous inference for the bradykinin data: DFs for the many-to-one comparisons
of treatments at all occasions except baseline.
Naive Residual ESS “Adjusted” Pinheiro-Bates Kenward-Roger MMM
DF 97 545 171 99 107 109 109
So far we have been relying on asymptotics because we felt the sample sizes per group (37
for placebo and EACA, 38 for HOE 140) were large enough to do so. To assess whether
this was justified, we compare the results of the asymptotic evaluation with some “small-
sample” analyses. Table 2 shows different DF approximations for the bradykinin data:
we see that most of them are not much larger than νnaive = 97, only νESS = 171 (based
on an estimated ρˆ = 0.71 in the AR(1) pattern) is considerably different, and of course
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Figure 29: Bradykinin data: 95% simultaneous confidence intervals for many-to-one comparisons
of treatments per time point (except baseline) based on the AICc-selected joint ELM, with different
approximations to the degrees of freedom, and asymptotic results (for comparison).
νres = 545. MMM refers to the smallest residual DF of the occasion-specific marginal
linear models, which happens to be identical to the Kenward-Roger DF here.
These differences between DFs have a negligible impact on the results of the analysis.
For example, the 95% equicoordinate quantile of the multivariate t-distribution with
Σ̂ estimated from the AICc-selected ELM that is used for constructing SCIs is 7.092
with 97 DF and 7.041 with 109 DF. We can view the practical impact of different DF
approximation on the width of the ELM-based SCIs in Figure 29. Using the asymptotic
reference distribution (multivariate normal) or a multivariate t-distribution with νres
makes the intervals slightly narrower, but this small difference is most likely irrelevant in
practice. Therefore the asymptotic analysis seems justified for this dataset.
Comparing multiple occasions simultaneously for multiple drugs: Now suppose
we were to gauge the D-dimer levels at various time points in comparison to baseline
separately and simultaneously for the three treatment arms. As our power simulations
have shown, here it can be way more painful not to incorporate serial correlation than it
is with comparisons of treatments at several points in time.
Again we use the AICc-selected joint models as well as the MMM approach and perform
an asymptotic analysis, and again there is considerable discrepancy between pooled-
treatment and treatment-specific SE estimates, and they bring about p-values that differ
quite a bit between the modeling strategies (Table 3). The widths of the corresponding
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95% SCIs shown in Figure 30 also vary according to the SE estimates involved, but the
discrepancies appear less drastic than when looking at the adjusted p-values. The latter
are probably hardly meaningful anyway when the actual task is not to test point-zero
hypotheses but to quantify the uncertainty of estimated differences, which is much better
done by SCIs.
Table 3: Simultaneous inference for the bradykinin data: estimated differences of D-dimer log-
concentrations, standard errors, and adjusted p-values for treatment-wise many-to-one compar-
isons of occasions against baseline.
Estimate SE(ELM) SE(CIM) SE(MMM) SE(Bonf) p(ELM) p(CIM) p(MMM) p(Bonf)
Placebo: 30 min on-pump - Baseline 0.361 0.100 0.098 0.094 0.134 0.004 0.003 0.001 0.075
Placebo: 60 min on-pump - Baseline 0.886 0.149 0.138 0.161 0.134 <0.001 <0.001 <0.001 <0.001
Placebo: Post-bypass - Baseline 1.511 0.149 0.155 0.164 0.134 <0.001 <0.001 <0.001 <0.001
Placebo: Postoperative day 1 - Baseline 1.354 0.143 0.139 0.124 0.134 <0.001 <0.001 <0.001 <0.001
EACA: 30 min on-pump - Baseline 0.210 0.081 0.098 0.059 0.126 0.098 0.289 0.004 0.838
EACA: 60 min on-pump - Baseline 0.312 0.107 0.138 0.081 0.126 0.039 0.220 0.001 0.140
EACA: Post-bypass - Baseline 0.517 0.117 0.155 0.128 0.126 <0.001 0.010 0.001 0.001
EACA: Postoperative day 1 - Baseline 1.189 0.151 0.139 0.146 0.126 <0.001 <0.001 <0.001 <0.001
HOE140: 30 min on-pump - Baseline 0.615 0.113 0.097 0.129 0.163 <0.001 <0.001 <0.001 0.002
HOE140: 60 min on-pump - Baseline 1.135 0.150 0.136 0.161 0.163 <0.001 <0.001 <0.001 <0.001
HOE140: Post-bypass - Baseline 1.744 0.186 0.153 0.159 0.163 <0.001 <0.001 <0.001 <0.001
HOE140: Postoperative day 1 - Baseline 1.127 0.118 0.137 0.141 0.163 <0.001 <0.001 <0.001 <0.001
The log-concentrations of D-dimer raise quickly above baseline as the surgical procedure
takes its course in patients treated with either HOE 140 or placebo. However, the sit-
uation is quite different for the EACA arm: D-dimer levels remain rather close to the
baseline value until the patient is separated from the heart-lung machine. So it makes
good sense to do the comparisons versus baseline separately (but simultaneously) for the
three treatment arms.
Comparing multiple drugs and multiple occasions simultaneously: We can also
combine all hypotheses into one family so that the set of elementary comparisons now
contains both comparisons among treatments and among occasions, and we strive after
protecting a joint FWER of 5%. We see from Table 4 that the p-values increase but
not by much, which means the correlation between contrasts is exploited. All of the
hypotheses that could be rejected in the previous analysis can still be rejected now, as
we see also from the SCIs in Figure 31.
4.4.2 Mercuric Chloride
Data from a study investigating toxic effects of mercuric chloride were presented in 2.2
and will now be analyzed using longitudinal MCTs. Here we will see the effect of missing
values on the effect sizes estimated with our different modeling approaches.
Comparing multiple doses simultaneously at multiple occasions: The research
question with the mercuric chloride data is: by how much do the treatment doses (2.5
and 5 mg/kg HgCl2) differ from control at our three measurement time points of in-
terest? Hence the main objective of our analysis shall be to construct one-sided 95%
upper SCI bounds for the differences of low and high dose versus control separately and
simultaneously for all three measurement occasions.
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HOE140: Postoperative day 1 − Baseline
HOE140: Post−bypass − Baseline
HOE140: 60 min on−pump − Baseline
HOE140: 30 min on−pump − Baseline
EACA: Postoperative day 1 − Baseline
EACA: Post−bypass − Baseline
EACA: 60 min on−pump − Baseline
EACA: 30 min on−pump − Baseline
Placebo: Postoperative day 1 − Baseline
Placebo: Post−bypass − Baseline
Placebo: 60 min on−pump − Baseline
Placebo: 30 min on−pump − Baseline
0.0 0.5 1.0 1.5 2.0
Estimated Difference of log(Concentration) [ng/ml]
MCTs + Bonferroni CIM ELM MMM
Figure 30: Bradykinin data: 95% simultaneous confidence intervals for asymptotic many-to-one
comparisons of time points per treatment arm based on AICc-selected joint models (CIM and
ELM), combined marginal models (MMM), and Bonferroni-adjusted MCTs per treatment arm.
This is again a fairly large dataset with sample sizes of 60 for control and 56 for each of
the active dose groups at the first measurement occasion. However, the sample sizes are
substantially smaller at the end of the study due to animals being sacrificed for interim
measurements of body and organ weights.
We model the data using either a joint CIM or ELM or occasion-specific marginal models.
Various different CIMs are conceivable, and it is not clear from the start which random-
effects structure suits best. Animal-specific intercepts seem indispensable, but do animal-
specific slopes bring about an improvement? Moreover, several animals were housed
together in cages, so we could add cage-specific intercepts, and possibly also slopes? And
can we assume that random intercepts and slopes are uncorrelated?
Our indecision calls for the assistance of a selection criterion. We build several LMMs
with body weight as dependent variable, the interactions of dose levels and occasions
as independent factor, and different random-effects structures as described above. AICc
selection indicates that the best LMM fit is achieved with animal-specific intercepts and
slopes but without random cage effects. Other reasonable models include, in addition to
the random animal effects, cage-specific random intercepts and slopes (∆AICc = 0.36),
cage-specific random intercepts only (∆AICc = 1.95), or cage-specific random intercepts
and slopes that are uncorrelated (∆AICc = 2.12). On the contrary, models without
animal-specific slopes are out of the question with ∆AICc > 100. So we choose as our
final model to be used for simultaneous inference the one including random animal effects
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Table 4: Simultaneous inference for the bradykinin data: estimated differences of D-dimer log-
concentrations, standard errors, and adjusted p-values for occasion-wise many-to-one comparisons
of HOE 140 and EACA against placebo and treatment-wise many-to-one comparisons of occasions
against baseline.
Estimate SE(ELM) SE(CIM) SE(MMM) p(ELM) p(CIM) p(MMM)
30 min on-pump: EACA - Placebo -0.246 0.170 0.176 0.176 0.878 0.908 0.905
30 min on-pump: HOE140 - Placebo 0.191 0.213 0.174 0.174 0.997 0.985 0.984
60 min on-pump: EACA - Placebo -0.668 0.208 0.208 0.208 0.022 0.023 0.023
60 min on-pump: HOE140 - Placebo 0.186 0.250 0.207 0.207 1.000 0.997 0.997
Post-bypass: EACA - Placebo -1.088 0.176 0.211 0.211 <0.001 <0.001 <0.001
Post-bypass: HOE140 - Placebo 0.169 0.249 0.210 0.210 1.000 0.999 0.999
Postoperative day 1: EACA - Placebo -0.259 0.155 0.144 0.144 0.734 0.654 0.651
Postoperative day 1: HOE140 - Placebo -0.290 0.127 0.143 0.143 0.289 0.475 0.473
Placebo: 30 min on-pump - Baseline 0.361 0.100 0.098 0.094 0.006 0.004 0.002
Placebo: 60 min on-pump - Baseline 0.210 0.081 0.098 0.059 0.143 0.395 0.007
Placebo: Post-bypass - Baseline 0.615 0.113 0.097 0.129 <0.001 <0.001 <0.001
Placebo: Postoperative day 1 - Baseline 0.886 0.149 0.138 0.161 <0.001 <0.001 <0.001
EACA: 30 min on-pump - Baseline 0.312 0.107 0.138 0.081 0.061 0.310 0.002
EACA: 60 min on-pump - Baseline 1.135 0.150 0.136 0.161 <0.001 <0.001 <0.001
EACA: Post-bypass - Baseline 1.511 0.149 0.155 0.164 <0.001 <0.001 <0.001
EACA: Postoperative day 1 - Baseline 0.517 0.117 0.155 0.128 <0.001 0.015 0.001
HOE140: 30 min on-pump - Baseline 1.744 0.186 0.153 0.159 <0.001 <0.001 <0.001
HOE140: 60 min on-pump - Baseline 1.354 0.143 0.139 0.124 <0.001 <0.001 <0.001
HOE140: Post-bypass - Baseline 1.189 0.151 0.139 0.146 <0.001 <0.001 <0.001
HOE140: Postoperative day 1 - Baseline 1.127 0.118 0.137 0.141 <0.001 <0.001 <0.001
on both intercepts and slopes.
The choice of a joint ELM is not obvious either, therefore we select one from a candidate
set as in the bradykinin example (twelve models) using AICc again. The best-fitting ELM
includes occasion-specific variances and an UN residual correlation matrix. Modeling
variance separately for occasions and doses is considerably inferior (∆AICc = 1.75), and
all other models are very poor with ∆AICc > 60.
Compared to these considerations on LMM specification, defining the marginal linear
models for each of the three occasions is child’s play: the dependent variable is body
weight, and dose is the independent factor. If we wanted to include random cage effects,
combining marginal LMMs as in Jensen et al. (2015) would be the method of choice.
The correlation matrices of test statistics are very similar for ELM-, CIM-, and MMM-
based comparisons (Figure 32). However, unlike in the bradykinin example, now the
point estimates differ between CIM-, ELM-, and MMM-based analyses (Table 5); this is
the case for all comparisons that involve unequal numbers of recorded observations due
to dropout. We recall that the MMM estimates the effects of interest as “raw” averages
whereas the LMMs borrow information from adjoining time points via the intra-animal
correlation. The estimates of this correlation differ between the ELM and CIM, and in
consequence the point estimates differ, too.
One crucial issue in this context is the assumed missing data mechanism, which can
be MCAR or MAR for the LMM but must be MCAR for MMM. The animals to be
sacrificed for interim analyses were picked at random, so their missingness should be
unrelated to both measured and unmeasured outcomes. The ones found moribund or
dead, however, might easily have had lower body weights i.e., their dropping out could
be causally determined by previously measured values, so MCAR is certainly debatable
for these animals, not least because all non-completers within the first year come from
the HgCl2 groups and none from the control group.
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EACA: Post−bypass − Baseline
EACA: 60 min on−pump − Baseline
EACA: 30 min on−pump − Baseline
Placebo: Postoperative day 1 − Baseline
Placebo: Post−bypass − Baseline
Placebo: 60 min on−pump − Baseline
Placebo: 30 min on−pump − Baseline
Postoperative day 1: HOE140 − Placebo
Postoperative day 1: EACA − Placebo
Post−bypass: HOE140 − Placebo
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Figure 31: Bradykinin data: 95% simultaneous confidence intervals for asymptotic many-to-
one comparisons of treatments per time point (except baseline) and time points per treatment
arm simultaneously based on AICc-selected joint models (CIM and ELM) and combined marginal
models (MMM).
We see from the 95% SCIs in Figure 33 that the body weight reduction in animals treated
with HgCl2 in comparison to control animals is significant for both dose groups at all
measurement time points. Whereas the upper SCI bounds are fairly close to the point
estimates for week 53 and for the interim analysis (week 65), the uncertainty is sizeably
greater at the end of the study, and the bounds for the low-dose group (2.5 mg/kg) are
fairly close to zero so that the effect may, although statistically significant, no longer be
biologically relevant. The SEs are now much larger than before because of the reduced
sample sizes.
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1 0.48 0.91 0.44 0.35 0.17
0.48 1 0.44 0.91 0.17 0.36
0.91 0.44 1 0.48 0.35 0.17
0.44 0.91 0.48 1 0.17 0.36
0.35 0.17 0.35 0.17 1 0.46
0.17 0.36 0.17 0.36 0.46 1
Extended linear model
1 0.48 0.80 0.39 0.36 0.18
0.48 1 0.39 0.80 0.17 0.36
0.80 0.39 1 0.48 0.58 0.28
0.39 0.80 0.48 1 0.28 0.59
0.36 0.17 0.58 0.28 1 0.47
0.18 0.36 0.28 0.59 0.47 1
Conditional independence model
1 0.48 0.92 0.44 0.29 0.22
0.48 1 0.44 0.85 0.22 0.39
0.92 0.44 1 0.48 0.30 0.23
0.44 0.85 0.48 1 0.22 0.41
0.29 0.22 0.30 0.22 1 0.46
0.22 0.39 0.23 0.41 0.46 1
Multiple marginal models
Figure 32: Mercuric chloride data: correlation matrices of test statistics for many-to-one com-
parisons of treatment groups per time point.
Table 5: Simultaneous inference for the mercuric chloride data: estimated differences of body
weights, standard errors, and adjusted p-values for occasion-wise many-to-one comparisons of 2.5
and 5 mg/kg mercuric chloride against control.
Est(ELM) Est(CIM) Est (MMM) SE(ELM) SE(CIM) SE(MMM) p(ELM) p(CIM) p(MMM) p(Bonf)
Week 53: 2.5 mg/kg - control -22.338 -22.338 -22.338 3.225 3.466 3.225 <0.001 <0.001 <0.001 <0.001
Week 53: 5 mg/kg - control -29.251 -29.251 -29.251 3.225 3.466 3.225 <0.001 <0.001 <0.001 <0.001
Week 65: 2.5 mg/kg - control -30.491 -30.432 -30.206 3.774 3.646 3.705 <0.001 <0.001 <0.001 <0.001
Week 65: 5 mg/kg - control -35.881 -36.098 -36.938 3.774 3.646 3.705 <0.001 <0.001 <0.001 <0.001
Week 105: 2.5 mg/kg - control -24.734 -23.913 -26.367 8.685 7.675 9.141 0.011 0.005 0.009 0.023
Week 105: 5 mg/kg - control -35.920 -32.687 -38.600 8.535 7.580 8.959 <0.001 <0.001 <0.001 <0.001
Week 105: 5 mg/kg − control
Week 105: 2.5 mg/kg − control
Week 65: 5 mg/kg − control
Week 65: 2.5 mg/kg − control
Week 53: 5 mg/kg − control
Week 53: 2.5 mg/kg − control
−40 −30 −20 −10 0
Estimated Difference of Body Weight [g]
MCTs + Bonferroni CIM ELM MMM
Figure 33: Mercuric chloride data: 95% simultaneous confidence intervals for asymptotic many-
to-one comparisons of treatments per time point based on AICc-selected joint models (CIM and
ELM), combined marginal models (MMM), and Bonferroni-adjusted MCTs per time point.
So far we have relied on asymptotics because we felt the sample sizes were sufficiently
large. We now take the asymptotic analysis based on the joint CIM and compare it to one
using the Kenward-Roger adjustment. As is to be expected in the presence of substan-
tial dropout and heteroscedasticity, the Kenward-Roger DFs differ considerably between
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comparisons (Table 6). This raises the question which DF to use for the longitudinal
MCTs: straightforward choices are the mean DF (171.1, rounded down to 171) or the
minimum DF (141.4, rounded down to 141).
Table 6: Simultaneous inference for the mercuric chloride data: Kenward-Roger DFs for the
many-to-one comparisons of treatments at all three occasions.
Week 53 Week 65 Week 105
2.5 mg/kg vs. control 181.8 189 143.7
5 mg/kg vs. control 181.8 189 141.4
Table 7 shows the impact of the Kenward-Roger adjustment on the variance estimates.
They are identical to the unadjusted ones for all groups in week 53 and the control group
in week 65 (those without missing values). The inflation for the active dose groups in
week 65 is minimal because there is only one data point missing in each group. The
substantial amount of missingness at the last time points is reflected by variance inflation
that is still small but noticeable.
Table 7: Simultaneous inference for the mercuric chloride data: unadjusted and Kenward-Roger-
adjusted variance estimates.
Unadjusted Kenward-Roger
Week 53 Control 5.7983 5.7983
2.5 mg/kg 6.2125 6.2125
5 mg/kg 6.2125 6.2125
Week 65 Control 6.3947 6.3947
2.5 mg/kg 6.8955 6.8959
5 mg/kg 6.8955 6.8959
Week 105 Control 27.1003 27.3544
2.5 mg/kg 31.8122 32.1706
5 mg/kg 30.3539 30.6645
From the resulting SCIs in Figure 34 we see that there is practically no difference between
the average and minimum DF here, and both make the SCIs just marginally wider than
the asymptotic ones. The difference in width between asymptotic and finite-sample ap-
proaches is slightly bigger for week 105, but this is mainly due to the inflated covariance
matrix.
4.4.3 Heart Rates
We evaluate the heart rate data introduced in 2.3 using longitudinal MCTs. Here we
have truly small sample sizes (eight per treatment arm) and certainly cannot rely on
asymptotics as with the previous examples in 4.4.1 and 4.4.2.
Comparing multiple drugs simultaneously at multiple occasions: The first
question we want to answer is: when do which active treatments differ significantly from
control, and by how much? To this end we perform Dunnett comparisons separately and
simultaneously for each of the four time points, based on either a joint ELM, a joint CIM,
or marginal models.
Once again we employ AICc model selection and use the same structures for heteroscedas-
ticity, residual correlation, and random effects for the candidate models as in the previous
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Week 105: 5 mg/kg − control
Week 105: 2.5 mg/kg − control
Week 65: 5 mg/kg − control
Week 65: 2.5 mg/kg − control
Week 53: 5 mg/kg − control
Week 53: 2.5 mg/kg − control
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Figure 34: Mercuric chloride data: 95% simultaneous confidence intervals for many-to-one com-
parisons of treatments per time point based on the AICc-selected joint CIM with average and
minimum Kenward-Roger degrees of freedom, and asymptotic results (for comparison).
1 0.50 0.82 0.41 0.68 0.34 0.56 0.28
0.50 1 0.41 0.82 0.34 0.68 0.28 0.56
0.82 0.41 1 0.50 0.82 0.41 0.68 0.34
0.41 0.82 0.50 1 0.41 0.82 0.34 0.68
0.68 0.34 0.82 0.41 1 0.50 0.82 0.41
0.34 0.68 0.41 0.82 0.50 1 0.41 0.82
0.56 0.28 0.68 0.34 0.82 0.41 1 0.50
0.28 0.56 0.34 0.68 0.41 0.82 0.50 1
Extended linear model
1 0.50 0.78 0.39 0.78 0.39 0.78 0.39
0.50 1 0.39 0.78 0.39 0.78 0.39 0.78
0.78 0.39 1 0.50 0.78 0.39 0.78 0.39
0.39 0.78 0.50 1 0.39 0.78 0.39 0.78
0.78 0.39 0.78 0.39 1 0.50 0.78 0.39
0.39 0.78 0.39 0.78 0.50 1 0.39 0.78
0.78 0.39 0.78 0.39 0.78 0.39 1 0.50
0.39 0.78 0.39 0.78 0.39 0.78 0.50 1
Conditional independence model
1 0.50 0.85 0.47 0.86 0.43 0.72 0.34
0.50 1 0.47 0.83 0.43 0.81 0.34 0.52
0.85 0.47 1 0.50 0.81 0.47 0.68 0.39
0.47 0.83 0.50 1 0.47 0.76 0.39 0.68
0.86 0.43 0.81 0.47 1 0.50 0.84 0.45
0.43 0.81 0.47 0.76 0.50 1 0.45 0.80
0.72 0.34 0.68 0.39 0.84 0.45 1 0.50
0.34 0.52 0.39 0.68 0.45 0.80 0.50 1
Multiple marginal models
Figure 35: Heart rate data: correlation matrices of test statistics for many-to-one comparisons
of treatments per time point.
examples. The selected ELM has an AR(1) residual correlation pattern and equal variance
across treatment groups and occasions. The second-best model specifies separate variance
parameters for the treatment groups, but it has already a relatively large ∆AICc of 3.05.
The selected CIM is also a simple one with only random patient effects; the runner-up
(treatment-specific random effects) has a ∆AICc of 9.40. Given the low sample size of
the data, it is not surprising that very simple models with few parameters are selected.
We see the consequences of these model choices in the estimated correlation matrices of
test statistics (Figure 35): the selected CIM assumes equicorrelation whereas the selected
ELM reveals an AR(1) pattern with decreasing correlation as the distance between time
points increases. MMM estimates a matrix with lower correlation between later measure-
ments than between earlier ones.
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Table 8: Simultaneous inference for the heart rate data: estimated differences of heart rates,
standard errors, and adjusted p-values for occasion-wise many-to-one comparisons of AX23 and
BWW9 against control.
Estimate SE(ELM) SE(CIM) SE(MMM) p(ELM) p(CIM) p(MMM) p(Bonf)
T1: AX23 - control -2.250 2.850 2.890 2.762 0.918 0.918 0.897 1.000
T1: BWW9 - control 9.000 2.850 2.890 2.762 0.026 0.021 0.018 0.028
T2: AX23 - control 8.125 2.850 2.890 3.132 0.048 0.042 0.074 0.125
T2: BWW9 - control 11.625 2.850 2.890 3.132 0.004 0.002 0.007 0.010
T3: AX23 - control 9.500 2.850 2.890 2.794 0.018 0.014 0.013 0.021
T3: BWW9 - control 7.125 2.850 2.890 2.794 0.097 0.089 0.081 0.137
T4: AX23 - control 2.125 2.850 2.890 2.859 0.935 0.935 0.928 1.000
T4: BWW9 - control 8.750 2.850 2.890 2.859 0.031 0.025 0.029 0.045
We use νKR as a DF approximation for the longitudinal MCTs based on the CIM, νESS
for the ELM-based procedure, and the νres of the marginal models for MMM. The results
in Table 8 show that AX23 leads to a significantly increased heart rate only at T2 and T3
whereas the increase in the BWW9 group is significant at all time points except T3—this
is exactly where the mean profiles of AX23 and BWW9 (Figure 3) cross paths. The
adjusted p-values are similar across modeling approaches, as are the SCIs (Figure 36);
discrepancies are due to different SE and correlation estimates and small differences in
DFs. Ignoring the correlation and adjusting with Bonferroni results in larger p-values
and wider SCIs.
T4: BWW9 − control
T4: AX23 − control
T3: BWW9 − control
T3: AX23 − control
T2: BWW9 − control
T2: AX23 − control
T1: BWW9 − control
T1: AX23 − control
−10 0 10 20
Estimated Difference of Heart Rates [1/min]
MCTs + Bonferroni CIM (Kenward−Roger) ELM (ESS) MMM
Figure 36: Heart rate data: 95% simultaneous confidence intervals for many-to-one comparisons
of treatments per time point based on AICc-selected joint models (CIM and ELM), combined
marginal models (MMM), and Bonferroni-adjusted MCTs per time point, with small-sample ap-
proximations to the degrees of freedom.
Comparing different DF approximations for the AICc-selected ELM, we find that νESS,
νadj, and νPB2 yield very similar SCIs (Figure 37). Not surprisingly, the intervals con-
structed with the naive DF are unnecessarily wide, and using the residual DF makes the
SCIs almost as narrow as for the asymptotic procedure, which is clearly inadequate given
the small sample sizes.
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T4: BWW9 − control
T4: AX23 − control
T3: BWW9 − control
T3: AX23 − control
T2: BWW9 − control
T2: AX23 − control
T1: BWW9 − control
T1: AX23 − control
−10 0 10 20
Estimated Difference of Heart Rates [1/min]
Asymptotic Residual Pinheiro−Bates Adjusted ESS Naive
Figure 37: Heart rate data: 95% simultaneous confidence intervals for many-to-one comparisons
of treatments per time point based on the AICc-selected ELM with different approximations to
the degrees of freedom, and asymptotic results (for comparison).
Comparing multiple occasions simultaneously for multiple drugs: Another in-
teresting problem is to assess by how much the heart rates differ across time points in
the three treatment arms. This can be solved with Tukey comparisons separately and
simultaneously for all treatments. Again we compare the AICc-selected joint models and
MMM. The correlation matrices of test statistics are displayed in Figure 38.
In the AX23 arm, the heart rate is significantly higher at T2 and T3 compared to T1
and T4 (Table 9) and SCIs (Figure 39). Such clear effects cannot be found for BWW9
or control, whose mean profiles are relatively constant over time. Only T2 and T3 differ
significantly for BWW9. The Bonferroni-adjusted separate MCTs do not always yield
larger p-values and wider SCIs as would perhaps be expected, simply because each of
them uses its own SE estimate whereas the AICc-selected joint models only estimate one
common SE.
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1 0 0 0.68 0 0 0.53 0 0 −0.09 0 0 −0.12 0 0 −0.07 0 0
0 1 0 0 0.68 0 0 0.53 0 0 −0.09 0 0 −0.12 0 0 −0.07 0
0 0 1 0 0 0.68 0 0 0.53 0 0 −0.09 0 0 −0.12 0 0 −0.07
0.68 0 0 1 0 0 0.78 0 0 0.68 0 0 0.41 0 0 −0.12 0 0
0 0.68 0 0 1 0 0 0.78 0 0 0.68 0 0 0.41 0 0 −0.12 0
0 0 0.68 0 0 1 0 0 0.78 0 0 0.68 0 0 0.41 0 0 −0.12
0.53 0 0 0.78 0 0 1 0 0 0.52 0 0 0.78 0 0 0.53 0 0
0 0.53 0 0 0.78 0 0 1 0 0 0.52 0 0 0.78 0 0 0.53 0
0 0 0.53 0 0 0.78 0 0 1 0 0 0.52 0 0 0.78 0 0 0.53
−0.09 0 0 0.68 0 0 0.52 0 0 1 0 0 0.68 0 0 −0.09 0 0
0 −0.09 0 0 0.68 0 0 0.52 0 0 1 0 0 0.68 0 0 −0.09 0
0 0 −0.09 0 0 0.68 0 0 0.52 0 0 1 0 0 0.68 0 0 −0.09
−0.12 0 0 0.41 0 0 0.78 0 0 0.68 0 0 1 0 0 0.68 0 0
0 −0.12 0 0 0.41 0 0 0.78 0 0 0.68 0 0 1 0 0 0.68 0
0 0 −0.12 0 0 0.41 0 0 0.78 0 0 0.68 0 0 1 0 0 0.68
−0.07 0 0 −0.12 0 0 0.53 0 0 −0.09 0 0 0.68 0 0 1 0 0
0 −0.07 0 0 −0.12 0 0 0.53 0 0 −0.09 0 0 0.68 0 0 1 0
0 0 −0.07 0 0 −0.12 0 0 0.53 0 0 −0.09 0 0 0.68 0 0 1
Extended linear model
1 0 0 0.50 0 0 0.50 0 0 −0.50 0 0 −0.50 0 0 0 0 0
0 1 0 0 0.50 0 0 0.50 0 0 −0.50 0 0 −0.50 0 0 0 0
0 0 1 0 0 0.50 0 0 0.50 0 0 −0.50 0 0 −0.50 0 0 0
0.50 0 0 1 0 0 0.50 0 0 0.50 0 0 0 0 0 −0.50 0 0
0 0.50 0 0 1 0 0 0.50 0 0 0.50 0 0 0 0 0 −0.50 0
0 0 0.50 0 0 1 0 0 0.50 0 0 0.50 0 0 0 0 0 −0.50
0.50 0 0 0.50 0 0 1 0 0 0 0 0 0.50 0 0 0.50 0 0
0 0.50 0 0 0.50 0 0 1 0 0 0 0 0 0.50 0 0 0.50 0
0 0 0.50 0 0 0.50 0 0 1 0 0 0 0 0 0.50 0 0 0.50
−0.50 0 0 0.50 0 0 0 0 0 1 0 0 0.50 0 0 −0.50 0 0
0 −0.50 0 0 0.50 0 0 0 0 0 1 0 0 0.50 0 0 −0.50 0
0 0 −0.50 0 0 0.50 0 0 0 0 0 1 0 0 0.50 0 0 −0.50
−0.50 0 0 0 0 0 0.50 0 0 0.50 0 0 1 0 0 0.50 0 0
0 −0.50 0 0 0 0 0 0.50 0 0 0.50 0 0 1 0 0 0.50 0
0 0 −0.50 0 0 0 0 0 0.50 0 0 0.50 0 0 1 0 0 0.50
0 0 0 −0.50 0 0 0.50 0 0 −0.50 0 0 0.50 0 0 1 0 0
0 0 0 0 −0.50 0 0 0.50 0 0 −0.50 0 0 0.50 0 0 1 0
0 0 0 0 0 −0.50 0 0 0.50 0 0 −0.50 0 0 0.50 0 0 1
Conditional independence model
1 0 0 0.66 0 0 0.46 0 0 −0.20 0 0 −0.06 0 0 0.08 0 0
0 1 0 0 0.11 0 0 0.01 0 0 −0.77 0 0 −0.73 0 0 −0.08 0
0 0 1 0 0 0.13 0 0 0.52 0 0 −0.69 0 0 −0.19 0 0 0.63
0.66 0 0 1 0 0 0.87 0 0 0.61 0 0 0.60 0 0 0.44 0 0
0 0.11 0 0 1 0 0 0.41 0 0 0.54 0 0 0.20 0 0 −0.40 0
0 0 0.13 0 0 1 0 0 0.72 0 0 0.62 0 0 0.73 0 0 0.12
0.46 0 0 0.87 0 0 1 0 0 0.65 0 0 0.86 0 0 0.83 0 0
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Figure 38: Heart rate data: correlation matrices of test statistics for all-pairwise comparisons of
time points per treatment group.
Table 9: Simultaneous inference for the heart rate data: estimated differences of heart rates,
standard errors, and adjusted p-values for treatment-wise all-pairwise comparisons of occasions.
Estimate SE(ELM) SE(CIM) SE(MMM) p(ELM) p(CIM) p(MMM) p(Bonf)
AX23: T2 - T1 10.000 1.200 1.365 1.417 <0.001 <0.001 0.002 <0.001
AX23: T3 - T1 10.500 1.621 1.365 1.066 <0.001 <0.001 <0.001 <0.001
AX23: T4 - T1 2.625 1.898 1.365 1.324 0.850 0.529 0.504 0.468
AX23: T3 - T2 0.500 1.200 1.365 1.673 1.000 1.000 1.000 1.000
AX23: T4 - T2 -7.375 1.621 1.365 1.924 0.003 <0.001 0.056 <0.001
AX23: T4 - T3 -7.875 1.200 1.365 1.319 <0.001 <0.001 0.005 <0.001
BWW9: T2 - T1 2.250 1.200 1.365 1.532 0.551 0.725 0.779 0.855
BWW9: T3 - T1 -3.125 1.621 1.365 1.411 0.516 0.291 0.395 0.242
BWW9: T4 - T1 -2.000 1.898 1.365 2.217 0.964 0.836 0.976 1.000
BWW9: T3 - T2 -5.375 1.200 1.365 1.943 0.004 0.003 0.207 0.004
BWW9: T4 - T2 -4.250 1.621 1.365 1.925 0.175 0.042 0.398 0.033
BWW9: T4 - T3 1.125 1.200 1.365 1.544 0.983 0.996 0.993 1.000
Control: T2 - T1 -0.375 1.200 1.365 0.816 1.000 1.000 1.000 1.000
Control: T3 - T1 -1.250 1.621 1.365 1.009 0.995 0.990 0.884 1.000
Control: T4 - T1 -1.750 1.898 1.365 1.613 0.984 0.918 0.937 1.000
Control: T3 - T2 -0.875 1.200 1.365 0.778 0.997 0.999 0.925 1.000
Control: T4 - T2 -1.375 1.621 1.365 1.438 0.991 0.981 0.967 1.000
Control: T4 - T3 -0.500 1.200 1.365 0.891 1.000 1.000 0.999 1.000
Comparing multiple occasions and multiple drugs simultaneously: In a final
step, we combine the Dunnett comparisons of treatment groups and the Tukey compar-
isons of time points into one claim for which we want to protect a joint FWER of 5%. We
apply the duplex procedure introduced in 4.3. Based on our AICc-selected joint CIM, the
Kenward-Roger DF for comparisons of treatments is 29 and for comparisons of occasions
it is 63. Since the model involves constant variance and there are no missing values, the
Kenward-Roger DF is the same for all comparisons of each type.
The resulting SCIs are shown in Figure 40. For comparisons of time points, the method
using separate DFs yields slightly shorter SCIs because it can use 63 DF here whereas
the minimum DF is 29 and the (weighted) average is 52. For comparisons of treatment
groups, the SCIs using minimum and separate DF are identical because they use both 29
DF whereas the intervals using the average DF of 52 are narrower (in fact narrower than
they should be).
Compared to the previous analyses, the “bigger” claim including more elementary hy-
potheses makes the SCIs wider than those in Figures 36 and 39. As a consequence of this,
we can no longer claim that BWW9 raises the heart rate significantly at the first and last
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Figure 39: Heart rate data: 95% simultaneous confidence intervals for all-pairwise comparisons of
time points per treatment group based on AICc-selected joint models (CIM and ELM), combined
marginal models (MMM), and Bonferroni-adjusted MCTs per treatment arm, with small-sample
approximations to the degrees of freedom.
time point. This is the price we pay for controlling the FWER at 5% over comparisons
of treatment groups and time points simultaneously.
4.5 Power
All power investigations in this chapter were done via simulation, but it is also possible to
work out the power of longitudinal MCTs—at least approximately. Exact any-pair power
calculations for standard MCTs are outlined in Genz and Bretz (1999) and Bretz et al.
(2001b). We extend their work in that we show how to calculate various types of powers
(see 3.9) for our longitudinal MCTs. Our subsequent considerations are, however, only
approximate because correlations of time points have to be estimated from sample values
and hence the reference quantiles are random variables rather than fixed quantities.
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Figure 40: Heart rate data: 95% simultaneous confidence intervals for many-to-one compar-
isons of treatments per time point and all-pairwise comparisons of time points per treatment
group simultaneously based on the AICc-selected joint CIM with average, minimum, and separate
(comparison-specific) Kenward-Roger degrees of freedom.
Global Power: The global power for two-sided problems can be approximated as
P{∃ h : |Th| > ttwoz,1−α(ν,Γ)} = 1− Tz(−ttwoz,1−α(ν,Γ), ttwoz,1−α(ν,Γ),Γ, ν,κ)
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where Tz(a, b,Γ, ν,κ) is the z-variate t-probability with integration bounds a and b (same
in all z dimensions), correlation matrix Γ, degrees of freedom ν, and noncentrality vector
κ. The one-sided analogues are
P{∃ h : Th > tonez,1−α(ν,Γ)} = 1− Tz(−∞, tonez,1−α(ν,Γ),Γ, ν,κ)
and for the opposite direction
P{∃ h : Th < −tonez,1−α(ν,Γ)} = 1− Tz(−tonez,1−α(ν,Γ),∞,Γ, ν,κ).
Any-Pair Power: The approximate any-pair power for testing two-sided hypotheses
is
P{∃ h ∈ A : |Th| > ttwoz,1−α(ν,Γ)} = 1− Tz∗(−ttwoz,1−α(ν,Γ), ttwoz,1−α(ν,Γ),Γ∗, ν,κ∗)
with Tz∗ a z
∗-variate t-probability, and z∗ is the number of elementary hypotheses that
is under the alternative. Now Γ∗ is the submatrix of Γ containing the elements of Γ that
correspond to the elementary hypotheses under the alternative, and likewise κ∗ is the
subvector of κ that contains only the z∗ values referring to the set A (see 3.9). Note
that 1 ≤ z∗ ≤ z; in case all contrasts are under H0, the any-pair power is set to α. The
expressions for upper- and lower-tailed tests, respectively, are
P{∃ h ∈ A : Th > tonez,1−α(ν,Γ)} = 1− Tz∗(−∞, tonez,1−α(ν,Γ),Γ∗, ν,κ∗)
and
P{∃ h ∈ A : Th < −tonez,1−α(ν,Γ)} = 1− Tz∗(−tonez,1−α(ν,Γ),∞,Γ∗, ν,κ∗).
All-Pairs Power: An approximation for the all-pairs power with two-sided hypotheses
is
P{|Th| > ttwoz,1−α(ν,Γ) ∀ h ∈ A}
and is best found via simulation. If all contrasts are under the null, the all-pairs power
is α by definition. The corresponding expressions for one-sided alternatives are
P{Th > tonez,1−α(ν,Γ) ∀ h ∈ A} = Tz∗(−tonez,1−α(ν,Γ),∞,Γ∗, ν,κ∗)
and
P{Th < tonez,1−α(ν,Γ) ∀ h ∈ A} = Tz∗(−∞, tonez,1−α(ν,Γ),Γ∗, ν,κ∗)
with the symbols defined as for the any-pair power.
It is arguable which type of power to consider for a given problem. The choice should
depend on the win criterion (Dmitrienko et al. 2013): if the research question is such that
an effect can be successfully claimed if at least one difference (and no matter which one)
is significant, then the any-pair power is appropriate. For practical purposes, however,
the global power is probably more relevant; it is “contaminated” with elementary type
I errors, but in practice they will be indistinguishable from true effects. The all-pairs
power is in demand if we want to show that all differences are significant, a situation
which is rather hard to think of in the context of longitudinal MCTs.
An R program for computing the approximate global, any-pair, and all-pairs power is
given in Appendix E.
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5 Longitudinal MCTs with Discrete Endpoints
Numerous biological and medical outcomes are not measured on a continuous scale but
rather as counts or proportions. Such discrete data have signature characteristics that
are incompatible with the assumption of a Gaussian distribution:
• Proportions are always between 0 and 1.
• Counts are integers and cannot become negative.
• The variance is not independent of the mean.
Therefore the methods proposed in the previous Chapter 4 are not directly applicable
to discrete data, but they can be modified. A joint model for discrete data may come
from the class of generalized linear mixed-effects models (GLMMs) or be fitted with
generalized estimating equations (GEEs). Likewise, the MMM method can be built on
occasion-specific generalized linear models (GLMs).
We describe asymptotic approaches to comparisons of treatments at multiple occasions
and comparisons of occasions within multiple treatment groups for discrete endpoints,
focusing on binomial proportions in 5.1 and Poisson rates in 5.2, and we outline how to
create a duplex procedure (analogous to that for Gaussian data in 4.3) in the presence of
discrete outcomes in 5.3. We assess via simulation the finite-sample properties of these
asymptotic procedures, devise their achieved size under H0, and compare their powers.
Moreover, we show how to evaluate three real datasets in 5.4.
5.1 Binomial Data
Imagine an experiment where binomial proportions are measured repeatedly at a number
of occasions within multiple treatment groups i.e., a number of successes and failures is
recorded for each treatment at each time point. We are interested in multiple compar-
isons (adjusted p-values and SCIs) of binomial proportions pi among treatment groups at
several occasions or among occasions within several treatment groups under control of α.
Such comparisons can be useful for repeatable or reversible events; on the other hand,
irreversible events like death are better analyzed with time-to-event methods.
We propose two basic approaches, one based on a joint model for the entire timespan
of interest, and the other using marginal occasion-specific models, in 5.1.1. As the pro-
cedures are asymptotic in nature, satisfactory control of type I error rates cannot be
guaranteed with small sample sizes. Thus we employ numerical simulations in 5.1.2 to
assess minimum sample sizes that ensure α control within a sufficient range. In ad-
dition, we compare the powers of the joint modeling and MMM approaches with each
other and also with simple Bonferroni adjustments that ignore any correlation over time.
Application to real data from a study in pest control is showcased in 5.4.3.
5.1.1 Procedure
Suppose the outcome of an experiment with independent units i = 1, . . . , n randomized
to treatment groups k = 1, . . . , q is binomial, and it is measured repeatedly at occasions
j = 1, . . . ,m. The random variable of outcomes Y has realizations y = (y111, . . . , ynmq)
T
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where yijk refers to the observation recorded from individual i belonging to treatment
group k at time point j. Further nk denotes the number of individuals randomized to
the kth treatment group, and n(j) is the number of individuals measured at occasion j,
which may vary (because of dropout etc.) from occasion to occasion. Superscript index
(j) pertains to the marginal model for the jth occasion.
Within every single occasion j the observations are (assumed to be) distributed as
Y
(j)
i ∼ Bin(pi(j)i , w(j)i )
where w
(j)
i denotes the total number of success and failures for unit i at occasion j.
According to binomial theory,
E(Y
(j)
i ) = w
(j)
i pi
(j)
i
and
V ar(Y
(j)
i ) = w
(j)
i pi
(j)
i (1− pi(j)i ).
Our aim is now to compare treatment means at multiple occasions or occasion means at
multiple treatments using a procedure that is a variation of the longitudinal MCTs for
Gaussian endpoints described in 4.1.1 and 4.2.1. Instead of fitting a joint LMM, however,
we now use binomial GEEs (as in 3.4) with some working correlation Ri(α) as a joint
model. Solving the GEE yields consistent estimates of β, and the sandwich estimate
Σ̂ is a consistent estimate of Σ even under misspecification of the working correlation;
naive covariance estimates may be calculated as well. These estimates can readily be
used for tests and SCIs as detailed in 4.1.1. Multiple testing of GEE parameters was
also described in Orelien et al. (2002). We do not consider GLMMs as joint models here
because we want to focus on the interpretation of population rather than within-subject
effects.
The alternative to joint modeling is once again to combine multiple occasion-specific
models. Instead of marginal linear models, we now fit one marginal binomial GLM (as
in 3.3)
logit(pi(j)) = log
(
pi(j)
1− pi(j)
)
= η(j) = X(j)β(j)
per time point j with pi = (pi
(j)
1 , . . . , pi
(j)
n(j)
)T and η = (η
(j)
1 , . . . , η
(j)
n(j)
)T . In a simple one-way
model without covariates, X(j) will be an n(j)×q matrix, and β(j) = (β(j)1 , . . . , β(j)q )T . The
correlation among the parameters β = (β(1), . . . ,β(m))T can be estimated as described in
3.5 by stacking their respective score contributions from the m marginal binomial GLMs.
The Ψij are now obtained from the first coordinate of
−E
(
pi(j)(1− pi(j))x(j)i x(j)Ti
)−1
x
(j)
i
(
y
(j)
i − pi(j)
)
.
Following the further steps in 3.5 provides us with estimates of β and Σ that can be used
for testing hypotheses and building SCIs.
Comparisons of treatments per occasion or occasions per treatment are defined in co-
efficient matrices C as outlined in 4.1.1 and 4.2.1. The testing procedure controls the
FWER asymptotically at level α, and the SCIs have an asymptotic coverage probability
of (1−α). Finite-sample properties of this asymptotic method have not been investigated
so far, so we will dedicate the next subsection to an exploration of which sample sizes are
necessary to achieve a reasonable test size.
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5.1.2 Simulation Study
As pointed out by Pipper et al. (2012) the procedure combining marginal GLMs is asymp-
totic i.e., it may fail to control the prespecified rate of type I errors with small sample
sizes. Thus we set up a simulation study to gauge which sample sizes are necessary to
come close to nominal α control. Moreover, we are interested in power comparisons of
the joint GEE and multiple marginal GLM approaches.
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Figure 41: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-mean
comparisons of binomial data (pi = {0.5, 0.6, 0.7, 0.8}) involving q = 3 treatments and m = 3
occasions, with nk independent subjects per treatment group, based on multiple marginal GLMs
(1000 simulation runs). Top: comparisons of treatment means separately and simultaneously
within occasions; bottom: comparisons of occasion means separately and simultaneously within
treatment groups.
Type I error: To investigate the actual size of the tests under H0, we generate cor-
related multivariate binary data using Gaussian copulae (see Appendices B and E) in
balanced longitudinal settings with nk = {10, 20, . . . , 300} independent units in each of
q = {3, 4, 5} treatment groups, measured at m = {3, 4, 5} points in time. For layouts
with q = 3 and m = 3 we investigate four different correlations:
B1 =
 1 0.95 0.901 0.95
1
 , B2 =
 1 0.90 0.801 0.90
1
 ,
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B3 =
 1 0.80 0.501 0.80
1
 , B4 =
 1 0.50 0.201 0.50
1
 .
For settings with q = 4 or 5 treatments and m = 3, we use B2 as correlation matrix. For
m = 4 with q = 3 we use
B5 =

1 0.90 0.80 0.70
1 0.90 0.80
1 0.90
1
 ,
and for m = 5 with q = 3
B6 =

1 0.90 0.80 0.70 0.60
1 0.90 0.80 0.70
1 0.90 0.80
1 0.90
1
 .
All these settings are simulated with binomial probabilities pi = {0.5, 0.6, 0.7, 0.8} for the
simplest case where w
(j)
i = 1 for all independent units at all occasions, so the outcomes
yijk can only take values 0 or 1. . We apply two different modeling strategies: fitting
a binomial GEE with AR(1) working correlation, or fitting one binomial GLM per time
point and proceed with MMM. Based on either of these, we simultaneously test many-to-
one, all-pairwise, or grand-mean contrasts of treatment means per occasion, or occasion
means per treatment, at a nominal α = 0.05 level. Then we record for each of 1000
simulation runs whether the minimum adjusted p-value falls below 0.05.
Figure 41 displays simulated type I error rates with m = q = 3 and correlation B2
for the multiple marginal GLMs approach. We see that this asymptotic procedure is
conservative in the presence of small samples. The extent of conservatism tends to be more
pronounced as pi diverges from 0.5. For samples as small as nk = 10, many-to-one and
all-pairwise comparisons of occasions within several treatment groups have practically no
power whereas the realized α level for comparisons of treatments at multiple time points
is between 0 and 0.02 when nk = 10. The situation appears somewhat more relaxed with
grand-mean contrasts. Broadly speaking, a minimum sample size of at least 50 (in the
setting where all w
(j)
i = 1) seems to be required for type I error rates reliably close to the
nominal α.
The situation is slightly different for the GEE-based procedure (Figure 42). When com-
paring multiple treatments per occasion, using the naive SE makes the tests conservative
with small sample sizes (where small refers to nk < 50) whereas the robust SE appears
to be very unstable if the sample size is pathologically small (nk < 10), especially for pi
equal to 0.7 and 0.8. For comparisons of occasions per treatment, using the naive SE
leads to a slightly liberal procedure with type I error rates around 0.07 to 0.08 even for
large samples.
Simulation results with m and q values other than 3 are shown in Appendix D: Figures
64, 65, and 66 for multiple marginal GLMs, and Figures 67, 68, and 69 for joint GEEs.
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Figure 42: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-mean
comparisons of binomial data (pi = {0.5, 0.6, 0.7, 0.8}) involving q = 3 treatments and m = 3
occasions, with nk independent subjects per treatment group, based on GEEs (1000 simulation
runs). Top: comparisons of treatment means separately and simultaneously within occasions;
bottom: comparisons of occasion means separately and simultaneously within treatment groups.
Power: We study power with the sample size fixed at nk = 100 for which we have
observed proper control of α in the preceding simulations. We investigate the same
scenarios as above i.e., m = {3, 4, 5} and q = {3, 4, 5} with correlations B1 through B6.
The true proportion of success is set to pi + ∆ with ∆ = {−0.30,−0.28, . . . , 0.28, 0.30}
for the qth treatment at the mth occasion, and pi for all other combinations of k and
j. We apply the following asymptotic procedures to compare treatments per occasion or
occasions per treatment:
1. pairwise two-sample tests (z-tests) of GLM parameters, adjusted with Bonferroni
for the multiplicity of treatments and occasions (this ignores any correlation among
test statistics),
2. one standard (asymptotic) MCT of GLM parameters per time point, adjusted with
Bonferroni for the multiplicity of occasions (i.e., ignoring correlation over time),
3. longitudinal MCTs based on multiple marginal GLMs with MMM,
4. longitudinal MCTs based on a joint GEE with AR(1) working correlation.
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Figure 43: Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons of
binomial data (pi = {0.5, 0.6, 0.7, 0.8}) involving q = 3 treatments and m = 3 occasions, with
nk = 100 independent subjects per treatment group (1000 simulation runs). Top: comparisons of
treatment means separately and simultaneously within occasions; bottom: comparisons of occasion
means separately and simultaneously within treatment groups.
Power curves from 1000 simulation runs are presented in Figure 43. We see that the
power advantage of longitudinal MCTs over Bonferroni-based procedures is only a few
percent when treatments are compared per occasion. There is almost no difference in
power between joint GEEs and multiple marginal GLMs. However, when comparing
occasions per treatment, the Bonferroni-based procedures that ignore any longitudinal
correlation are severely inferior and have practically no power for −0.1 < ∆ < 0.1. All
this is in line with the findings for Gaussian data in 4.1.3 and 4.2.3. The curves are
asymmetric around ∆ = 0 because the theoretical upper limit of the pi or pi+ ∆ is 1, and
the power goes down to zero as soon as the bound of 1 is reached.
Further simulation results for m, q > 3 are depicted in Figure 71, and for m = q = 3 with
correlation matrices B1, B3, and B4 in Figure 72, both in Appendix D.
5.2 Poisson Data
Now suppose the outcome of an experiment are Poisson rates (e.g., counts of events within
a defined period of time) measured repeatedly from individuals that were randomized to
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treatment groups. The goal is to perform multiple comparisons of Poisson rates λ between
treatment groups at several occasions and/or between occasions within several treatment
groups, so as to obtain adjusted p-values as well as SCIs.
This section is structured similar to 5.1: the basic methodology for longitudinal MCTs
based on joint modeling as well as a set of marginal GLMs is to be presented in 5.2.1.
We devise minimum sample size requirements for proper α control via simulation in 5.2.2
and compare the respective powers of procedures incorporating and ignoring longitudinal
correlation. Application to real data from an experiment in entomology and a clinical
trial is illustrated in 5.4.1 and 5.4.2.
5.2.1 Procedure
Assume an experiment where independent units i = 1, . . . , n are randomized to treatment
groups k = 1, . . . , q, and some Poisson outcome is measured repeatedly at occasions
j = 1, . . . ,m. The random variable of outcomes Y has realizations y = (y111, . . . , ynmq)
T
where yijk refers to the observation recorded from individual i belonging to treatment
group k at time point j. Further nk denotes the number of individuals randomized to
the kth treatment group, and n(j) is the number of individuals measured at occasion j,
which may vary (because of dropout etc.) from occasion to occasion. Superscript index
(j) pertains to the marginal model for the jth occasion.
Within every single occasion j the observations are (assumed to be) distributed as
Y
(j)
i ∼ Pois(λ(j)i ),
and we know from Poisson theory that
E(Y
(j)
i ) = V ar(Y
(j)
i ) = λ
(j)
i .
We want to carry out comparisons among treatment means at multiple occasions or
occasion means for multiple treatment groups using an asymptotic longitudinal MCT
procedure similar to the one introduced for binomial data in 5.1.1 but now for Poisson
outcomes. The joint modeling approach is now a Poisson GEE with some working cor-
relation Ri(α), and the alternative is the MMM-type combination of occasion-specific
Poisson GLMs
log(λ(j)) = η(j) = X(j)β(j)
with λ = (λ
(j)
1 , . . . , λ
(j)
n(j)
)T , and η, X, and β as defined in 5.1.1.
We estimate the correlation among the parameter estimates β = (β(1), . . . ,β(m))T as
outlined in 3.5 by stacking their respective score contributions from the m marginal
Poisson GLMs and obtain the Ψij from the first coordinate of
−E
(
λ(j)x
(j)
i x
(j)T
i
)−1
x
(j)
i
(
y
(j)
i − λ(j)
)
.
Completing the steps in 3.5 yields estimates of both β and Σ that can be used for tests
with asymptotic control of α and SCIs with asymptotic coverage probability of (1− α).
We investigate the finite-sample properties of this method in the following.
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5.2.2 Simulation Study
We have noted that the method combining multiple binomial GLMs controls α only
asymptotically, and that small sample sizes may lead to undesirable behavior. Similar
concerns pertain to combining marginal Poisson GLMs, which we will investigate numer-
ically. We seek to assess minimum sample size requirements for the asymptotic method
to control α in an acceptable range.
Type I error: Correlated multivariate Poisson data under H0 are drawn by means
of Gaussian copulae (see Appendices B and E) as in 5.1.2, with the difference that the
marginal distributions are now Poisson with rates λ = {3, 5, 10, 20}. The simulation
setups resemble those for the binomial investigation but with nk = {4, 6, . . . , 50} inde-
pendent units within each of q = {3, 4, 5} treatment groups measured at m = {3, 4, 5}
occasions. We use as correlation matrices B1 through B6 from 5.1.2, and the variances
are obviously determined by the choice of λ.
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Figure 44: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons of Poisson data (λ = {3, 5, 10, 20}) involving q = 3 treatments and m = 3
occasions, with nk independent subjects per treatment group, based on multiple marginal GLMs
(1000 simulation runs). Top: comparisons of treatment means separately and simultaneously
within occasions; bottom: comparisons of occasion means separately and simultaneously within
treatment groups. Note that the vertical axes differ widely in their scaling.
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Estimates of the test size based on multiple marginal GLMs with 1000 simulation runs
are shown in Figure 44. We find comparisons of treatment means at multiple occasions to
be unproblematic even with small samples: they may get a little conservative (around 3
to 4 %) for nk < 10, but apart from that they stick to the nominal 5% level very closely.
Comparisons of occasions within multiple treatment groups, however, are exceedingly
liberal with type I error rates of up to 60% under H0, and approach their nominal size
rather slowly. Only with nk = 50 acceptable α levels around 6 to 7% are achieved.
When using GEE estimates as a basis for longitudinal MCTs, the tests can as well
become very liberal if the sample size is too small, for both comparisons of treatments
and occassions (Figure 45). Interestingly, the naive SE estimate seems to cushion the
extent of conservatism somewhat. With the naive SE, sample sizes nk between 20 and 30
are sufficient to control the level α whereas at least 40 to 50 are needed with the robust
SE estimates.
Appendix D holds more simulation results: type I error estimates for scenarios with m
or q > 3 are shown in Figures 73, 74, and 75 for multiple marginal GLMs, and in Figures
76, 77, and 78 for joint GEEs.
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Figure 45: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons of Poisson data (λ = {3, 5, 10, 20}) involving q = 3 treatments and m = 3
occasions, with nk independent subjects per treatment group, based on GEEs (1000 simulation
runs). Top: comparisons of treatment means separately and simultaneously within occasions;
bottom: comparisons of occasion means separately and simultaneously within treatment groups.
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Power: To simulate the finite sample power, we fix the sample size at nk = 50 and
study scenarios involving m = {3, 4, 5} and q = {3, 4, 5} with correlation matrices B1
through B6. The true Poisson rate for the qth treatment at the mth occasion is set to
λ+ ∆ with ∆ = {0, 0.02, . . . , 0.28, 0.30}, and λ for all other combinations of k and j.
The power curves based on 1000 simulation runs (Figure 46) look somewhat similar
to those for Gaussian data in 4.1.3 and 4.2.3. Longitudinal MCTs based on GEEs or
MMM have almost identical power, and they are marginally superior to the Bonferroni-
based procedures for comparing treatments per occasion, and clearly more powerful when
occasions are compared per treatment group. These power advantages increase with λ,
but on the other hand, increasing λ reduces the power of all procedures because in a
Poisson framework the mean equals the variance.
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Figure 46: Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons of
Poisson data (λ = {3, 5, 10, 20}) involving q = 3 treatments and m = 3 occasions, with nk = 50
independent subjects per treatment group (1000 simulation runs). Top: comparisons of treatment
means separately and simultaneously within occasions; bottom: comparisons of occasion means
separately and simultaneously within treatment groups.
Additional power curves are presented in Appendix D with Figure 80 for m, q > 3, and
Figure 81 for correlation matrices B1, B3, and B4 with m = q = 3.
5 LONGITUDINAL MCTS WITH DISCRETE ENDPOINTS 107
5.3 A Duplex Procedure
We want to extend our asymptotic longitudinal MCTs for discrete data along the lines of
the duplex procedure in 4.3 i.e., we wish to enable ourselves to obtain adjusted p-values
and SCIs for sets of elementary hypotheses that contain both simultaneous comparisons
of treatment means and simultaneous comparisons of occasion means, with asymptotic
FWER control over all elementary hypotheses.
5.3.1 Procedure
We have learned from the simulations in 5.1.2 and 5.2.2 that the sample size requirements
for sufficient α control are usually higher with comparisons of occasions within multiple
treatment groups than with comparisons of treatments at multiple occasions. Now that
we want to blend the two types of tests, the data samples should obviously be large
enough for both components (comparisons of treatments per occasion, and comparisons
of occasions per treatment) to achieve proper control of α.
Longitudinal MCTs for discrete data are inherently asymptotic, and thus the duplex
procedure is considerably easier to contrive than the one for Gaussian outcomes: one
does not have to worry about how to deal with widely different DFs because there are
none involved.
5.3.2 Simulation Study
We study the finite-sample type I error rate and power of the asymptotic duplex procedure
based on either a GEE or multiple marginal GLMs via simulation, for both binomial
and Poisson data. The simulation setups are similar to those in 5.1.2 and 5.2.2, but the
contrast matrix now embraces comparisons among treatments as well as among occasions
as shown in 4.3.
Type I error: For binomial outcomes, the tests based on GEEs using robust SEs or
multiple marginal GLMs are severely conservative for nk < 50 whereas the GEE with
naive SEs comes closer to the nominal α (Figure 47). As pi moves away from 0.5, the
degree of conservatism tends to increase. With sufficiently large sample sizes all methods
keep the desired type I error rate.
For Poisson counts, all asymptotic methods are wildly liberal when the sample size is
too small (Figure 48). With nk = 4, the GEE with naive SEs leads to type I error rates
around 20 to 25%, whereas they can even be inflated up to 40 to 60% for the GEE with
robust SEs and for multiple marginal GLMs. As a consequence, nk should be at least
around 30 for the former and 40 to 50 for the latter methods to ensure reasonable control
of α. The choice of λ does not seem to have any influence here.
Detailed simulation results with different numbers of treatment groups and time points
are shown in Figure 70 for binomial outcomes and in Figure 79 for Poisson counts.
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Figure 47: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons of binomial data (pi = {0.5, 0.6, 0.7, 0.8}) among q = 3 treatment means
separately and simultaneously at m = 3 occasions and among m = 3 occasion means separately
and simultaneously for q = 3 treatments, with nk independent subjects per treatment group,
based on GEEs or multiple marginal GLMs (1000 simulation runs).
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Figure 48: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons of Poisson data (λ = {3, 5, 10, 20}) among q = 3 treatment means separately
and simultaneously at m = 3 occasions and among m = 3 occasion means separately and simulta-
neously for q = 3 treatments, with nk independent subjects per treatment group, based on GEEs
or multiple marginal GLMs (1000 simulation runs).
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Power: We want to gauge the gain in power when uniting all comparisons in one family
(or “claim”) compared to performing separate longitudinal MCTs for comparisons among
treatments and comparisons among occasions and then adjusting with Bonferroni (i.e.,
multiplying the p-values by two). The resulting power curves are shown in Figure 49 for
binomial and in Figure 50 for Poisson data. The power advantage of the joint analysis
(all comparisons in the same test family) is never more than 2 to 3 percentage points,
and the powers of the GEE- and MMM-based analyses are practically the same.
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Figure 49: Simulated powers for asymptotic many-to-one, all-pairwise, and grand-mean com-
parisons of binomial data (pi = {0.5, 0.6, 0.7, 0.8}) among q = 3 treatment means separately and
simultaneously at m = 3 occasions and among m = 3 occasion means separately and simultane-
ously for q = 3 treatments, with nk = 100 independent subjects per treatment group, based on
GEEs or multiple marginal GLMs (1000 simulation runs).
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Figure 50: Simulated powers for asymptotic many-to-one, all-pairwise, and grand-mean com-
parisons of Poisson data (λ = {3, 5, 10, 20}) among q = 3 treatment means separately and simul-
taneously at m = 3 occasions and among m = 3 occasion means separately and simultaneously
for q = 3 treatments, with nk = 50 independent subjects per treatment group, based on GEEs or
multiple marginal GLMs (1000 simulation runs).
5.4 Application to Example Data
We illustrate longitudinal MCTs for discrete outcomes with the count data of greenhouse
whiteflies and epileptic seizures that we introduced in 2.4 and 2.5 and with the proportions
of larval and pupal mortalities under azadirachtin treatment as exposed in 2.6.
5.4.1 Greenhouse Whiteflies
We evaluate the greenhouse whitefly data of 2.4 with longitudinal MCTs for discrete
endpoints. The sample sizes are large enough to justify the asymptotic method. A
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reasonable distributional assumption is Poisson: the outcome is measured as counts, and
the data are skewed to the right.
Comparing multiple environments simultaneously for multiple plant parts:
We want to investigate whether the type of microclimatic environment (glasshouse or
one of two types of foil tunnels) makes an impact on how many whiteflies are found at
the bottom, middle, and top of the plants after introduction of the predator Macrolo-
phus pygmaeus. To this end we perform all-pairwise comparisons of the environments
separately and simultaneously for each plant part.
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Figure 51: Greenhouse whitefly data: correlation matrices of test statistics for all-pairwise
comparisons of environments per part of the plant.
One strategy is to fit a joint GEE with Poisson assumption, logarithmic link function, and
an unstructured working correlation matrix; the other one is to fit separate quasi-Poisson
GLMs for each of the plant parts. The estimated overdispersion parameters are 8.32,
9.21, and 4.71, so the quasi-likelihood analysis is obviously justified. Figure 51 shows the
estimated correlations based on the joint model and MMM, which are all very similar.
Table 10: Simultaneous inference for the greenhouse whitefly data: estimated differences of log-
numbers of whiteflies, standard errors, and adjusted p-values for part-wise all-pairwise comparisons
of environments.
Est(GEE) Est(MMM) SE(robust) SE (naive) SE(MMM) p(robust) p(naive) p(MMM) p(Bonf)
Bottom: Tunnel 1 - Glasshouse -0.398 -0.453 0.207 0.236 0.262 0.331 0.478 0.455 0.574
Bottom: Tunnel 2 - Glasshouse 0.161 0.161 0.185 0.176 0.188 0.953 0.938 0.956 1.000
Bottom: Tunnel 2 - Tunnel 1 0.559 0.614 0.210 0.252 0.279 0.061 0.180 0.189 0.208
Middle: Tunnel 1 - Glasshouse -0.841 -0.834 0.277 0.269 0.304 0.020 0.014 0.047 0.048
Middle: Tunnel 2 - Glasshouse -0.084 -0.084 0.200 0.193 0.217 0.999 0.999 0.999 1.000
Middle: Tunnel 2 - Tunnel 1 0.757 0.750 0.282 0.293 0.331 0.057 0.073 0.162 0.175
Top: Tunnel 1 - Glasshouse -0.030 0.043 0.619 0.839 0.661 1.000 1.000 1.000 1.000
Top: Tunnel 2 - Glasshouse 0.141 0.141 0.624 0.776 0.625 1.000 1.000 1.000 1.000
Top: Tunnel 2 - Tunnel 1 0.171 0.098 0.654 0.931 0.736 1.000 1.000 1.000 1.000
Results of asymptotic all-pairwise comparisons of environments are presented in Table
10. We know there are a few values missing for foil tunnel 1; this is why the estimates
differ between GEE and MMM for all comparisons that involve tunnel 1. The robust and
naive SEs from the GEE and those from the MMM approach are mostly similar, but a bit
higher with MMM for the bottom and middle parts, and with the naive GEE approach
for the top part. Overall the SEs associated with measurements from the top part are
around three times as large as those from the bottom and middle of the plant, which is
due to the low counts with many zeroes.
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Figure 52: Greenhouse whitefly data: 95% simultaneous confidence intervals for asymptotic all-
pairwise comparisons of environments per plant part based on a joint GEE (with robust or naive
covariance estimation), combined marginal GLMs (MMM), and Bonferroni-adjusted MCTs per
plant part.
In the environment of tunnel 1 infestation with whiteflies at the middle of the plant is
significantly reduced in comparison to the glasshouse; the upper boundaries of the SCIs
are, however, very close to the point no effect (Figure 52), implying that the difference
might not be seen as biologically important. There is also some indication that tunnel
1 is better than tunnel 2 in reducing infestation at the bottom and middle, although
these comparisons are not significant at the familywise 5% level. For the top of the
plant all effect estimates are close to 0, with very wide SCIs around them. The p-values
obtained from separate MCTs per plant part that were adjusted with Bonferroni for the
multiplicity of measurements are always larger than those from the GEE with robust SE
estimates and MMM, and correspondingly the SCIs are always wider.
Comparing multiple plant parts simultaneously in multiple environments:
Next we want compare the mean numbers of whiteflies at the different plant parts sepa-
rately and simultaneously for each type of environment. The relevant correlation matrices
of test statistics are depicted in Figure 53, and we see clearly that the bottom and middle
parts are highly correlated with each other but not with the top.
Table 11 summarizes the results of the analysis using all-pairwise comparisons. Again,
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Figure 53: Greenhouse whitefly data: correlation matrices of test statistics for all-pairwise
comparisons of plant parts per environment.
the comparisons involving tunnel 1 have slightly different estimates with GEE and MMM.
From the SEs in Table 11 and the SCIs in Figure 54 we can tell that the differences be-
tween middle and bottom parts are estimated much more precisely than their differences
to the top parts. Numbers of whiteflies do not differ significantly between the middle and
the bottom in any microclimatic environment.
Table 11: Simultaneous inference for the greenhouse whitefly data: estimated differences of log-
numbers of whiteflies, standard errors, and adjusted p-values for environment-wise all-pairwise
comparisons of plant parts.
Est(GEE) Est(MMM) SE(robust) SE (naive) SE(MMM) p(robust) p(naive) p(MMM) p(Bonf)
Glasshouse: Middle - Bottom -0.021 -0.021 0.143 0.111 0.127 1.000 1.000 1.000 1.000
Tunnel 1: Middle - Bottom -0.463 -0.402 0.229 0.245 0.322 0.262 0.328 0.790 0.900
Tunnel 2: Middle - Bottom -0.266 -0.266 0.149 0.155 0.177 0.409 0.445 0.613 0.822
Glasshouse: Top - Bottom -2.957 -2.957 0.434 0.475 0.394 <0.001 <0.001 <0.001 <0.001
Tunnel 1: Top - Bottom -2.589 -2.461 0.477 0.712 0.564 <0.001 0.002 <0.001 <0.001
Tunnel 2: Top - Bottom -2.977 -2.977 0.457 0.626 0.489 <0.001 <0.001 <0.001 <0.001
Glasshouse: Top - Middle -2.936 -2.936 0.402 0.455 0.365 <0.001 <0.001 <0.001 <0.001
Tunnel 1: Top - Middle -2.126 -2.059 0.461 0.671 0.511 <0.001 0.011 <0.001 <0.001
Tunnel 2: Top - Middle -2.712 -2.712 0.459 0.600 0.493 <0.001 <0.001 <0.001 <0.001
Comparing multiple environments and multiple plant parts simultaneously:
We can combine the comparisons among environments and among plant parts into one
claim and analyze it under joint control of α at 5%. The results of this analysis are
summarized in Table 12, and the corresponding SCIs are plotted in Figure 55. Unsur-
prisingly, we find that the adjusted p-values are a bit higher and the SCIs a bit wider
than before, but this does not change the conclusions fundamentally.
Given the large number of zero counts, in particular for observations from the top part
of the plant, an alternative for this dataset could be a zero-inflated Poisson model.
5.4.2 Epileptic Seizures
We analyze the counts of epileptic seizures introduced in 2.5 with longitudinal MCTs for
Poisson data.
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Figure 54: Greenhouse whitefly data: 95% simultaneous confidence intervals for asymptotic all-
pairwise comparisons of plant parts per environment based on a joint GEE (with robust or naive
covariance estimation), combined marginal GLMs (MMM), and Bonferroni-adjusted MCTs per
environment.
Comparing active drug and placebo at multiple occasions: The question of inter-
est is whether progabide accomplishes an improvement over placebo (i.e., fewer seizures)
at any of the time points except baseline, and if so, at which one(s). We apply the
longitudinal MCT procedures for count data introduced in 5.2 and rely on asymptotics,
which should be acceptable given the sample sizes of 31 in the progabide group and 28
with placebo. This results in four two-sample comparisons of progabide versus placebo,
one at each of the four measurement times. Since only a reduction compared to placebo
would be an interesting effect, we carry out one-sided comparisons.
One option is GEE modeling with a Poisson assumption, a logarithmic link function for
the number of seizures, AR(1) working correlation, and log(age) as a covariate. The
alternative is marginal quasi-Poisson GLMs, also with a logarithmic link and log(age) as
a covariate, separately for each time point. The GLMs reveal a substantial amount of
overdispersion at all time points. Figure 56 shows that MMM estimates slightly lower
correlation between time points than the GEE.
The test results are summarized in Table 13. The effect estimates from GEE and MMM
are similar, but the SEs differ quite a bit: especially the naive SEs from the GEE are
much more homogeneous than the robust ones and those from MMM. The conclusions
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Table 12: Simultaneous inference for the greenhouse whitefly data: estimated differences of log-
numbers of whiteflies, standard errors, and adjusted p-values for part-wise all-pairwise comparisons
of environments and environment-wise all-pairwise comparisons of plant parts.
Est(GEE) Est(MMM) SE(robust) SE (naive) SE(MMM) p(robust) p(naive) p(MMM)
Bottom: Tunnel 1 - Glasshouse -0.398 -0.453 0.207 0.236 0.262 0.473 0.639 0.617
Bottom: Tunnel 2 - Glasshouse 0.161 0.161 0.185 0.176 0.188 0.989 0.983 0.990
Bottom: Tunnel 2 - Tunnel 1 0.559 0.614 0.210 0.252 0.279 0.100 0.275 0.291
Middle: Tunnel 1 - Glasshouse -0.841 -0.834 0.277 0.269 0.304 0.034 0.024 0.079
Middle: Tunnel 2 - Glasshouse -0.084 -0.084 0.200 0.193 0.217 1.000 1.000 1.000
Middle: Tunnel 2 - Tunnel 1 0.757 0.750 0.282 0.293 0.331 0.094 0.119 0.253
Top: Tunnel 1 - Glasshouse -0.030 0.043 0.619 0.839 0.661 1.000 1.000 1.000
Top: Tunnel 2 - Glasshouse 0.141 0.141 0.624 0.776 0.625 1.000 1.000 1.000
Top: Tunnel 2 - Tunnel 1 0.171 0.098 0.654 0.931 0.736 1.000 1.000 1.000
Glasshouse: Middle - Bottom -0.021 -0.021 0.143 0.111 0.127 1.000 1.000 1.000
Tunnel 1: Middle - Bottom -0.463 -0.402 0.229 0.245 0.322 0.402 0.486 0.905
Tunnel 2: Middle - Bottom -0.266 -0.266 0.149 0.155 0.177 0.576 0.619 0.771
Glasshouse: Top - Bottom -2.957 -2.957 0.434 0.475 0.394 <0.001 <0.001 <0.001
Tunnel 1: Top - Bottom -2.589 -2.461 0.477 0.712 0.564 <0.001 0.004 <0.001
Tunnel 2: Top - Bottom -2.977 -2.977 0.457 0.626 0.489 <0.001 <0.001 <0.001
Glasshouse: Top - Middle -2.936 -2.936 0.402 0.455 0.365 <0.001 <0.001 <0.001
Tunnel 1: Top - Middle -2.126 -2.059 0.461 0.671 0.511 <0.001 0.021 0.001
Tunnel 2: Top - Middle -2.712 -2.712 0.459 0.600 0.493 <0.001 <0.001 <0.001
about the treatment effect, however, are the same with all methods: progabide leads to
no relevant and no significant improvement over placebo at any of the four time points.
This becomes also clear from the upper SCI bounds in Figure 57, which are all on the
“wrong” side, with point estimates close to 0 (on the logarithmic scale). Even though
we could not detect any “significant” effects, at least our longitudinal MCTs enable us
to quantify the uncertainty around the estimates.
Table 13: Simultaneous inference for the epileptic seizures data: estimated differences of log-rates
of seizures, standard errors, and adjusted p-values for occasion-wise comparisons of progabide and
placebo (except baseline).
Est(GEE) Est(MMM) SE(robust) SE (naive) SE(MMM) p(robust) p(naive) p(MMM) p(Bonf)
2 weeks -0.090 -0.089 0.406 0.371 0.266 0.588 0.566 0.592 1.000
4 weeks 0.013 -0.006 0.293 0.384 0.319 0.692 0.676 0.718 1.000
6 weeks -0.081 -0.087 0.419 0.382 0.486 0.599 0.579 0.656 1.000
8 weeks -0.175 -0.184 0.327 0.410 0.313 0.458 0.490 0.483 1.000
5.4.3 Azadirachtin
We analyze the azadirachtin data presented in 2.6 with a view to comparing dose ef-
fects on both larval and pupal mortality of whiteflies. In particular, we seek to compare
the mortalities associated with the different doses separately and simultaneously for both
developmental stages. Once more we pursue either of two modeling strategies: a combina-
tion of two stage-specific binomial GLMs for larval and pupal mortalities, or alternatively
a joint GEE approach. In addition we illustrate the parameterization issue with MMM
that was described in 3.5.2.
Comparing multiple doses at multiple stages: We fit a joint binomial model for
numbers of dead and alive whitefly larvae and pupae with GEE using the logit link
and an AR(1) working correlation. Our independent variables are the combinations of
developmental stages and dose levels, the culture substrates, and their interaction. The
single plants are taken as clusters. A Wald-type test for sequentially added model terms
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Estimated Difference of log(Number) of Whiteflies
GEE (naive) GEE (robust) MMM
Figure 55: Greenhouse whitefly data: 95% simultaneous confidence intervals for asymptotic all-
pairwise comparisons of environments per plant part and all-pairwise comparisons of plant parts
per environment simultaneously based on a joint GEE (with robust or naive covariance estimation)
and combined marginal GLMs (MMM).
yields a p-value of 0.560 for the interaction term, thus we can leave it out with confidence,
and the model is simplified to main effects only.
In an alternative approach, we fit two separate quasibinomial GLMs with logit link func-
tion and overdispersion parameter φ to the larval and pupal data, respectively. The
models include main effects for dose and substrate as well as an interaction term of the
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GEE (robust covariance)
1 0.90 0.81 0.72
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GEE (naive covariance)
1 0.71 0.61 0.64
0.71 1 0.71 0.84
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Multiple marginal models
Figure 56: Epileptic seizures data: correlation matrices of test statistics for many-to-one com-
parisons of treatments per time point (except baseline).
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2 weeks
−0.25 0.00 0.25 0.50 0.75 1.00
Estimated Difference of log(Rate) of Seizures
z−tests + Bonferroni GEE (naive) GEE (robust) MMM
Figure 57: Epileptic seizures data: 95% simultaneous confidence intervals for asymptotic com-
parisons of treatments per time point (except baseline) based on a joint GEE (with robust or
naive covariance estimation), combined marginal GLMs (MMM), and Bonferroni-adjusted z-tests
per time point.
two. The interactions turn out to be nonsignificant in the analysis-of-deviance F -tests
(p-values of 0.683 and 0.364) and are thus removed to simplify the models. The main
effect of substrate is significant with both modeling strategies, but having said that, we
focus our interpretation on the comparisons of dose levels separately and simultaneously
for larvae and pupae.
The estimated mortality differences on the logit link (i.e., log odds ratios) for pairwise
comparisons of neem doses separately for larvae and pupae are displayed in Table 14
along with SE estimates and adjusted p-values. When comparing GEE and MMM, the
estimated differences, SEs, and p-values are just slightly different for larval mortality but
there is substantial disagreement for pupae.
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Figure 58: Azadirachtin data: 95% simultaneous confidence intervals for asymptotic all-pairwise
comparisons of doses per developmental stage based on a joint GEE (with robust covariance
estimation), combined marginal GLMs (MMM), and Bonferroni-adjusted MCTs per stage.
We observe that uncertainty of estimation is considerably larger for pupae than larvae,
and it also tends to increase with dosage. As concerns larval mortality, both 1.5 and 2
ml/kg are found to be significantly superior to the manufacturer-recommended dose of 1
ml/kg (p < 0.001), and the SCI boundaries are far away from the point of no effect. By
contrast, such clear effects cannot be detected for pupal mortality: only the difference
between 1 and 2 ml/kg is significant—and only with the GEE-based procedure (p =
0.011) but not with MMM (p = 0.069). We see this also from the corresponding 95%
SCIs in Figure 58: the discrepancy between methods is minor for comparisons of larval
mortality but noticeable for comparisons of pupal mortality. One explanation for this
may be that sample sizes are too small for the longitudinal MCTs. Nonetheless, the
correlation matrices of test statistics look overall very similar (Figure 59).
Table 14: Simultaneous inference for the azadirachtin data: estimated log odds ratios of death,
standard errors, and adjusted p-values for all-pairwise stage-wise comparisons of dose levels.
Est(GEE) Est(MMM) SE(GEE) SE(MMM) p(GEE) p(MMM) p(Bonf)
Larvae: 1.5 vs. 1 ml/kg 0.880 0.875 0.228 0.223 <0.001 <0.001 <0.001
Larvae: 2 vs. 1 ml/kg 1.581 1.582 0.287 0.292 <0.001 <0.001 <0.001
Larvae: 2 vs. 1.5 ml/kg 0.701 0.706 0.310 0.338 0.113 0.163 0.132
Pupae: 1.5 vs. 1 ml/kg 0.235 0.253 0.350 0.279 0.947 0.853 1.000
Pupae: 2 vs. 1 ml/kg 1.324 1.368 0.429 0.558 0.011 0.068 0.085
Pupae: 2 vs. 1.5 ml/kg 1.089 1.115 0.499 0.600 0.135 0.260 0.293
Parameterization with multiple marginal GLMs: We have broached in 3.5.2 that
parameterization of the marginal models is an issue with finite sample sizes and can
have substantial impact on the covariance and SE estimates because the observed Fisher
information may be widely different from the expected one due to estimation problems.
We can parameterize the quasi-binomial GLMs for larval and pupal mortalities in var-
ious ways. Table 15 lists four parameterizations of the stage-specific GLMs along with
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Figure 59: Azadirachtin data: correlation matrices of test statistics for all-pairwise comparisons
of dose levels per developmental stage.
Table 15: Simultaneous inference for the azadirachtin data: four different options of parameter-
izing the quasi-binomial GLMs for larval and pupal mortalities. The effects are log odds of death,
and differences are on the logit scale.
β1 β2 β3 β4
a) effect with 1 ml/kg difference of 1.5 vs. 1 ml/kg difference of 2 vs. 1 ml/kg effect of sand
b) effect with 1.5 ml/kg difference of 1.5 vs. 1 ml/kg difference of 2 vs. 1.5 ml/kg effect of sand
c) effect with 2 ml/kg difference of 2 vs. 1 ml/kg difference of 2 vs. 1.5 ml/kg effect of sand
d) effect with 1 ml/kg effect with 1.5 ml/kg effect with 2 ml/kg effect of sand
the interpretations of the single parameters. Our longitudinal MCT procedure can be
conducted with any of these parameterizations, but they lead to different results for the
azadirachtin data.
Table 16: Simultaneous inference for the azadirachtin data: standard error estimates and ad-
justed p-values with different parameterizations of the quasi-binomial GLMs in the MMM approach
for larval and pupal mortalities.
a) b), d) c)
Stage Comparison SE p SE p SE p
Larvae 1.5 vs. 1 ml/kg 0.223 < 0.001 0.216 < 0.001 0.237 0.001
2 vs. 1 ml/kg 0.292 < 0.001 0.290 < 0.001 0.296 < 0.001
2 vs. 1.5 ml/kg 0.338 0.163 0.318 0.121 0.318 0.127
Pupae 1.5 vs. 1 ml/kg 0.279 0.853 0.282 0.856 0.442 0.970
2 vs. 1 ml/kg 0.558 0.068 0.510 0.037 0.576 0.087
2 vs. 1.5 ml/kg 0.600 0.261 0.606 0.268 0.606 0.279
The SE estimates and adjusted p-values associated with the treatment differences of
interest are printed in Table 16. Note that they are identical for parameterizations b)
and d), which we also used for Table 14, but considerably different from a) and c). This
should make clear that SE estimates and p-values from multiple marginal GLMs are to
be treated with caution as the experiment’s sample size is probably insufficient.
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6 Extensions and Alternatives
The methods studied in this thesis can be expanded in various directions, and we spotlight
some ideas here: using ratios rather than differences of means (6.1); including further
sources of “repeatedness” e.g., multiple endpoints in addition to repeated measurements
over time (6.2); and employing profile likelihood test statistics for discrete data to better
cope with small sample sizes (6.3). As possible alternatives to our methods, we discuss
in brief multiple contrast rotation tests to speed up computation with larger dimensions
(6.4), and nonparametric rank tests for longitudinal setups (6.5).
6.1 Ratios
It may be desirable for various applications to estimate effects and SCIs on a percentage
scale. To this end our longitudinal MCTs could be modified so that SCIs for ratios instead
of differences of treatments means per occasion, or occasion means per treatment, are
computed.
A generic method for constructing a CI around a ratio of normal variates is suggested
by the theorem of Fieller (1954)5. Based on this result, Zerbe et al. (1982) and Young
et al. (1997) developed SCIs for fixed- and mixed-effects model parameters, respectively.
Dilba et al. (2004 2006) extended these works to MCTs for ratios so that simultaneous
tests and SCIs are available for arbitrary sets of linear contrasts involving ratios.
Ratio-type MCTs for multivariate Gaussian data were considered in Hasler and Hothorn
(2012) and Hasler and Bo¨hlendorf (2013). In similar fashion it should be a simple task to
put the puzzle together and build a longitudinal MCT for Gaussian endpoints that yields
SCIs for ratios of interest, in the framework of a joint LMM or multiple occasion-specific
linear models.
6.2 Multivariate Longitudinal Data
As already hinted at in the introduction, there may be “more repeatedness” in the data
than just longitudinal replication. For instance, several endpoints could be measured
repeatedly over time from the same experimental units. This calls for a model that
captures correlation both across endpoints and repeated measurements to be the basis
for simultaneous inferences of endpoints and/or time points. Bandyopadhyay et al. (2011)
and Verbeke et al. (2014) review joint modeling options for such multivariate longitudinal
data. As an alternative, a recently published extension of the combination of multiple
models (Jensen et al. 2015) allows to extend the method to marginal models with random
effects i.e., one LMM for every endpoint.
5This theorem appeared in the literature way earlier than 1954 e.g., in Fieller (1940) and Fieller
(1944).
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6.3 Signed Likelihood Root Tests
We have observed rather poor performance of our longitudinal MCTs for discrete data
in the presence of small sample sizes. This is not surprising due to the method being
inherently asymptotic, but still accurate multiple tests and SCIs for linear combinations
of GLM parameters might be required in practice from time to time.
Recently Gerhard (2014b) proposed replacing the common Wald-type test statistics in
MCTs with profile likelihood statistics in order to achieve nicer small-sample properties,
especially close to the borders of the parameter space. The basic idea is to use a signed
root deviance statistic (Chen and Jennrich 1996) or alternatively a modified likelihood
root relying on a higher order density approximation (Barndorff-Nielsen 1983), details
on both of which are given in Brazzale and Davison (2008). It could be a worthwhile
expansion of our longitudinal MCTs for discrete outcomes to use profile statistics.
6.4 Rotation Tests
Rotation tests are a flexible alternative for simultaneous inference based on a multivariate
model or on multiple marginal models. Similar to resampling methods such as bootstrap-
ping (Westfall and Young 1993), adjusted p-values and SCIs are found via Monte Carlo
simulation, with the orthogonalized residuals being randomly rotated rather than per-
muted a large number of times (Langsrud 2005). Like with the MMM approach of 3.5,
no specification of the covariance is required.
Rotation tests have recently gained attention for applications in high-dimensional gene
expression analysis where the n  p problem occurs (Dørum et al. 2009; Wu et al.
2010; Dørum et al. 2014; Solari et al. 2014) but are also useful in smaller-scale sce-
narios (Langsrud et al. 2007; Gerhard and Schaarschmidt 2015). In our specific set-
ting of outcomes measured repeatedly over time, each occasion would be modeled sepa-
rately and then the residuals could be combined for the rotation procedure. Extensions
that use GLMs or LMMs for the marginal outcomes are available as well (Gerhard and
Schaarschmidt 2015).
6.5 Nonparametric Rank Tests
Testing differences of means in correlated longitudinal data settings has been a research
topic in the nonparametric statistics community for at least two decades. Most of their
rank-based methods take account of the nonparametric Behrens-Fisher problem; this is
sensible not only because repeated measures over time are often heteroscedastic them-
selves, but even if the original data have equal variances across time points, the ranks do
not (Akritas 1990).
Konietschke et al. (2010) proposed MCTs involving relative effects pj for comparing
means of different time points j = 1, . . . ,m in one treatment group. These pj can be
estimated using the ranks of the original observations, and they have interpretation as
the probability that a randomly chosen measurement taken at time point j is larger than
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a randomly chosen measurement from the mean distribution. The null hypothesis
H0 :
m⋂
j=1
{pj = 0.5}
can be specified in MCT representation as
H0 : Cp = 0
where C is an adequate contrast matrix, and p = (p1, . . . , pm)
T . This method yields
threefold information just like classical MCTs: a global decision, adjusted p-values for
multiple comparisons, and compatible SCIs. Unfortunately, it is slightly liberal as long as
sample sizes are not large (type I error rates of 0.07 with n = 10 and 0.06 with n = 20).
A similar nonparametric strategy for one or two treatment groups was proposed before by
Munzel and Tamhane (2002); however, as the authors pointed out, their method applies
to large samples only and does not allow for comparisons among groups. The hypothe-
ses of most other nonparametric procedures for (heteroscedastic) longitudinal data (e.g.,
Brunner and Langer 2000; Brunner and Puri 2001) contain marginal distribution func-
tions as introduced by Akritas and Arnold (1994) instead of the relative effects p and
hence do not offer SCIs for the pi which limits their practical applicability. More on
nonparametric inference in factorial longitudinal designs can be found in Brunner et al.
(2002).
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7 Discussion
In this thesis we proposed different approaches for simultaneous inference in longitudinal
scenarios, evaluated their small- and finite-sample performances via numerical simulation,
and exemplified their use with data from various areas of research in the life sciences.
The methods are an extension and application of MCTs to settings where randomized
units are measured repeatedly over time. This is useful whenever the research question of
interest can be answered with separate and simultaneous comparisons of treatment groups
and/or time points and FWER control over the entire set of comparisons is desirable. In
a broader sense, the methods of this thesis can be applied whenever multiple comparisons
are demanded in a setting with correlation such as longitudinal or spatial data, multiple
endpoints, etc. MCT methods for correlated and repeated measurements were available
before (Hasler and Hothorn 2011; Hasler 2013), but their lack of flexibility makes them
inapplicable to many realistic longitudinal scenarios.
None of the test procedures and SCI methods we considered in this work is “exact”
because we have to plug in the estimated covariance matrix Σ̂ when calculating the MCTs.
The MMM approach has an additional asymptotic element: the observed information
matrix is used instead of the expected one. We gauged via simulation what sample sizes
are required for the asymptotic procedures to achieve good control of the FWER, and
they are usually in the order of a few dozens (see also Pallmann et al. 2015). Such sample
sizes are not always feasible in real-world experiments or trials, therefore approximate
small-sample methods are practically relevant. However, they come with the additional
complication of having to approximate the DF of the multivariate t-distribution.
We do not want to create the impression that any approximation to the DF is “correct”
in general. Our simulations show that various DF methods work well over a range of
different situations. Some of them are perhaps more appealing because they are built on
a solid theoretical footing (Kenward-Roger, ESS, Pinheiro-Bates) which gives hope that
they maintain their decent performance also in scenarios not covered by simulations. On
the other hand, approximations that behave nicely in simulation studies but lack any
deeper justification, such as our own “adjusted” DF or the one devised by Hasler (2013),
might fail in cases that go beyond those considered in simulations. So from this point
of view, Kenward-Roger, ESS, and Pinheiro-Bates are preferable, but we need to keep in
mind that they are only approximations to a problem that cannot be solved exactly to
date. This being said, the question which DF approximation is applied only matters with
small samples of less than 15 or even less than ten subjects per group. And as soon as the
sample sizes exceed 30 or 40 per group, the discrepancy between results from asymptotic
and small-sample longitudinal MCTs is negligible in practice.
Pipper et al. (2012) pointed out explicitly that the MMM method may break down with
small sample sizes. We showed that this problem can be cushioned with appropriate
DFs, and then the longitudinal MCT procedure based on MMM behaves well even with
sample sizes of less than ten per group. While this is certainly true for comparisons
of treatment means per time point, the procedure is much harder to tame when time
points are compared per treatment group. This is consistent with the observation that
the asymptotic procedures based on a joint LMM or MMM achieve very similar type I
error rates under H0 with small to moderate sample sizes when treatments are compared
per occasion whereas MMM does considerably worse than joint modeling for comparisons
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of occasions per treatment group.
When it comes to deciding whether a joint model or MMM should be used to estimate
the parameters for the longitudinal MCTs, there is no hard and fast answer as both have
their strengths and weaknesses. MMM saves the trouble of devising a suitable structure
for the random effects and/or error covariance matrix, which can be tricky with joint
modeling. In practice, the decision which type of joint model to fit (ELM, CIM, or
some more sophisticated LMM with both random effects and non-zero correlation of the
residuals) will be guided by characteristics of the data-generating process. Failure to
capture serial dependencies adequately may affect the joint model-based tests and SCIs;
in addition, numerical convergence problems might prevent fitting a more complex (and
more appropriate) model. Both these problems can be evaded to a certain degree with
AICc model selection—and entirely by fitting and combining simple univariate occasion-
specific models with MMM.
If model selection is applied, we think that AICc should be the criterion of choice because
it is deeply rooted in information theory, and the small-sample version (AICc rather than
AIC) is clearly preferable unless sample sizes are very large, as suggested by Burnham
and Anderson (2002). The use of AIC(c) is not undisputed though: Littell et al. (2000),
for instance, picked the BIC because they felt they needed a criterion that tends to select
sparser models than AIC does.
An evident virtue of the joint modeling strategy is that it can handle missing data and
dropout rather straightforwardly assuming MAR, and “borrow strength” from adjoining
occasions, whereas the MMM approach requires the harsher MCAR condition, and no
information can be “borrowed” across time points. Missing values are indeed an im-
portant aspect with longitudinal data analysis; especially dropout is a common problem
when subjects are measured repeatedly over time. We have pointed out that the validity
of any statistical analysis in the presence of missing data will depend on the underlying
mechanism of missingness. MCAR is the easiest one to deal with in practice but also
involves the most stringent assumptions. Fitzmaurice et al. (2011, p. 498) recommend
MAR as default “unless there is a strong and compelling rationale to support the MCAR
assumption”. From this point of view, methods that yield valid results under MAR are
superior. Laborious techniques like multiple imputation fulfill this criterion but it is
clearly preferable to avoid them if a joint LMM serves the same purpose—but only if its
mean and covariance structures are correctly specified!
Our power simulations demonstrate that taking dependencies of time points into account
pays off. In particular with high correlation, the longitudinal MCT procedures outperform
simple Bonferroni adjustments. This effect is much more pronounced for comparisons of
treatments than for comparisons of time points. On the other hand, the powers of the
longitudinal MCTs based on joint modeling and the MMM approach are very similar
across the board; only for small-sample comparisons among occasions MMM falls a little
short of power.
Performing comparisons among treatment groups and among time points simultaneously
within the same analysis is possible as well and extends our flexibility when formulating
“claims”. However, such a duplex procedure creates extra challenges, especially with
small sample sizes and when the DFs for the two types of comparisons are widely different
e.g., because there are relatively few comparisons of treatments and relatively many
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comparisons of time points, or vice versa. We argued that using comparison-specific DFs
is the most accurate solution, but applying the minimum DF works well, too, and will not
be very conservative in most settings. Despite its practical feasibility though, we think
that the duplex procedure should be carried out with some care because it involves a lot
of single comparisons even for setups with few treatment groups and time points, and
one should always question whether all these comparisons are sensible and meaningful.
The extension to discrete endpoints such as Poisson counts and binomial proportions is
important because many outcomes in biological and medical research are measured as
rates, counts, proportions, etc. We choose GEEs over GLMMs to fit a joint model because
only GEE estimates have the desired population-average interpretation. The alternative
is again the MMM approach, now built on occasion-specific GLMs rather than linear
models. When data points are missing, both MMM and the joint GEE require MCAR
because the latter does not involve specification of a full likelihood for all time points.
On the other hand, devising a joint model is less cumbersome in a GEE framework than
with LMMs because consistent estimates are ensured even under misspecification of the
working correlation.
The longitudinal MCTs for discrete data using either GEEs or MMM are inherently
asymptotic, and we explored their finite-sample properties via simulation: we found
that when sample sizes are insufficient, the tests can be either conservative or liberal,
depending on whether the endpoint is binomial or Poisson, which modeling strategy is
applied, whether treatments are compared per occasion or occasions per treatment group,
and how the SEs are estimated with the GEE (naive or robust). As a rule of thumb, the
sample sizes should be at least as large as for the asymptotic Gaussian procedure i.e.,
a minimum of 30 to 40 subjects per group are necessary for acceptable FWER control.
Note that we have only studied asymptotic procedures for discrete outcomes, and better
small-sample properties might be achieved with profile likelihood rather than Wald-type
statistics as in Gerhard (2014a), or with DF approximations as suggested by Li and
Redden (2015) in the context of GLMMs. Other methods for inference about repeatedly
measured binary outcomes are described in Klingenberg and Satopa¨a¨ (2013).
The power curves of the longitudinal MCT procedures for discrete data are very similar
for GEEs and the MMM approach, and both have a slight advantage over Bonferroni-
adjusted pairwise tests when treatments are compared at multiple time points, and a
substantial advantage when time points are compared within multiple treatment groups.
We did not investigate overdispersed Poisson or binomial data explicitly, but we presume
this might add complexity to the problem, especially if the amount of overdispersion
varies over time.
We believe that gauging the magnitude and uncertainty of interesting effects is much more
relevant than testing their “significance” in almost any real-world application. Therefore
we suggest that results of our longitudinal MCTs be principally presented as SCIs and
not—or at least not only—as adjusted p-values. The SCIs are compatible with the test
decisions based on the p-values and always more informative than those.
We parameterized the fixed effects in our joint LMMs such that treatment groups and
time points are combined in a single factor i.e., a pseudo-one-way layout or cell means
model. This obviously gives us great flexibility to do all sorts of comparisons across
treatment groups and time points but on the other hand requires to estimate lots of
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parameters and associated SEs. Littell et al. (2000) proposed that fitting a sparser mean
model than cell means could be considered to get smaller SEs; a formal treatment of this
issue is given by Altham (1984).
People raising fundamental objections to (multiple) hypothesis testing will most certainly
argue against our methods. We shall not pursue this line of argumentation here but rather
emphasize two important points related to such criticism.
First, we urge that time points should be carefully chosen so that each elementary com-
parison has its right to exist as part of the overall “claim”. It makes no sense to analyze
day 1, day 2, day 3, day 4, etc. all separately in a longitudinal study—simply because the
data are available. This would be like going on a fishing trip for significances. Indeed,
we want to stress that the time points in our data examples were never an arbitrary
selection. The measurement occasions in the bradykinin trial, for instance, are all closely
linked with important medical steps such as initiation of anesthesia or separation from
the heart-lung machine.
And second, we do not believe that loads of p-values lead to any scientific insight. Our
methods are inappropriate as soon as there are more than five or six time points, because
then it can hardly be meaningful to direct one’s attention to all of them separately. If
the primary interest lies in the temporal evolution rather than specific points on the time
line, summary measures like the slope or AUC are clearly favorable. Another possibility
are simultaneous confidence bands (Sudhagoni and Djira 2012; Mun and Chun 2014), but
they require a linear time trend. A more flexible option could be based on generalized
additive mixed-effects models (GAMMs) as proposed by Herberich et al. (2014).
All simulations, data analyses, and graphics in this thesis were programmed in R (R Core
Team 2015). Example code as well as some useful functions are provided in Appendix E.
In conclusion, we recommend using the MMM technique in many repeated measures
settings where one would conventionally fit an ELM or CIM or any other joint LMM
to obtain estimates for multiple testing or constructing SCIs. For the standard case
where Gaussian treatment means are compared at multiple correlated occasions, one can
simply model each time point separately without racking one’s brain about random effects
and residual correlation structures. We have shown that small sample sizes are not an
impediment because a fairly straightforward DF approximation helps to achieve good
FWER control, and the power is very similar to the joint modeling approach.
Caution should be exercised when comparing time points within multiple treatment
groups: here the MMM approach can be substantially liberal with too small sample
sizes, and in the approximate small-sample procedure it may also be less powerful than
joint modeling. If there are missing values and MCAR is called into question, a joint
LMM that allows to assume MAR—at least if its mean and covariance are adequately
specified—is probably favorable.
MMM is also an attractive option for binomial and Poisson endpoints, although the
asset of not having to think about covariance structures is not quite as relevant here
because GEEs are capable of estimating the covariance consistently even if the working
correlation is misspecified. On the other hand, the biggest advantage of joint modeling in
the Gaussian setting also ceases to apply: GEEs require the stricter MCAR assumption
for missing values because they are not based on a joint likelihood.
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8 Conclusion
The key conclusions from this work are:
1. When comparisons of treatments per time point and/or comparisons of time points
per treatment group are desired, classical methods for analyzing longitudinal Gaus-
sian data, such as repeated measures ANOVA, are of little avail as they only produce
p-values for the global hypothesis. By contrast, MCTs provide adjusted p-values
and informative SCIs for single comparisons, plus a global decision.
2. Existing MCT methodology for correlated measurements is inflexible. Multivariate
MCTs (Hasler and Hothorn 2011; Hasler 2014a) allow for comparisons among treat-
ments only and cannot cope with covariates or missing values properly. Repeated
measures MCTs (Hasler 2013) that allow for comparisons among occasions are lim-
ited to single-group designs and come with similar restrictions as the multivariate
MCTs.
3. These limitations can be overcome by jointly modeling the data with an LMM where
including covariates is straightforward and the assumption of MAR is sufficient for
missing values. When faced with the choice between competing random-effects
and/or residual covariance structures, AICc may serve as a decision criterion.
4. An elegant alternative strategy is to combine occasion-specific linear models (Pip-
per et al. 2012), which saves the trouble of specifying random effects and error
covariances. One limitation of this MMM approach is that inference is only valid
under MCAR, and no information can be “borrowed” across time points.
5. Longitudinal MCTs based on either of these methods control the FWER asymp-
totically. For small-sample inference, approximate control can be achieved using a
DF method such as Kenward-Roger, Pinheiro-Bates, or a novel approach based on
the ESS (Faes et al. 2009).
6. The powers of MCTs based on a joint LMM or MMM are very similar. There is
more power to gain (in comparison to Bonferroni) when serial correlation is high and
there are more occasions. Ignoring serial correlation is much more detrimental with
comparisons of time points than with comparisons of treatment groups. It is also
possible to calculate the power of the longitudinal MCTs, at least approximately.
7. Performing comparisons of treatments and time points simultaneously in a du-
plex procedure is possible, too. When the DFs for the two types of comparisons
are widely different, including multiple comparison-specific DFs (as in Hasler and
Hothorn 2008) can pay off. Using the minimum DF is always a safe and simple—but
perhaps conservative—alternative.
8. The methods for Gaussian data are extendable to the case of binomial and Poisson
endpoints. GLMMs provide a way to fit a joint model, but their estimates have an
inherent subject-specific interpretation. GEEs on the other hand yield estimates
with the desired population-average interpretation. The occasion-specific models
for the MMM approach are now GLMs. The longitudinal MCTs based on either
modeling strategy are asymptotic and may break down with small sample sizes.
For Poisson GEEs, naive covariance estimation seems to be preferable to the robust
8 CONCLUSION 128
sandwich estimates. GEE- and MMM-based MCTs have practically the same large-
sample power. Joint modeling with GEEs no longer has the advantage of allowing
MAR.
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A Multivariate Normal and t-Distribution
A.1 Multivariate Normal Distribution
A random variable X is (univariate) normal with mean µ and variance σ2 > 0
X ∼ N (µ, σ2)
if it has density function (PDF)
f(x;µ, σ2) =
1√
2piσ2
e−
(x−µ)2
2σ2 .
The corresponding distribution function (CDF) is
F (x) =
1√
2piσ2
x∫
−∞
e−
(t−µ)2
2σ2 dt.
The special case µ = 0 and σ2 = 1 is called standard normal.
The normal distribution be extended to the multivariate case as follows. A vector of
random variables X = (X1, . . . , Xp)
T is nonsingular p-variate normal with mean vector
µ = (µ1, . . . , µp)
T and positive definite covariance matrix Σp×p
X ∼ Np(µ,Σ).
if it has joint density function
f(x;µ,Σ) =
1√
(2pi)p|Σ|e
− (x−µ)TΣ−1(x−µ)
2
where |Σ| denotes the determinant of Σ. This is a central multivariate normal distribution
if µ = 0.
The distribution function is not available in closed form, except for a few special cases
such as bivariate (Siddiqui 1967). Numerical methods for evaluating the integral
Φp(x; a,b,µ,Σ) =
1√
(2pi)p|Σ|
∫ b1
a1
. . .
∫ bp
ap
e−
(x−µ)TΣ−1(x−µ)
2 dxp . . . dx1
are described in Genz and Bretz (2009). Extensive treatments of the properties of the
multivariate normal distribution can be found in Tong (1990) and in chapter 2 of Kotz
et al. (2000).
A.2 Multivariate t-Distribution
The distribution of a random variable T is (univariate) Student t with ν > 0 degrees of
freedom (DF)
T ∼ T (ν)
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if it has density function
g(t; ν) =
Γ(ν+1
2
)√
νpiΓ(ν
2
)
(
1 +
t2
ν
)− ν+1
2
=
1√
νB(1
2
, ν
2
)
(
1 +
t2
ν
)− ν+1
2
where Γ denotes the gamma function
Γ(x) =
∞∫
0
ax−1e−a da
and B the beta function
B(x, y) =
1∫
0
ax−1(1− a)y−1 da.
The corresponding distribution function is
G(t; ν) =
1
2
+
t
2|t|I t2t2+ν
(
1
2
,
ν
2
)
with Iz the regularized incomplete beta function
Iz(x, y) =
B(z;x, y)
B(x, y)
where the numerator is the incomplete beta function
B(z;x, y) =
z∫
0
ax−1(1− a)y−1 da.
Student’s t-distribution with ν DF can be derived as the ratio of a standard normal
variable divided by an independent χ2 variable with ν DF:
Z
√
ν
χ2ν
∼ T (ν)
where
Z ∼ N (0, 1).
The special case of ν = 1 is known as Cauchy, and for ν →∞ the Student t converges in
distribution to normality.
There exists no unique extension to the multivariate case. One typical form of the multi-
variate t-distribution (but not the only possible one) is achieved by dividing a multivariate
Gaussian vector by a common χ2 variable with ν DF. The “most natural” form (Kotz and
Nadarajah 2004) defines the distribution of a vector of (univariate) t random variables
T = (T1, . . . , Tn)
T , and its density function is given by
g(t; ν,µ,Σ) =
Γ(ν+p
2
)√
(piν)pΓ(ν
2
)
√|Σ|
(
1 +
(t− µ)TΣ−1(t− µ)
ν
)− ν+p
2
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where µ = 0 makes the distribution a central multivariate t. Setting ν = 1 yields a mul-
tivariate Cauchy distribution, and for ν →∞ the multivariate t converges in distribution
to multivariate normality.
There is again no analytical expression for the distribution function, but Genz and Bretz
(2009) provide numerical and computational methods for solving
Tp(t; a,b, ν,µ,Σ) =
Γ(ν+p
2
)√
(piν)pΓ(ν
2
)
√|Σ|
∫ b1
a1
. . .
∫ bp
ap
(
1 +
(t− µ)TΣ−1(t− µ)
ν
)− ν+p
2
dxp . . . dx1.
A plethora of other possible multidimensional t-distributions (some of which are e.g.,
skewed or have variable DFs) are summarized in Nadarajah and Kotz (2004) and Nadara-
jah and Dey (2005).6
6These two journal articles are nearly identical to chapters 4 and 5 of Kotz and Nadarajah (2004).
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B Copulas
A copula is a joint multivariate CDF with marginal univariate CDFs that are continuous
uniform on the unit interval [0, 1]. Suppose the marginal CDFs of the random variables
X1, . . . , Xn are known to be F1, . . . , Fn but their joint CDF F is unclear. We can define
Uj = Fj(Xj) for j = 1, . . . , n so that
Uj ∼ U(0, 1)
and the joint CDF of U1, . . . , Un is C.
By the theorem of Sklar (1959) any multivariate joint CDF F can be written as an
n-dimensional copula of n univariate marginal CDFs F1, . . . , Fn:
F (x1, . . . , xn) = C{F1(x1), . . . , Fn(xn)},
or likewise:
F{F−11 (u1), . . . , F−1n (un)} = C(u1, . . . , un).
Copulas can be used as a means for “gluing” marginal CDFs together so as to arrive at
a joint multivariate CDF, given some dependence structure. We exploit this property in
Chapter 5 to draw correlated binary and Poisson data. A more thorough introduction to
copulas can be found in the textbook by Nelsen (2006).
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C Example Datasets
The following tables show the raw data of all six example dataset described in Chapter
2 and evaluated in Chapters 4 and 5.
C.1 Bradykinin Receptor Antagonism
Table 17 displays the summary statistics of the original data on bradykinin receptor
antagonism (Balaguer et al. 2013) that were used to create the simulated dataset that
was described in 2.1 and analyzed in 4.4.1.
Table 17: Summary statistics of the log-concentrations of the original bradykinin dataset: number
of independent units, sample means, sample covariances, and correlations for each treatment group.
n µ Σ R
Placebo 37

4.359
4.830
5.332
5.982
5.654


0.470 0.314 0.216 0.217 0.172
0.314 0.435 0.368 0.278 0.072
0.216 0.368 0.690 0.287 −0.007
0.217 0.278 0.287 0.805 0.287
0.172 0.072 −0.007 0.287 0.594


1 0.696 0.380 0.353 0.326
0.696 1 0.672 0.470 0.142
0.380 0.672 1 0.384 −0.010
0.353 0.470 0.384 1 0.415
0.326 0.142 −0.010 0.415 1

EACA 37

4.275
4.586
4.695
4.882
5.224


0.640 0.520 0.525 0.301 0.039
0.520 0.595 0.593 0.408 0.085
0.525 0.593 0.674 0.435 0.068
0.301 0.408 0.435 0.476 0.168
0.039 0.085 0.068 0.168 0.734


1 0.857 0.796 0.548 0.057
0.857 1 0.937 0.766 0.128
0.796 0.937 1 0.767 0.097
0.548 0.766 0.767 1 0.285
0.057 0.128 0.097 0.285 1

HOE 140 38

4.243
4.920
5.403
6.170
5.627


0.532 0.371 0.278 0.261 0.074
0.371 0.686 0.654 0.563 0.141
0.278 0.654 0.898 0.470 0.184
0.261 0.563 0.470 1.092 0.236
0.074 0.141 0.184 0.236 0.407


1 0.613 0.426 0.342 0.159
0.613 1 0.834 0.650 0.267
0.426 0.834 1 0.481 0.296
0.342 0.650 0.481 1 0.354
0.159 0.267 0.296 0.354 1

ID Drug Baseline Bypass (30 min) Bypass (60 min) Post-Bypass Postoperative Day 1
1 Placebo 5.0328 5.3976 5.7022 6.9740 6.6857
2 Placebo 3.2558 4.6634 4.9376 4.7945 6.1281
3 Placebo 4.3291 4.9985 5.3642 4.6745 5.6563
4 Placebo 5.0445 5.6254 6.8620 7.1506 6.0146
5 Placebo 4.6330 5.3544 5.0056 5.7522 5.4053
6 Placebo 4.4899 4.7122 5.5447 5.9043 5.1270
7 Placebo 5.5365 5.4413 4.5876 6.6356 5.2526
8 Placebo 4.7983 5.0799 5.2646 6.6610 6.8176
9 Placebo 5.6800 6.3052 5.8627 7.5499 5.8322
10 Placebo 4.2362 4.6818 5.1980 5.4522 5.7017
11 Placebo 4.6783 5.3148 5.4520 6.3755 5.9469
12 Placebo 4.6946 4.8387 6.0578 5.2295 5.0096
13 Placebo 5.0146 4.6146 5.7012 4.5909 5.2785
14 Placebo 2.9159 4.1731 4.1696 6.6341 5.2684
15 Placebo 4.7121 3.9182 5.0801 5.7692 6.0655
16 Placebo 4.5448 4.9799 5.0404 6.5512 6.3418
17 Placebo 3.7075 4.4197 5.4676 5.6720 4.7158
18 Placebo 4.0451 4.2258 5.2906 5.4650 5.7607
19 Placebo 4.7075 5.4494 6.2947 6.3584 5.4620
20 Placebo 4.5409 4.6756 5.2056 5.4788 5.4775
21 Placebo 5.4544 5.6356 6.9267 5.7817 6.3965
22 Placebo 3.5622 4.6621 4.6821 5.5313 5.8226
23 Placebo 4.0237 4.1471 4.4944 4.8059 5.5482
24 Placebo 4.0242 4.6737 4.0138 4.9760 6.3968
25 Placebo 4.8555 5.2929 5.5312 6.8874 6.7966
26 Placebo 4.4740 4.9425 6.4587 5.6305 5.4560
27 Placebo 3.3500 3.7805 6.5075 6.6543 5.6083
28 Placebo 5.4953 5.7717 6.0502 5.9109 6.5771
29 Placebo 4.3722 4.1659 5.5897 6.1666 6.6083
30 Placebo 3.2259 4.4792 6.2273 6.3012 5.8045
31 Placebo 3.9048 4.0390 4.3449 5.9357 5.3479
32 Placebo 5.1379 5.1654 5.5610 6.3409 6.9182
33 Placebo 4.4870 4.9854 5.5398 5.6722 5.2836
34 Placebo 3.8467 4.0678 4.7957 7.1809 5.4543
35 Placebo 5.3440 5.2924 4.3547 7.2827 6.0409
36 Placebo 5.1262 4.0154 4.6562 5.2560 6.8244
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37 Placebo 4.5716 5.2354 4.8145 5.7797 5.1237
38 EACA 3.6417 4.2443 4.3455 4.1988 5.9690
39 EACA 5.2347 5.4318 5.3544 5.0166 6.3620
40 EACA 2.6799 3.1637 2.7691 4.1240 5.7665
41 EACA 4.7959 4.7436 4.6865 4.6506 6.1241
42 EACA 5.2384 5.3986 5.3641 6.3473 6.9881
43 EACA 3.5313 3.3329 3.6316 4.2515 6.2711
44 EACA 5.4374 5.4060 5.3116 5.1482 5.7317
45 EACA 4.7497 5.2387 5.6755 5.9061 6.4901
46 EACA 3.9994 4.5213 4.4003 4.9266 4.7635
47 EACA 4.8602 5.1202 5.3856 4.6021 4.4033
48 EACA 3.9622 4.8755 5.2243 5.4294 6.4295
49 EACA 3.9181 4.7215 4.8748 4.8122 4.4851
50 EACA 3.3999 3.8630 4.6350 4.7032 4.8127
51 EACA 4.9221 5.1586 5.5928 5.3106 4.7746
52 EACA 5.2920 5.3436 5.4094 5.0067 4.4851
53 EACA 4.5566 5.4543 5.3121 5.4264 5.7615
54 EACA 4.7541 4.3777 4.9523 4.7395 5.4966
55 EACA 5.4079 5.1810 5.2174 5.3912 6.6474
56 EACA 5.1635 5.4551 5.5464 6.1374 6.1371
57 EACA 3.9581 4.3298 4.1104 5.0314 6.0722
58 EACA 3.4613 3.8509 4.4477 4.7059 4.6487
59 EACA 3.7405 4.2339 4.4179 5.1570 5.7681
60 EACA 5.6767 5.6736 5.7947 5.6614 6.8070
61 EACA 4.3312 4.7918 5.0311 5.2973 4.9566
62 EACA 4.3916 4.5870 4.1308 4.4881 5.0201
63 EACA 4.7908 4.2328 4.6065 4.7723 5.5932
64 EACA 4.0540 4.3076 4.3098 4.4834 4.6896
65 EACA 3.1456 2.8166 2.8126 2.9901 5.5030
66 EACA 3.7806 3.5349 3.3830 4.2426 5.1109
67 EACA 3.1163 3.5123 3.0519 3.7246 5.4771
68 EACA 5.3308 5.2923 5.6081 5.4353 4.3036
69 EACA 3.8724 3.3093 3.7313 4.0622 6.2560
70 EACA 4.2644 4.3283 3.7426 4.0981 6.1142
71 EACA 6.1016 5.7934 5.8101 5.3895 5.4321
72 EACA 4.0072 4.5687 4.8483 5.2821 5.3571
73 EACA 5.5426 5.6376 6.0201 4.6867 5.1257
74 EACA 3.2589 4.3041 4.3615 5.8699 6.2428
75 HOE140 4.5445 4.8873 5.4660 6.3073 5.5362
76 HOE140 3.9803 4.8262 5.4041 6.2802 5.1087
77 HOE140 3.9903 4.3823 5.4635 5.4369 4.8006
78 HOE140 3.7487 4.3809 4.4025 5.0761 5.4158
79 HOE140 4.5056 6.4541 7.2489 5.2038 5.2371
80 HOE140 4.7335 4.5281 4.9957 5.9588 5.5508
81 HOE140 3.8898 5.5183 6.1211 4.6945 4.5179
82 HOE140 5.0462 5.0754 4.7602 6.8555 6.1951
83 HOE140 4.2530 5.3592 5.8218 7.3369 5.5629
84 HOE140 5.2032 4.1962 4.6478 4.7834 5.6296
85 HOE140 4.8197 4.6761 4.6860 7.1969 6.2184
86 HOE140 3.8338 3.2804 4.4123 3.2687 5.3690
87 HOE140 4.3278 5.4680 7.8066 5.9094 6.4212
88 HOE140 4.7870 5.4737 6.2346 7.5477 5.5188
89 HOE140 5.3246 7.6445 9.1348 8.1383 5.4224
90 HOE140 4.4823 5.2752 5.6341 7.2637 6.0082
91 HOE140 4.8353 5.3661 5.7152 7.9531 4.9737
92 HOE140 4.0152 4.3153 4.0224 7.0902 5.7680
93 HOE140 5.2540 5.8040 5.2497 7.5609 6.5343
94 HOE140 4.5069 5.4298 5.0879 5.0988 5.7403
95 HOE140 5.2905 5.7389 5.3995 6.4169 4.7768
96 HOE140 3.7707 4.9903 5.8444 5.9301 6.1398
97 HOE140 4.5504 6.0234 7.2443 5.4204 5.8115
98 HOE140 3.4947 5.4485 6.5225 6.7342 6.5223
99 HOE140 4.7115 4.3043 5.4028 5.6985 5.5124
100 HOE140 4.2983 4.2313 4.4258 6.1352 5.1057
101 HOE140 3.9304 4.8874 4.9906 6.4953 4.9962
102 HOE140 4.7710 4.8861 5.6303 6.6411 5.9891
103 HOE140 4.6426 5.3947 5.6087 7.6143 5.7604
104 HOE140 3.2668 4.3548 4.4293 6.2312 5.1774
105 HOE140 4.0637 2.8750 3.9118 3.6200 5.1403
106 HOE140 5.1109 5.3725 5.5433 5.4071 4.6849
107 HOE140 4.0725 4.7567 5.0518 4.8867 5.2484
108 HOE140 4.6810 5.2553 5.8034 4.6827 5.9189
109 HOE140 3.9481 5.5836 5.8453 8.1567 5.2388
C EXAMPLE DATASETS 152
110 HOE140 4.3871 5.2834 6.1268 6.6257 5.6175
111 HOE140 4.5206 5.8390 6.3119 6.7712 5.6876
112 HOE140 4.3511 3.7497 4.6832 5.7740 5.9268
C.2 Mercuric Chloride
Animal Cage Dose Week 53 Week 65 Week 105
30233 13 Vehicle Control 281.40 307.50 369.20
30234 13 Vehicle Control 263.00 284.90 297.90
30235 13 Vehicle Control 283.10 313.10 NA
30236 13 Vehicle Control 272.00 300.40 NA
30237 13 Vehicle Control 272.20 308.40 330.80
30238 14 Vehicle Control 277.80 333.60 NA
30239 14 Vehicle Control 246.20 281.20 NA
30240 14 Vehicle Control 291.60 317.40 360.60
30241 14 Vehicle Control 306.00 330.60 364.80
30242 14 Vehicle Control 284.50 315.00 NA
30243 15 Vehicle Control 257.30 286.00 339.10
30244 15 Vehicle Control 288.60 306.00 NA
30245 15 Vehicle Control 250.90 274.50 298.50
30246 15 Vehicle Control 300.30 330.50 334.80
30247 15 Vehicle Control 288.50 321.00 330.10
30248 16 Vehicle Control 274.10 310.60 NA
30249 16 Vehicle Control 297.70 327.00 361.50
30250 16 Vehicle Control 267.40 290.40 NA
30251 16 Vehicle Control 277.80 311.50 338.20
30252 16 Vehicle Control 286.20 324.50 349.30
30253 17 Vehicle Control 291.10 305.20 NA
30254 17 Vehicle Control 263.80 290.40 NA
30255 17 Vehicle Control 261.20 295.20 332.30
30256 17 Vehicle Control 244.70 285.90 NA
30257 17 Vehicle Control 286.40 317.30 271.70
30258 18 Vehicle Control 271.60 304.60 NA
30259 18 Vehicle Control 254.90 283.20 329.50
30260 18 Vehicle Control 297.00 334.30 NA
30261 18 Vehicle Control 289.10 322.30 352.50
30262 18 Vehicle Control 235.90 247.80 280.00
30263 19 Vehicle Control 244.80 266.20 299.10
30264 19 Vehicle Control 251.30 276.40 NA
30265 19 Vehicle Control 260.40 289.90 NA
30266 19 Vehicle Control 280.00 301.30 NA
30267 19 Vehicle Control 247.00 265.10 NA
30268 20 Vehicle Control 297.00 334.60 NA
30269 20 Vehicle Control 296.60 319.50 NA
30270 20 Vehicle Control 270.30 282.30 NA
30271 20 Vehicle Control 273.80 299.10 NA
30272 20 Vehicle Control 292.10 323.30 377.60
30273 21 Vehicle Control 273.60 309.40 343.90
30274 21 Vehicle Control 272.70 291.70 318.10
30275 21 Vehicle Control 261.50 291.10 324.70
30276 21 Vehicle Control 277.00 305.60 NA
30277 21 Vehicle Control 282.50 300.30 NA
30278 22 Vehicle Control 292.90 318.80 NA
30279 22 Vehicle Control 280.30 304.00 NA
30280 22 Vehicle Control 301.10 331.00 NA
30281 22 Vehicle Control 275.30 302.80 NA
30282 22 Vehicle Control 264.80 300.70 313.60
30283 23 Vehicle Control 280.80 320.50 345.70
30284 23 Vehicle Control 293.60 324.30 NA
30285 23 Vehicle Control 261.30 290.50 326.20
30286 23 Vehicle Control 279.50 307.40 334.50
30287 23 Vehicle Control 278.20 303.70 321.60
30288 24 Vehicle Control 258.70 288.20 254.90
30289 24 Vehicle Control 271.30 306.10 303.30
30290 24 Vehicle Control 266.20 296.70 327.20
30291 24 Vehicle Control 267.50 288.00 303.80
30292 24 Vehicle Control 268.30 302.60 315.40
30353 37 2.5 mg/kg 237.10 245.00 314.60
30354 37 2.5 mg/kg 253.30 287.20 326.90
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30355 37 2.5 mg/kg 283.00 307.20 NA
30356 37 2.5 mg/kg 255.30 276.60 323.10
30357 37 2.5 mg/kg 287.40 314.50 NA
30358 38 2.5 mg/kg 283.10 305.70 NA
30359 38 2.5 mg/kg 232.40 255.40 NA
30360 38 2.5 mg/kg 262.50 273.00 NA
30362 38 2.5 mg/kg 247.70 278.40 309.60
30363 39 2.5 mg/kg 253.10 273.80 327.30
30364 39 2.5 mg/kg 247.90 275.40 NA
30365 39 2.5 mg/kg 258.00 274.70 319.00
30366 39 2.5 mg/kg 250.60 263.10 338.00
30367 39 2.5 mg/kg 257.70 277.60 NA
30368 40 2.5 mg/kg 231.80 253.50 NA
30369 40 2.5 mg/kg 255.70 279.90 324.90
30370 40 2.5 mg/kg 273.10 303.80 326.50
30371 40 2.5 mg/kg 257.80 289.30 278.60
30372 40 2.5 mg/kg 318.50 342.80 NA
30373 41 2.5 mg/kg 246.10 257.70 260.10
30374 41 2.5 mg/kg 271.70 286.00 NA
30375 41 2.5 mg/kg 245.30 258.80 335.30
30376 41 2.5 mg/kg 257.00 277.80 NA
30377 41 2.5 mg/kg 260.40 281.60 359.00
30378 42 2.5 mg/kg 252.80 256.00 NA
30379 42 2.5 mg/kg 230.50 250.80 257.70
30380 42 2.5 mg/kg 230.30 255.70 NA
30381 42 2.5 mg/kg 239.50 245.70 302.90
30382 42 2.5 mg/kg 243.50 263.10 308.00
30383 43 2.5 mg/kg 260.60 281.40 NA
30384 43 2.5 mg/kg 247.90 259.80 291.70
30385 43 2.5 mg/kg 258.70 291.10 NA
30386 43 2.5 mg/kg 276.50 303.30 NA
30387 43 2.5 mg/kg 259.30 301.40 345.60
30388 44 2.5 mg/kg 252.80 280.20 NA
30390 44 2.5 mg/kg 252.00 268.40 NA
30391 44 2.5 mg/kg 223.40 231.70 279.90
30392 44 2.5 mg/kg 253.30 279.50 303.50
30393 45 2.5 mg/kg 247.70 280.50 NA
30394 45 2.5 mg/kg 243.40 253.40 NA
30395 45 2.5 mg/kg 259.20 279.50 328.10
30396 45 2.5 mg/kg 238.00 251.00 NA
30397 45 2.5 mg/kg 237.60 NA NA
30399 46 2.5 mg/kg 240.50 263.10 184.90
30400 46 2.5 mg/kg 238.70 260.00 NA
30401 46 2.5 mg/kg 287.70 301.50 227.60
30402 46 2.5 mg/kg 242.30 266.90 NA
30403 47 2.5 mg/kg 254.50 275.30 NA
30405 47 2.5 mg/kg 254.90 265.00 307.30
30406 47 2.5 mg/kg 241.20 255.60 NA
30407 47 2.5 mg/kg 228.20 244.60 NA
30408 48 2.5 mg/kg 211.70 242.00 267.00
30409 48 2.5 mg/kg 244.70 255.30 NA
30410 48 2.5 mg/kg 260.20 280.30 NA
30411 48 2.5 mg/kg 259.20 277.80 NA
30412 48 2.5 mg/kg 235.60 264.60 258.30
30473 61 5 mg/kg 227.60 248.50 258.40
30474 61 5 mg/kg 240.00 265.90 318.20
30476 61 5 mg/kg 237.10 264.20 298.10
30477 61 5 mg/kg 217.30 228.70 NA
30478 62 5 mg/kg 241.90 249.70 313.60
30479 62 5 mg/kg 247.80 274.20 NA
30480 62 5 mg/kg 230.40 269.40 NA
30481 62 5 mg/kg 268.20 295.80 327.90
30482 62 5 mg/kg 243.60 253.20 NA
30483 63 5 mg/kg 233.90 235.80 251.30
30485 63 5 mg/kg 265.10 306.30 332.60
30486 63 5 mg/kg 233.20 250.70 306.70
30487 63 5 mg/kg 208.30 236.50 260.10
30488 64 5 mg/kg 238.40 262.00 287.90
30489 64 5 mg/kg 275.40 291.80 304.40
30490 64 5 mg/kg 228.90 246.20 NA
30491 64 5 mg/kg 271.20 299.60 330.90
30492 64 5 mg/kg 232.70 238.40 NA
30493 65 5 mg/kg 264.90 280.90 273.60
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30494 65 5 mg/kg 257.30 277.80 NA
30495 65 5 mg/kg 230.90 248.30 300.60
30496 65 5 mg/kg 224.10 233.50 279.50
30497 65 5 mg/kg 281.10 301.40 NA
30498 66 5 mg/kg 229.40 246.60 310.50
30499 66 5 mg/kg 248.10 272.10 NA
30500 66 5 mg/kg 246.90 259.20 290.50
30501 66 5 mg/kg 242.80 259.40 300.70
30502 66 5 mg/kg 268.80 280.40 NA
30503 67 5 mg/kg 244.00 246.60 293.70
30504 67 5 mg/kg 240.60 273.90 NA
30505 67 5 mg/kg 245.30 275.80 296.00
30507 67 5 mg/kg 256.50 290.20 NA
30508 68 5 mg/kg 249.70 256.60 290.10
30509 68 5 mg/kg 241.40 278.20 NA
30510 68 5 mg/kg 258.20 280.60 NA
30511 68 5 mg/kg 280.30 298.70 NA
30512 68 5 mg/kg 222.80 247.60 NA
30513 69 5 mg/kg 230.10 247.00 NA
30514 69 5 mg/kg 242.50 271.90 293.70
30515 69 5 mg/kg 251.10 269.10 302.40
30516 69 5 mg/kg 237.10 262.90 306.40
30517 69 5 mg/kg 259.60 298.10 NA
30518 70 5 mg/kg 200.60 226.40 177.10
30519 70 5 mg/kg 260.80 295.50 NA
30520 70 5 mg/kg 244.50 275.40 301.80
30521 70 5 mg/kg 235.80 271.50 NA
30522 70 5 mg/kg 249.70 269.10 NA
30523 71 5 mg/kg 247.70 284.70 NA
30524 71 5 mg/kg 237.30 262.70 NA
30525 71 5 mg/kg 251.50 288.70 NA
30526 71 5 mg/kg 300.20 NA NA
30527 71 5 mg/kg 235.90 250.70 NA
30529 72 5 mg/kg 255.30 262.30 NA
30530 72 5 mg/kg 244.30 270.10 NA
30531 72 5 mg/kg 252.40 271.70 184.60
30532 72 5 mg/kg 235.30 250.50 272.00
C.3 Heart Rates
Person Drug Time 1 Time 2 Time 3 Time 4
1 AX23 72 86 81 77
2 AX23 78 83 88 81
3 AX23 71 82 81 75
4 AX23 72 83 83 69
5 AX23 66 79 77 66
6 AX23 74 83 84 77
7 AX23 62 73 78 70
8 AX23 69 75 76 70
9 BWW9 85 86 83 80
10 BWW9 82 86 80 84
11 BWW9 71 78 70 75
12 BWW9 83 88 79 81
13 BWW9 86 85 76 76
14 BWW9 85 82 83 80
15 BWW9 79 83 80 81
16 BWW9 83 84 78 81
17 Control 69 73 72 74
18 Control 66 62 67 73
19 Control 84 90 88 87
20 Control 80 81 77 72
21 Control 72 72 69 70
22 Control 65 62 65 61
23 Control 75 69 69 68
24 Control 71 70 65 63
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C.4 Epileptic Seizures
Patient Treatment Baseline 2 Week 4 Weeks 6 Weeks 8 Weeks Age
1 Placebo 11 5 3 3 3 31
2 Placebo 11 3 5 3 3 30
3 Placebo 6 2 4 0 5 25
4 Placebo 8 4 4 1 4 36
5 Placebo 66 7 18 9 21 22
6 Placebo 27 5 2 8 7 29
7 Placebo 12 6 4 0 2 31
8 Placebo 52 40 20 23 12 42
9 Placebo 23 5 6 6 5 37
10 Placebo 10 14 13 6 0 28
11 Placebo 52 26 12 6 22 36
12 Placebo 33 12 6 8 5 24
13 Placebo 18 4 4 6 2 23
14 Placebo 42 7 9 12 14 36
15 Placebo 87 16 24 10 9 26
16 Placebo 50 11 0 0 5 26
17 Placebo 18 0 0 3 3 28
18 Placebo 111 37 29 28 29 31
19 Placebo 18 3 5 2 5 32
20 Placebo 20 3 0 6 7 21
21 Placebo 12 3 4 3 4 29
22 Placebo 9 3 4 3 4 21
23 Placebo 17 2 3 3 5 32
24 Placebo 28 8 12 2 8 25
25 Placebo 55 18 24 76 25 30
26 Placebo 9 2 1 2 1 40
27 Placebo 10 3 1 4 2 19
28 Placebo 47 13 15 13 12 22
29 Progabide 76 11 14 9 8 18
30 Progabide 38 8 7 9 4 32
31 Progabide 19 0 4 3 0 20
32 Progabide 10 3 6 1 3 20
33 Progabide 19 2 6 7 4 18
34 Progabide 24 4 3 1 3 24
35 Progabide 31 22 17 19 16 30
36 Progabide 14 5 4 7 4 35
37 Progabide 11 2 4 0 4 57
38 Progabide 67 3 7 7 7 20
39 Progabide 41 4 18 2 5 22
40 Progabide 7 2 1 1 0 28
41 Progabide 22 0 2 4 0 23
42 Progabide 13 5 4 0 3 40
43 Progabide 46 11 14 25 15 43
44 Progabide 36 10 5 3 8 21
45 Progabide 38 19 7 6 7 35
46 Progabide 7 1 1 2 4 25
47 Progabide 36 6 10 8 8 26
48 Progabide 11 2 1 0 0 25
49 Progabide 151 102 65 72 63 22
50 Progabide 22 4 3 2 4 32
51 Progabide 42 8 6 5 7 25
52 Progabide 32 1 3 1 5 35
53 Progabide 56 18 11 28 13 21
54 Progabide 24 6 3 4 0 41
55 Progabide 16 3 5 4 3 32
56 Progabide 22 1 23 19 8 26
57 Progabide 25 2 3 0 1 21
58 Progabide 13 0 0 0 0 36
59 Progabide 12 1 4 3 2 37
C.5 Greenhouse Whiteflies
Sample Environment Bottom Middle Top
1 Greenhouse 0 0 0
2 Greenhouse 0 1 0
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3 Greenhouse 0 3 0
4 Greenhouse 0 0 0
5 Greenhouse 0 0 0
6 Greenhouse 0 0 0
7 Greenhouse 8 0 0
8 Greenhouse 6 6 0
9 Greenhouse 10 4 2
10 Greenhouse 1 0 0
11 Greenhouse 0 1 0
12 Greenhouse 1 2 0
13 Greenhouse 0 0 0
14 Greenhouse 0 3 0
15 Greenhouse 0 9 0
16 Greenhouse 1 0 0
17 Greenhouse 0 6 0
18 Greenhouse 0 2 0
19 Greenhouse 2 0 0
20 Greenhouse 4 5 0
21 Greenhouse 6 2 0
22 Greenhouse 2 1 0
23 Greenhouse 3 4 0
24 Greenhouse 3 2 0
25 Greenhouse 3 4 0
26 Greenhouse 1 23 0
27 Greenhouse 9 13 7
28 Greenhouse 7 8 0
29 Greenhouse 8 13 0
30 Greenhouse 8 10 0
31 Greenhouse 13 41 0
32 Greenhouse 11 25 0
33 Greenhouse 10 26 4
34 Greenhouse 1 14 0
35 Greenhouse 2 24 0
36 Greenhouse 9 15 0
37 Greenhouse 10 15 0
38 Greenhouse 11 18 5
39 Greenhouse 12 40 0
40 Greenhouse 21 6 0
41 Greenhouse 7 7 0
42 Greenhouse 8 0 0
43 Greenhouse 36 34 0
44 Greenhouse 8 2 0
45 Greenhouse 7 10 0
46 Greenhouse 8 0 0
47 Greenhouse 5 7 0
48 Greenhouse 5 3 0
49 Greenhouse 7 5 0
50 Greenhouse 16 4 0
51 Greenhouse 10 4 0
52 Greenhouse 7 2 0
53 Greenhouse 23 0 0
54 Greenhouse 2 1 0
55 Greenhouse 23 11 0
56 Greenhouse 8 0 0
57 Greenhouse 14 3 0
58 Greenhouse 6 0 0
59 Greenhouse 12 0 0
60 Greenhouse 10 0 0
61 Greenhouse 1 4 0
62 Greenhouse 11 7 1
63 Greenhouse 33 6 0
64 Greenhouse 3 0 0
65 Greenhouse 4 6 0
66 Greenhouse 0 1 0
67 Greenhouse 14 20 0
68 Greenhouse 3 1 0
69 Greenhouse 9 2 0
70 Greenhouse 1 8 0
71 Greenhouse 2 1 0
72 Greenhouse 5 2 0
73 Greenhouse 3 6 0
74 Greenhouse 0 23 10
75 Greenhouse 30 5 2
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76 Greenhouse 9 16 0
77 Greenhouse 6 10 1
78 Greenhouse 6 7 0
79 Greenhouse 55 32 0
80 Greenhouse 4 2 1
81 Greenhouse 8 9 0
82 Greenhouse 12 10 0
83 Greenhouse 3 4 0
84 Greenhouse 8 1 0
85 Tunnel 1 3 6 2
86 Tunnel 1 0 0 0
87 Tunnel 1 0 2 0
88 Tunnel 1 6 0 0
89 Tunnel 1 1 0 1
90 Tunnel 1 0 0 0
91 Tunnel 1 2 2 0
92 Tunnel 1 0 0 0
93 Tunnel 1 0 0 0
94 Tunnel 1 2 0 0
95 Tunnel 1 2 0 0
96 Tunnel 1 0 0 0
97 Tunnel 1 7 2 0
98 Tunnel 1 5 12 0
99 Tunnel 1 1 2 0
100 Tunnel 1 4 9 0
101 Tunnel 1 0 0 0
102 Tunnel 1 NA NA 0
103 Tunnel 1 6 11 6
104 Tunnel 1 2 4 0
105 Tunnel 1 NA 0 0
106 Tunnel 1 9 0 0
107 Tunnel 1 10 0 0
108 Tunnel 1 NA NA 0
109 Tunnel 1 10 0 0
110 Tunnel 1 5 6 0
111 Tunnel 1 NA 1 0
112 Tunnel 1 8 0 0
113 Tunnel 1 6 0 0
114 Tunnel 1 NA NA NA
115 Tunnel 1 10 1 0
116 Tunnel 1 NA 12 1
117 Tunnel 1 NA 1 2
118 Tunnel 1 5 4 0
119 Tunnel 1 5 1 0
120 Tunnel 1 NA NA NA
121 Tunnel 1 10 12 0
122 Tunnel 1 NA 18 1
123 Tunnel 1 NA 2 1
124 Tunnel 1 15 7 0
125 Tunnel 1 15 4 2
126 Tunnel 1 NA NA NA
127 Tunnel 2 3 6 0
128 Tunnel 2 0 0 0
129 Tunnel 2 0 0 0
130 Tunnel 2 0 0 0
131 Tunnel 2 0 4 0
132 Tunnel 2 0 0 0
133 Tunnel 2 1 6 0
134 Tunnel 2 0 0 0
135 Tunnel 2 0 2 0
136 Tunnel 2 0 0 0
137 Tunnel 2 9 5 0
138 Tunnel 2 0 2 0
139 Tunnel 2 10 12 0
140 Tunnel 2 4 7 0
141 Tunnel 2 18 8 0
142 Tunnel 2 3 15 0
143 Tunnel 2 9 7 0
144 Tunnel 2 3 6 0
145 Tunnel 2 15 3 0
146 Tunnel 2 4 4 0
147 Tunnel 2 7 9 0
148 Tunnel 2 20 14 0
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149 Tunnel 2 6 20 0
150 Tunnel 2 7 7 0
151 Tunnel 2 28 20 0
152 Tunnel 2 8 9 0
153 Tunnel 2 8 1 0
154 Tunnel 2 15 11 0
155 Tunnel 2 25 0 0
156 Tunnel 2 12 0 0
157 Tunnel 2 6 11 2
158 Tunnel 2 11 4 3
159 Tunnel 2 10 5 0
160 Tunnel 2 6 0 0
161 Tunnel 2 18 16 0
162 Tunnel 2 25 0 0
163 Tunnel 2 9 1 1
164 Tunnel 2 9 13 1
165 Tunnel 2 13 18 2
166 Tunnel 2 13 6 0
167 Tunnel 2 22 25 2
168 Tunnel 2 16 9 8
C.6 Azadirachtin
Substrate Dose Larvae (Total) Larvae (Dead) Pupae (Total) Pupae (Dead)
CS only 1ml/kg 50 48 2 2
CS only 1ml/kg 275 90 185 110
CS only 1ml/kg 266 112 154 75
CS only 1ml/kg 83 57 26 4
CS only 1ml/kg 81 75 6 6
CS only 1ml/kg 256 131 125 51
CS only 1ml/kg 106 79 27 5
CS only 1ml/kg 76 39 37 33
CS only 1ml/kg 133 62 71 66
CS only 1ml/kg 159 88 71 49
CS only 1.5ml/kg 87 73 14 10
CS only 1.5ml/kg 69 63 6 6
CS only 1.5ml/kg 151 99 52 44
CS only 1.5ml/kg 108 79 29 4
CS only 1.5ml/kg 149 102 47 31
CS only 1.5ml/kg 167 97 70 62
CS only 1.5ml/kg 50 45 5 5
CS only 1.5ml/kg 61 52 9 7
CS only 1.5ml/kg 187 137 50 25
CS only 1.5ml/kg 28 19 9 7
CS only 2ml/kg 54 52 2 2
CS only 2ml/kg 86 85 1 1
CS only 2ml/kg 28 26 2 2
CS only 2ml/kg 102 98 4 4
CS only 2ml/kg 74 62 12 6
CS only 2ml/kg 33 22 11 7
CS only 2ml/kg 55 41 14 11
CS only 2ml/kg 41 29 12 10
CS only 2ml/kg 56 54 2 2
CS only 2ml/kg 62 49 13 13
CS+sand 1ml/kg 99 71 28 23
CS+sand 1ml/kg 236 114 122 87
CS+sand 1ml/kg 86 78 8 7
CS+sand 1ml/kg 63 57 6 5
CS+sand 1ml/kg 156 108 48 29
CS+sand 1ml/kg 131 80 28 7
CS+sand 1ml/kg 162 94 68 51
CS+sand 1ml/kg 212 111 101 88
CS+sand 1ml/kg 122 66 56 38
CS+sand 1ml/kg 47 44 3 3
CS+sand 1.5ml/kg 131 109 22 20
CS+sand 1.5ml/kg 82 80 2 2
CS+sand 1.5ml/kg 178 102 76 52
CS+sand 1.5ml/kg 74 72 2 2
CS+sand 1.5ml/kg 99 59 40 12
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CS+sand 1.5ml/kg 31 30 1 1
CS+sand 1.5ml/kg 105 92 13 13
CS+sand 1.5ml/kg 139 101 38 29
CS+sand 1.5ml/kg 78 76 2 2
CS+sand 1.5ml/kg 91 89 2 2
CS+sand 2ml/kg 185 151 34 33
CS+sand 2ml/kg 176 129 47 47
CS+sand 2ml/kg 50 49 1 1
CS+sand 2ml/kg 35 32 3 2
CS+sand 2ml/kg 55 54 1 1
CS+sand 2ml/kg 57 55 2 2
CS+sand 2ml/kg 111 105 6 5
CS+sand 2ml/kg 61 51 10 8
CS+sand 2ml/kg 27 25 2 2
CS+sand 2ml/kg 67 63 4 2
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D Further Simulation Results
This appendix provides additional results from the simulation studies described in 4 and
5. Simulated small-sample power curves for longitudinal MCTs with Gaussian endpoints
are shown in in D.1. Simulated type I error rates and power curves for asymptotic
longitudinal MCTs with binomial and Poisson endpoints are presented in D.2 and D.3.
D.1 Gaussian Data
We show here additional simulation results for small-sample inference in longitudinal
settings with a Gaussian endpoint.
Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons of Gaussian
means in setups involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} time points
are shown in Figure 60 (for comparisons of treatment groups at multiple occasions) and
Figure 62 (for comparisons of occasions within multiple treatment groups).
Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons of Gaussian
means in setups involving q = 3 treatment groups and m = 3 time points under various
longitudinal correlations are shown in Figure 61 (for comparisons of treatment groups at
multiple occasions) and Figure 63 (for comparisons of occasions within multiple treatment
groups).
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Figure 60: Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons among
q = {3, 4, 5} Gaussian treatment means separately and simultaneously at m = {3, 4, 5} occasions,
with nk = 10 independent subjects per treatment group, and different small-sample degrees of
freedom (1000 simulation runs).
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Figure 61: Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons among
q = 3 Gaussian treatment means separately and simultaneously at m = 3 occasions, with nk = 10
independent subjects per treatment group, different longitudinal correlations, and different small-
sample degrees of freedom (1000 simulation runs).
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Figure 62: Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons among
m = {3, 4, 5} Gaussian occasion means separately and simultaneously for q = {3, 4, 5} treatments,
with nk = 10 independent subjects per treatment group, and different small-sample degrees of
freedom (1000 simulation runs).
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Figure 63: Simulated powers for many-to-one, all-pairwise, and grand-mean comparisons among
m = 3 Gaussian occasion means separately and simultaneously for q = 3 treatments, with nk = 10
independent subjects per treatment group, different longitudinal correlations, and different small-
sample degrees of freedom (1000 simulation runs).
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D.2 Binomial Data
We show here additional simulation results for asymptotic inference in longitudinal set-
tings with a binomial endpoint.
Type I Error
Simulated type I error rates for many-to-one, all-pairwise, and grand-mean comparisons
of binomial proportions with pi = {0.5, 0.6, 0.7, 0.8} in setups involving q = {3, 4, 5}
treatment groups and m = {3, 4, 5} time points are shown in Figures 64, 65, and 66 for
tests based on multiple marginal GLMs, and in Figures 67, 68, and 69 for tests based on
a joint GEE.
Additional simulated type I error rates for the duplex procedure with binomial data are
presented in Figure 70.
Power
Simulated powers for many-to-one comparisons of binomial proportions with pi = {0.5, 0.6,
0.7, 0.8} in setups involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} time points
are shown in Figure 71.
Simulated powers for many-to-one comparisons of binomial proportions with pi = {0.5, 0.6,
0.7, 0.8} in setups involving q = 3 treatment groups and m = 3 time points under various
longitudinal correlations are shown in Figure 72.
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Figure 64: Simulated type I error rates for asymptotic many-to-one comparisons of binomial data
(pi = {0.5, 0.6, 0.7, 0.8}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with
nk independent subjects per treatment group, based on multiple marginal GLMs (1000 simulation
runs). Left: comparisons of treatment means separately and simultaneously within occasions;
right: comparisons of occasion means separately and simultaneously within treatment groups.
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Figure 65: Simulated type I error rates for asymptotic all-pairwise comparisons of binomial data
(pi = {0.5, 0.6, 0.7, 0.8}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with
nk independent subjects per treatment group, based on multiple marginal GLMs (1000 simulation
runs). Left: comparisons of treatment means separately and simultaneously within occasions;
right: comparisons of occasion means separately and simultaneously within treatment groups.
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Figure 66: Simulated type I error rates for asymptotic grand-mean comparisons of binomial data
(pi = {0.5, 0.6, 0.7, 0.8}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with
nk independent subjects per treatment group, based on multiple marginal GLMs (1000 simulation
runs). Left: comparisons of treatment means separately and simultaneously within occasions;
right: comparisons of occasion means separately and simultaneously within treatment groups.
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Figure 67: Simulated type I error rates for asymptotic many-to-one comparisons of binomial data
(pi = {0.5, 0.6, 0.7, 0.8}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with
nk independent subjects per treatment group, based on GEEs (1000 simulation runs). Left: com-
parisons of treatment means separately and simultaneously within occasions; right: comparisons
of occasion means separately and simultaneously within treatment groups.
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Figure 68: Simulated type I error rates for asymptotic all-pairwise comparisons of binomial data
(pi = {0.5, 0.6, 0.7, 0.8}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with
nk independent subjects per treatment group, based on GEEs (1000 simulation runs). Left: com-
parisons of treatment means separately and simultaneously within occasions; right: comparisons
of occasion means separately and simultaneously within treatment groups.
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Figure 69: Simulated type I error rates for asymptotic grand-mean comparisons of binomial data
(pi = {0.5, 0.6, 0.7, 0.8}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with
nk independent subjects per treatment group, based on GEEs (1000 simulation runs). Left: com-
parisons of treatment means separately and simultaneously within occasions; right: comparisons
of occasion means separately and simultaneously within treatment groups.
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Figure 70: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons of binomial data (pi = {0.5, 0.6, 0.7, 0.8}) among q = {3, 4, 5} treatment
means separately and simultaneously at q = {3, 4, 5} occasions and among q = {3, 4, 5} occasion
means separately and simultaneously for q = {3, 4, 5} treatments, with nk independent subjects
per treatment group, based on GEEs or multiple marginal GLMs (1000 simulation runs).
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Figure 71: Simulated powers for asymptotic many-to-one comparisons of binomial data (pi =
{0.5, 0.6, 0.7, 0.8}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with
nk = 100 independent subjects per treatment group (1000 simulation runs). Left: comparisons of
treatment means separately and simultaneously within occasions; right: comparisons of occasion
means separately and simultaneously within treatment groups.
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Figure 72: Simulated powers for asymptotic many-to-one comparisons of binomial data (pi =
{0.5, 0.6, 0.7, 0.8}) involving q = 3 treatment groups and m = 3 occasions, with nk = 100
independent subjects per treatment group, and different longitudinal correlations (1000 simulation
runs). Left: comparisons of treatment means separately and simultaneously within occasions;
right: comparisons of occasion means separately and simultaneously within treatment groups.
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D.3 Poisson Data
We show here additional simulation results for asymptotic inference in longitudinal set-
tings with a Poisson endpoint.
Type I Error
Simulated type I error rates for many-to-one, all-pairwise, and grand-mean comparisons
of Poisson rates with λ = {3, 5, 10, 20} in setups involving q = {3, 4, 5} treatment groups
and m = {3, 4, 5} time points are shown in Figures 73, 74, and 75 for tests based on
multiple marginal GLMs, and in Figures 76, 77, and 78 for tests based on joint GEEs.
Additional simulated type I error rates for the duplex procedure with Poisson data are
presented in Figure 79.
Power
Simulated powers for many-to-one comparisons of Poisson rates with λ = {3, 5, 10, 20} in
setups involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} time points are shown
in Figure 80.
Simulated powers for many-to-one comparisons of Poisson rates with λ = {3, 5, 10, 20} in
setups involving q = 3 treatment groups and m = 3 time points under various longitudinal
correlations are shown in Figure 81.
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Figure 73: Simulated type I error rates for asymptotic many-to-one comparisons of Poisson data
(λ = {3, 5, 10, 20}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with nk
independent subjects per treatment group, based on multiple marginal GLMs (1000 simulation
runs). Left: comparisons of treatment means separately and simultaneously within occasions;
right: comparisons of occasion means separately and simultaneously within treatment groups.
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Figure 74: Simulated type I error rates for asymptotic all-pairwise comparisons of Poisson data
(λ = {3, 5, 10, 20}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with nk
independent subjects per treatment group, based on multiple marginal GLMs (1000 simulation
runs). Left: comparisons of treatment means separately and simultaneously within occasions;
right: comparisons of occasion means separately and simultaneously within treatment groups.
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Figure 75: Simulated type I error rates for asymptotic grand-mean comparisons of Poisson data
(λ = {3, 5, 10, 20}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with nk
independent subjects per treatment group, based on multiple marginal GLMs (1000 simulation
runs). Left: comparisons of treatment means separately and simultaneously within occasions;
right: comparisons of occasion means separately and simultaneously within treatment groups.
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Figure 76: Simulated type I error rates for asymptotic many-to-one comparisons of Poisson data
(λ = {3, 5, 10, 20}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with nk
independent subjects per treatment group, based on GEEs (1000 simulation runs). Left: compar-
isons of treatment means separately and simultaneously within occasions; right: comparisons of
occasion means separately and simultaneously within treatment groups.
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Figure 77: Simulated type I error rates for asymptotic all-pairwise comparisons of Poisson data
(λ = {3, 5, 10, 20}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with nk
independent subjects per treatment group, based on GEEs (1000 simulation runs). Left: compar-
isons of treatment means separately and simultaneously within occasions; right: comparisons of
occasion means separately and simultaneously within treatment groups.
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Figure 78: Simulated type I error rates for asymptotic grand-mean comparisons of Poisson data
(λ = {3, 5, 10, 20}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with nk
independent subjects per treatment group, based on GEEs (1000 simulation runs). Left: compar-
isons of treatment means separately and simultaneously within occasions; right: comparisons of
occasion means separately and simultaneously within treatment groups.
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Figure 79: Simulated type I error rates for asymptotic many-to-one, all-pairwise, and grand-
mean comparisons of Poisson data (λ = {3, 5, 10, 20}) among q = {3, 4, 5} treatment means
separately and simultaneously at q = {3, 4, 5} occasions and among q = {3, 4, 5} occasion means
separately and simultaneously for q = {3, 4, 5} treatments, with nk independent subjects per
treatment group, based on GEEs or multiple marginal GLMs (1000 simulation runs).
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Figure 80: Simulated powers for asymptotic many-to-one comparisons of Poisson data (λ = {3,
5, 10, 20}) involving q = {3, 4, 5} treatment groups and m = {3, 4, 5} occasions, with nk = 100
independent subjects per treatment group (1000 simulation runs). Left: comparisons of treatment
means separately and simultaneously within occasions; right: comparisons of occasion means
separately and simultaneously within treatment groups.
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Figure 81: Simulated powers for asymptotic many-to-one comparisons of Poisson data (λ = {3,
5, 10, 20}) involving q = 3 treatment groups and m = 3 occasions, with nk = 100 independent
subjects per treatment group, and different longitudinal correlations (1000 simulation runs). Left:
comparisons of treatment means separately and simultaneously within occasions; right: compar-
isons of occasion means separately and simultaneously within treatment groups.
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E Implementation in R
E.1 Example R Code
All simulations and data analyses presented in this work were executed in R (R Core Team
2015) and some add-on packages. MCTs and the MMM procedure are implemented in
multcomp (Hothorn et al. 2015, described in Hothorn et al. 2008). LMMs can be fitted
with nlme (Pinheiro et al. 2015, described in Pinheiro and Bates 2000) and lme4 (Bates
et al. 2015b, described in Bates et al. 2015a). The Kenward-Roger adjustment is available
in pbkrtest (Halekoh and Højsgaard 2014b, described in Halekoh and Højsgaard 2014a).
A package for GEEs is geepack (Højsgaard et al. 2014, described in Halekoh et al. 2006).
An implementation of AICc-based model selection is provided by MuMIn (Barton 2015).
Copulae are available in copula (Hofert et al. 2014, described in Yan 2007). All graphics
were generated with ggplot2 (Wickham and Chang 2015, described in Wickham 2009).
The R code shown in the following contains the essential building blocks used for the
simulations and data analyses.
Generating Correlated Gaussian Data
To obtain correlated normal data with heterogeneous variances σ2j = j, j = 1, . . . ,m and
a Toeplitz correlation pattern with off-diagonal parameters par, construct an nt × nt
covariance matrix:
co <- sqrt(diag(1:nt)) %*% toeplitz(c(1, par)) %*% sqrt(diag(1:nt))
Draw random values from an nt-dimensional normal distribution with mean me and
covariance matrix co for ng treatment groups with ni subjects per treatment group:
dalist <- list()
for(g in 1:ng){
dalist[[g]] <- data.frame(mvtnorm::rmvnorm(n = ni, mean = rep(me, nt),
sigma = co))
}
dada <- as.data.frame(abind::abind(dalist, along = 1))
dada$group <- as.factor(rep(LETTERS[1:ng], each = ni))
dada$person <- as.factor(1:(ng * ni))
mda <- reshape2::melt(da, c("group", "person"))
mda$tg <- with(mda, variable:group)
Generating Correlated Discrete Data
To obtain correlated binary data, construct an nt-dimensional distribution with binomial
margins that have probability pi and cluster size si using an nt-dimensional normal
copula characterized by a Toeplitz correlation structure with off-diagonal parameters
par:
cop <- copula::mvdc(copula = copula::normalCopula(param = par, dim = nt,
dispstr = "toep"),
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margins = rep("binom", nt),
paramMargins = list(list(size = si, prob = pi)),
marginsIdentical = TRUE)
To obtain correlated count data, construct an nt-dimensional distribution with Poisson
margins that have parameter lambda using an nt-dimensional normal copula character-
ized by a Toeplitz correlation structure with off-diagonal parameters par:
cop <- copula::mvdc(copula = copula::normalCopula(param = par, dim = nt,
dispstr = "toep"),
margins = rep("pois", nt),
paramMargins = list(list(lambda = lambda)),
marginsIdentical = TRUE)
Draw random values from the distribution cop for ng treatment groups with ni subjects
per treatment group:
dalist <- list()
for(g in 1:ng){
dalist[[g]] <- data.frame(copula::rMvdc(ni, cop))
}
da <- as.data.frame(abind::abind(dalist, along = 1))
da$group <- as.factor(rep(LETTERS[1:ng], each = ni))
da$person <- as.factor(1:(ng * ni))
mda <- reshape2::melt(da, c("group", "person"))
mda$tg <- with(mda, variable:group)
Contrast Coefficient Matrices
Construct a contrast matrix for many-to-one comparisons ("Dunnett") among ng treat-
ment means separately and simultaneously at nt occasions, with ni subjects per treat-
ment group:
K1 <- diag(nt) %x% multcomp::contrMat(rep(ni, ng), type = "Dunnett")
Construct a contrast matrix for many-to-one comparisons ("Dunnett") among nt occa-
sion means separately and simultaneously within ng treatment groups, with ni subjects
per treatment group:
K2 <- multcomp::contrMat(rep(ni, nt), type = "Dunnett") %x% diag(ng)
Unite the contrasts in K1 and K2 to carry out all comparisons simultaneously:
K12 <- rbind(K1, K2)
Other contrasts besides many-to-one are possible e.g., with type = "Tukey" for all-
pairwise comparisons, or type = "GrandMean" for ANOM.
Simultaneous Inference from Multiple Marginal Models
For Gaussian data, fit one linear model per time point:
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modlist <- apply(da[, 1:nt], 2, function(y) lm(y ~ da$group - 1))
For binary data, fit one binomial GLM with logit link function:
modlist <- apply(da[, 1:nt], 2, function(y)
glm(y ~ da$group - 1, family = binomial(link = "logit)))
For count data, fit one Poisson GLM with log link function:
modlist <- apply(da[, 1:nt], 2, function(y)
glm(y ~ da$group - 1, family = poisson(link = "log)))
Perform asymptotic multiple comparisons according to the contrast coefficients in K:
MMM <- glht(do.call(multcomp::mmm, modlist), linfct = K, df = 0)
Compute adjusted p-values and SCI bounds:
summary(MMM)$test$pvalues
confint(MMM)
For a small-sample adjustment with Gaussian data, choose an integer value greater than
0 for df.
Simultaneous Inference Based on a Joint CIM
Create a continuous time variable:
mda$timeC <- as.numeric(mda$variable)
Fit a CIM with time-stratified random effects:
CIM <- lme4::lmer(value ~ tg - 1 + (timeC|person), mda)
Perform asymptotic multiple comparisons according to the contrast coefficients in K:
multcomp::glht(CIM, linfct = K, df=0)
For a small-sample adjustment, choose an integer value greater than 0 for df. For exam-
ple, apply the Kenward-Roger method and use the average DF across all comparisons.
Compute the Kenward-Roger adjusted covariance matrix:
krMat <- pbkrtest::vcovAdj(CIM)
Calculate the average Kenward-Roger DF, rounded down to the nearest integer:
krDF <- floor(mean(apply(K, 1, function(x)
pbkrtest::ddf_Lb(VVa = krMat, Lcoef = x))))
Perform Kenward-Roger adjusted multiple comparisons according to the contrast coeffi-
cients in K:
multcomp::glht(parm(coef = fixef(CIM), vcov = as.matrix(krMat)),
linfct = K, df=krDF)
Compute adjusted p-values with summary() and SCI bounds with confint() as shown
above.
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Functionality for multiple tests using the Kenward-Roger method is also available in the
packages lsmeans (Lenth 2015) and lmerTest (Kuznetsova et al. 2015a, described in
Kuznetsova et al. 2015b).
Simultaneous Inference Based on a Joint ELM
Fit an ELM with occasion-specific variances σ2j and AR(1) residual correlation:
ELM <- nlme::gls(value ~ tg - 1, mda,
weights = varIdent(form = ~1|variable),
correlation = corAR1(form = ~1|person))
Perform asymptotic multiple comparisons according to the contrast coefficients in K:
multcomp::glht(ELM, linfct = K, df = 0)
For a small-sample adjustment, choose an integer value greater than 0 for df.
Compute adjusted p-values with summary() and SCI bounds with confint() as shown
above.
Simultaneous Inference Based on GEEs
Sort the data by clusters (necessary for working with geepack::geeglm):
mda <- mda[order(mda$person), ]
For binary data, fit binomial GEEs with AR(1) working correlation:
GEE <- geepack::geeglm(value ~ tg - 1, data = mda, id = person,
family = binomial, corstr = "ar1")
For count data, fit Poisson GEEs with AR(1) working correlation:
GEE <- geepack::geeglm(value ~ tg - 1, data = mda, id = person,
family = poisson, corstr = "ar1")
Perform asymptotic multiple comparisons according to the contrast coefficients in K, using
the naive covariance matrix of the data:
multcomp::glht(parm(coef = coef(GEE), vcov = GEE$geese$vbeta.naiv), linfct = K)
Perform asymptotic multiple comparisons according to the contrast coefficients in K, using
the robust (sandwich) covariance matrix:
multcomp::glht(parm(coef = coef(GEE), vcov = GEE$geese$vbeta), linfct = K)
Compute adjusted p-values with summary() and SCI bounds with confint() as shown
above.
AICc Model Selection
Assemble a set of candidate models e.g., ELMs with occasion-specific variances σ2j and
CS, AR(1), or UN residual correlation:
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ELM1 <- nlme::gls(value ~ tg - 1, mda,
weights = varIdent(form = ~1|variable),
correlation = corCompSymm(form = ~1|person))
ELM2 <- nlme::gls(value ~ tg - 1, mda,
weights = varIdent(form = ~1|variable),
correlation = corAR1(form = ~1|person))
ELM3 <- nlme::gls(value ~ tg - 1, mda,
weights = varIdent(form = ~1|variable),
correlation = corSymm(form = ~1|person))
Select the model that gets most support from the data using AICc:
MuMIn::model.sel(ELM1, ELM2, ELM3)
AICc model selection can also be applied to CIMs or other LMMs.
Approximative Power
The following function appPower calculates the approximative global, any-pair, and all-
pairs power as in 4.5 for longitudinal MCTs. It takes as input a Gaussian mean vector
mu, the associated covariance matrix cov, a vector of sample sizes n, degrees of freedom
df, a matrix of contrast coefficients cmat, a type I error rate alpha, and specifications
whether two-sided or directional one-sided hypotheses are to be tested and which type of
power is to be calculated. The output provides the approximate power. The function is
based on code from the R package MCPAN (Schaarschmidt et al. 2013).
appPower <- function(mu, cov, n, df, cmat, rhs = 0, alpha = 0.05,
alternative = c("two.sided", "less", "greater"),
power = c("global", "anypair", "allpairs")){
MU <- matrix(mu, ncol = 1)
COV <- cmat %*% (cov/n) %*% t(cmat)
R <- cov2cor(COV)
M <- nrow(cmat)
RHS <- rep(rhs, M)
ExpT <- (as.numeric(cmat %*% MU) - RHS) / sqrt(diag(COV))
switch(alternative,
two.sided = {
crit <- mvtnorm::qmvt(p = 1 - alpha, tail = "both.tails",
df = df, corr = R)[["quantile"]]
},
less = {
crit <- mvtnorm::qmvt(p = 1 - alpha, tail = "upper.tail",
df = df, corr = R)[["quantile"]]
},
greater = {
crit <- mvtnorm::qmvt(p = 1 - alpha, tail = "lower.tail",
df = df, corr = R)[["quantile"]]
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})
switch(power,
global = {
switch(alternative,
two.sided = {
beta <- mvtnorm::pmvt(lower = rep(-crit, M),
upper = rep(crit, M),
delta = ExpT, df = df,
corr = R)
whichHA <- which(ExpT != 0)
},
less = {
beta <- mvtnorm::pmvt(lower = rep(crit, M),
upper = rep(Inf, M),
delta = ExpT, df = df,
corr = R)
whichHA <- which(ExpT < 0)
},
greater = {
beta <- mvtnorm::pmvt(lower = rep(-Inf, M),
upper = rep(crit, M),
delta = ExpT, df = df,
corr = R)
whichHA <- which(ExpT > 0)
})
},
anypair = {
switch(alternative,
two.sided = {
whichHA <- which(ExpT != 0)
MHA <- length(whichHA)
if(MHA < 1){
warning("All contrasts are under their corresponding
null hypotheses, thus any-pair power cannot be
calculated.")
beta <- 1 - alpha
}else{
beta <- mvtnorm::pmvt(lower = rep(-crit, MHA),
upper = rep(crit, MHA),
delta = ExpT[whichHA],
df = df,
corr = R[whichHA, whichHA])
}
},
less = {
whichHA <- which(ExpT < 0)
MHA <- length(whichHA)
E IMPLEMENTATION IN R 191
if(MHA < 1){
warning("All contrasts are under their corresponding
null hypotheses, thus any-pair power cannot be
calculated.")
beta <- 1 - alpha
}else{
beta <- mvtnorm::pmvt(lower = rep(crit, MHA),
upper = rep(Inf, MHA),
delta = ExpT[whichHA],
df = df,
corr = R[whichHA, whichHA])
}
},
greater = {
whichHA <- which(ExpT > 0)
MHA <- length(whichHA)
if(MHA < 1){
warning("All contrasts are under their corresponding
null hypotheses, thus any-pair power cannot be
calculated.")
beta <- 1 - alpha
}else{
beta <- mvtnorm::pmvt(lower = rep(-Inf, MHA),
upper = rep(crit, MHA),
delta = ExpT[whichHA],
df = df,
corr = R[whichHA, whichHA])
}
})
},
allpairs = {
switch(alternative,
two.sided = {
whichHA <- which(ExpT != 0)
MHA <- length(whichHA)
if(MHA < 1){
warning("All contrasts are under their corresponding
null hypotheses, thus all-pairs power cannot be
calculated.")
beta <- 1 - alpha
}else{
nsim <- 100000
RT <- mvtnorm::rmvt(n = nsim,
delta = ExpT[whichHA],
df = df,
sigma = as.matrix(R[whichHA,
whichHA]),
method = "svd")
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nreject <- sum(apply(RT, 1, function(x){min(abs(x))})
> abs(crit))
beta <- 1 - (nreject/nsim)
}
},
less = {
whichHA <- which(ExpT < 0)
MHA <- length(whichHA)
if(MHA < 1){
warning("All contrasts are under their corresponding
null hypotheses, all-pairs power cannot be
calculated.")
beta <- 1 - alpha
}else{
beta <- 1 - mvtnorm::pmvt(lower = rep(-Inf, MHA),
upper = rep(crit, MHA),
delta = ExpT[whichHA],
df = df,
corr = R[whichHA, whichHA])
}
},
greater = {
whichHA <- which(ExpT > 0)
MHA <- length(whichHA)
if(MHA < 1){
warning("All contrasts are under their corresponding
null hypotheses, all-pairs power cannot be
calculated.")
beta <- 1 - alpha
}else{
beta <- 1 - mvtnorm::pmvt(lower = rep(crit, MHA),
upper = rep(Inf, MHA),
delta = ExpT[whichHA],
df = df,
corr = R[whichHA, whichHA])
}
})
})
pow <- round(1 - beta[[1]], 3)
return(pow)
}
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Comparison-Specific Degrees of Freedom
The following function multDF computes adjusted p-values for MCTs with comparison-
specific degrees of freedom. It takes as input a vector of Gaussian mean estimates Est,
the associated covariance matrix Sig, a matrix of contrast coefficients K, a vector of
contrast-specific degrees of freedom df, and a specification whether two-sided or direc-
tional one-sided hypotheses are to be tested. The output provides effect estimates, SEs,
test statistics, and adjusted p-values. The function is based on code from the R package
SimComp (Hasler 2014b).
multDF <- function(Est, Sig, K, df, alternative = "two.sided",
level = 0.95){
ncomp <- nrow(K)
MC <- summary(glht(parm(Est, Sig), K))
Ests <- MC$test$coefficients
Vars <- MC$test$sigma
Stats <- MC$test$tstat
R <- cov2cor(vcov(MC))
pvalue <- upper <- lower <- numeric(ncomp)
for(z in 1:ncomp){
if(alternative=="two.sided"){
pvalue[z] <- 1 - pmvt(lower = rep(-abs(Stats[z]), ncomp),
upper = rep(abs(Stats[z]), ncomp),
df = floor(df[z]),
corr = R)[1]
quan <- qmvt(p = level,
tail = "both.tails",
df = floor(df[z]),
corr = R)$quantile
upper[z] <- Ests[z] + quan * Vars[z]
lower[z] <- Ests[z] - quan * Vars[z]
}
if(alternative=="greater"){
pvalue[z] <- 1 - pmvt(lower = -Inf,
upper = rep(Stats[z], ncomp),
df = floor(df[z]),
corr = R)[1]
quan <- qmvt(p = level,
tail = "lower.tail",
df = floor(df[z]),
corr = R)$quantile
upper[z] <- Inf
lower[z] <- Ests[z] - quan * Vars[z]
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}
if(alternative=="less"){
pvalue[z] <- 1 - pmvt(lower = rep(Stats[z], ncomp),
upper = Inf,
df = floor(df[z]),
corr = R)[1]
quan <- qmvt(p = level,
tail = "upper.tail",
df = floor(df[z]),
corr = R)$quantile
upper[z] <- Ests[z] - quan * Vars[z]
lower[z] <- -Inf
}
}
return(round(cbind(estimate = Ests, sigma = Vars, tstat = Stats,
lower, upper, p = pvalue), 4))
}
E.2 R Package SimLongi
A development version of an R package SimLongi is available from https://github.com/
PhilipPallmann/SimLongi. It facilitates the implementation of the methods proposed
in this thesis. In particular, it enables to user to perform longitudinal MCTs for Gaussian
endpoints based on a joint ELM or LMM very easily with:
• specification of a set of candidate models,
• selection of the “best” model via AICc,
• construction of contrast coefficient matrices for comparisons of treatment groups
and/or time points,
• choice among various DF approximations.
We take as an example the bradykinin dataset described in 2.1, which is available in
SimLongi as object brady.
Example 1: Assume we want to carry out two-sided many-to-one comparisons of treat-
ment groups per time point (direction="gpt") based on an AICc-selected ELM. The
candidate set contains models with homo- and heteroscedastic variances (heteroscedastic
across treatment groups or time points or both) and CS, AR(1), or UN correlation of the
residuals, and the DF are to be approximated using the ESS:
SimLongi(data=brady, response="logConc", group="Drug", time="Time",
id="ID", covariates=NULL, var=list("hom", "het", "hett", "hetg"),
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cor=list("CS", "AR1", "UN"), type="Dunnett", base=1,
direction="gpt", alternative="two.sided", level=0.95, df="ess")
Example 2: Now suppose we want to perform all-pairwise comparisons of time points
per group (direction="tpg") based on an AICc-selected CIM. The candidate set con-
tains models with different structures of the random effects, and a Kenward-Roger ad-
justment is to be used:
SimLongiMix(data=brady, response="logConc", group="Drug", time="Time",
id="ID", covariates=NULL, rand=list("1|id", "time|id",
"group|id", "timegroup|id"), type="Tukey", direction="tpg",
alternative="greater", level=0.95, df="kr")
A ggplot2-style plotting function PlotCI for SCIs is provided by SimLongi as well.
This R package is far from being an all-purpose tool, simply because there is no way to
cover all possible structures of error covariance matrices and random effects, especially
when further covariates are involved. Instead it is meant to be an aid to get started and
explore the options that come with our longitudinal MCTs.
In addition, SimLongi contains a function PowApprox to calculate the approximate pow-
ers given in 4.5, and two generic functions ESSgls and ESSlme that compute the ESS
associated with parameter estimates of an ELM fitted with gls or an LMM fitted with
lme of the package nlme.
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